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ABSTRACT 
in pharmaceutical process development there is frequently a large element of process uncertainty since 
knowledge of the mechanisms of production and separation is often limited. The overall objective of this 
thesis is the development of a general methodology which combines process modelling with uncertainty 
techniques to support the process development of complete integrated sequences. In a structured approach 
the uncertainty can be managed and improved process performance may be obtained. 
The major concept of this work is the integration of stochastic methods into a general framework for batch 
and continuous process models, consisting of two main parts. The first combines systematic modelling 
procedures with Hammersley sampling based Uncertainty Analysis and a range of sample-based 
Sensitivity Analysis techniques, used to quantify predicted performance uncertainty and identify key 
uncertainty contributions. In the second, a stochastic optimisation approach is employed to solve different 
problems under uncertainty. The methodology was implemented on two case studies. 
The first study investigated a batch reactor process. Some undesirable performance characteristics were 
observed when the published nominal optimal isothermal operating policy was implemented in the 
uncertain system. It was found that a robust operating policy significantly improved the total process time 
characteristic but not the impurity content and an alternative non-isothermal policy strategy would be a 
better option. The second study investigated a complete process sequence. As models developed with 
incoming data, uncertainty in the reaction and crystallisation parameters were critical to the endpoint 
quality criteria. Expected performance was improved by considering the propagation of uncertainty in the 
complete process. Four different flowsheets were compared, considering profitability and control 
tolerance criteria under uncertainty. 
The case study results indicate the importance in considering uncertainty systematically and quantitatively 
when conventional modelling techniques are employed. The methodology showed the opportunity to C, 
improve process performance potential and provide more realistic information to support pharmaceutical 
process development. 
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CHAPTER 1 
INTRODUCTION AND MOTIVATION 
This thesis concerns the management of uncertainty in a model-based approach for the design of 
pharmaceutical processes. Process development may be aided by the application of a process systems 
approach based on reliable (accurate) process models. In this work the uncertainty contained in the 
available process models is considered with respect to the development of more reliable models and the 
optimisation of complete process sequences. 
Process development in the pharmaceutical industry is beset by challenges not encountered in the 
traditional chemical processing industries. These pressures mean that process design decisions often need 
to be made despite a scarcity of available process knowledge and with little understanding of the physico- 
chemical phenomena characterising the process. This can result in the development of low quality 
processes. A more structured approach to process development, particularly at the earlier stages, has the 
potential to save development resources, improve the quality of the final process and help ensure added 
value in the products. In addition, the efficiency of the process development may be enhanced. Therefore, 
it would be useful to structure the available process information and knowledge within a decision support 
tool, and where possible transform the knowledge into mechanistic understanding. 
A framework based on process models is one way to provide such a structure. In this way, the available 
information and process knowledge can be systematically documented and retained. This in turn may help 
improve the understanding of the process and provide opportunities to exploit the potential of a process 
with the use of computational optimisation techniques. To better exploit the full potential that can be 
achieved with the use of model-based approaches, they should be incorporated sooner rather than later 
into process development procedures. Simple models may provide useful information at earlier stages and 
as data. is obtained greater complexity may be incorporated to improve their reliability. However, the 
usefulness of a model-based approach in supporting and influencing decisions is limited by the confidence 
which can be placed in the results obtained. Most optimisation techniques do not explicitly account for the 
presence of model uncertainty and while methods incorporating uncertainty aspects are available, few 
appear to have been applied to non-linear batch systems let alone integrated sequences of batch process 
operations typical in the pharmaceutical industry. Since the lack of process knowledge often results in 
large amounts of uncertainty being contained in the models developed to describe the process, it is 
important the framework has the capacity to quantify the uncertainty from a wide range of sources in a 
meaningful manner. 
The objective of this work is to exploit the use of a model-based approach in order to provide a general 
framework within which it is able to quantify the combined influence of a range of uncertainties within an 
integrated process sequence model, identify the key sources of uncertainty, track the effect on the levels of 
uncertainty contained when new information is incorporated, determine the best process flowsheet 
18 
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operating conditions under the uncertainty and which can be used to Identify the best flowsheet between a 
set of topological alternatives according to the desired process criteria. It is believed that such a 
framework would provide a new and valuable contribution within the scope of process design for 
integrated process sequences in the pharmaceutical industry. 
In Chapter 2, a brief summary of the unique issues associated with process development in the 
pharmaceutical industry is presented. The current role, limitations and attitudes towards process modelling 
in the process development cycle is discussed and a future vision for this role is portrayed. Some of the 
mathematical aspects of uncertainty regarding its characterisation, quantification and sensitivity analysis 
methods associated with a model-based environment are discussed in Chapter 3. Chapter 4 reviews the 
main approaches which have been proposed for chemical process design optimisation under uncertainty, 
the term design may assume both the operating conditions and equipment design parameters. Chapter 5 
presents the proposed methodology. The mathematical techniques used to generate the characterisation of 
the uncertain process system within a systematic model building procedure are described in detail. 
General formulations describing different optimisation under uncertainty problems are stated. In Chapter 6 
an industrial reaction process taken from the literature is investigated. This case study shows the 
importance and benefits of incorporating uncertainty when using deterministic process models to support 
the assessment of process performance and in determining optimal operating policies. Chapters 7,8 and 9 
illustrate and verify the features of the methodology with regard to a comprehensive case study 
investigating a complete process sequence for a pharmaceutical product. This case study is derived from 
an industrial collaboration with a pharmaceutical company. Chapter 10 presents the conclusions of this 
thesis and summarises some important avenues of future work within the scope of this project. 
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CHAPTER 2 
BRIEF VIEW OF PROCESS DEVELOPMENT IN THE PHARMACEUTICAL 
INDUSTRY 
2.1 Introduction 
In this chapter a brief background to process development in the pharmaceutical industry is presented. 
This includes some of the unique aspects which characterise the current working cultures and attitudes. 
The current advance and utillsation of process modelling to support development is discussed together 
with a projected vision for process development in the future. 
2.2 Some unique challenges 
Research based companies within the pharmaceutical industry deliver new therapeutic products to health 
care providers. To achieve this, vast quantities of time, effort and capital are invested into research and 
development. The high risks involved are offset by a wide portfolio of projects and the potential pay-back 
for introducing a novel product to the market first. 
With the increasing emphasis for new products, the level of commercial competition is high. A significant 
proportion of the competitive success of a research based company may stem from the efficient manner in 
which it can manipulate the available data and execute process development. Basu (1998) defined process 
development in the pharmaceutical industry as "the process of converting a chemical synthesis into an 
optimum, economic, robust and reproducible process for the manufacture of a chemical of desired quality 
at the ultimate desired scale". The roles of process development and scale-up are inter-dependent, where 
the same author also defined scale-up as "designing for safe and cost-effective operation of a process 
giving predictable results, by using knowledge and data available at a particular point in time within 
equipment which may be of similar scale as the manufacturing plant". Ideally a high quality process would 
be developed with only a minimum number of scale-ups but this is limited by the science and current 
technology of scale-up (Basu et al., 1999). In addition, regulatory authorities stipulate that once an 
application for a process for a particular product has been made, opportunities to change the process 
become severely limited. This means that it is essential to arrive at a high quality process before the 
application is made or risk the disadvantages of a poor quality process in manufacture and even the need 
to reapply in case of problems requiring major changes. 
Stephanopoulos et al. (1999) interpreted batch process development as a series of phases before 
technology transfer to the manufacturing plant during which it is speculated that the 'added value' of the 
process or 'lost opportunity' decreases by several orders of magnitude. These phases involve a largely 
iterative process between the chemists, the development engineers, the pilot plant engineers and ultimately 
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Figure 2.1. Process development and key roles in the pharmaceutical industry. 
the production engineers. A basic view of process development based on that given by Basu (1998) is 
shown in Figure 2.1. Here the key roles of the different personnel are loosely defined, though some of 
these may overlap with the interactions shown. 
Good communication between the chemists, the development engineers and the pilot plant engineers is 
crucial so that problems during scale-up are resolved at earlier stages in the development. This view is 
endorsed by Mukesh (1999) and Carpenter (2001) who both stated that better processes will only result 
from a very close interaction between the synthetic chemists and the chemical engineers. It has also been 
argued that a little more time spent in the early in the development cycle would result in shorter and more 
productive laboratory and plant runs (Repic, 1998). In this way, the culture of 'learning by doing', though 
still essential, may be minimised so that the number of scale-up failures and the runs required to obtained 
reproducible scale-up data are reduced. In addition, there would be less reliance on the expertise of 
individual chemists in detern-uning how much the laboratory process characterisation passed to the pilot 
plant engineers takes into account the limiting effects of scale-up in the pilot plant equipment. 
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Process development in the pharmaceutical industry faces a number of unique challenges due to the nature 
of the products and the market pressures. Some of the key challenges and implications are surnmarised 
below: 
e limitations on development time and resource due to economic pressure to be first to the market, 
=* requirement for simultaneous process development, scale-up and chemical production for testing 
(often at short notice) with incomplete process knowledge, 
=> rapid transfer of laboratory processes into the pilot plant so that scale-up problems are identified 
and resolved quickly (Shah et al., 1999), 
=> early 'freezing' of process options with full scale operations typically based on experimental 
laboratory processes developed into existing manufacturing equipment, 
=> desire to achieve as much process validation as possible in the pilot plant rather than in the 
manufacturing plant, 
=> high reliance on experimentation and empiricism to obtain process feasibility with little time for 
model development and very little or none for process optimisation, 
=> only just enough process characterisation is passed to the pilot plant engineers to operate the 
process safely and achieve the desired product quality, 
=> when engineers require more data from the chemists or desire further plant measurements to be 
collected the added value must be apparent, 
e shortening product life cycles in a continually evolving market, 
=* a wide portfolio of products and reliance on existing multipurpose equipment in both the pilot and 
manufacturing plants, 
9 need for high quality chemical product for efficacy, safety, toxicological tests and clinical trials 
=> additional pressure on the pilot plant and requirement of good documentation, 
=> batch to batch conformity (scale-up reproducibility) is essential, 
9 high risk of project failure due to adverse tests or trials, 
=> less capital expenditure allocated to pilot plant stages of process development than resolving 
problems in the manufacturing plant (when project success is more certain), 
e complex organic syntheses sometimes with very high cost raw materials, 
=* high number of chemists to chemical engineers with the requirement for effective communication, 
==> high complexity of decision making, 
Increasing importance of process efficiency in the competitive market such that the need for cost ltý 
reduction may drive development (Basu, 1998), 
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restrictions on implementation of process changes after certain regulatory approvals, 
=> efficient process development and good planning are required to anticipate and validate 
performance enhancing process changes earlier, 
* adherence to regulatory authority guidelines, 
=> written evidence for a good understanding of the process (development report), 
=* iterative process between laboratory and plant to verify reproducibility of scale-up and ensure 
success of validation runs, 
=> documentation of all process changes made during development (process change control system), 
e adherence to safety and environmental constraints, 
=> limitations on the implementation of alternative chemistry, process routes and technology. 
Clearly the challenges and implications contribute immensely to the way in which process development is 
conducted in the pharmaceutical industry. In this work the benefits that may be derived from the use of a 
more system wide process modelling approach is of interest. The next section reviews some of the current 
literature reporting the current opinions and contributions of modelling in this field. 
2.3 Modelling applications 
Applications of process modelling techniques in the batch chemical processing industries have been 
previously identified (Wright, 1984, Barrera and Evans, 1984, Rippin, 1993, Terwiesch et al., 1994). A 
broad range of potential benefits which may be obtained through the implementation of model-based 
systems approaches to support process development in the batch processing and pharmaceutical industries 
have been acknowledged from sources within the chemical industry, the engineering software industry and 
academia (Allgor et al., 1996, Wright and Bramfitt, 1997, Basu, 1998, Basu et al., 1999, Shah et al., 
1999, Stephanopoulos et al., 1999): 
* production of higher quality processes, 
* increased efficiency of process development by reducing the number of experiments and scale-ups, 
0 improved scientific understanding of the process in terms of the physico-chemical phenomena and the 
interactions with external actions and identification of significant areas where process understanding is 
lacking, 
0 identification of important interactions and tracking of species concentrations within an integrated 
process sequence (otherwise expensive and difficult to measure on-line), 
systematic documentation and structure of process knowledge in the provision for a corporate 
knowledge warehouse, 
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9 identification of the information necessary for each stakeholder to complete their jobs more 
effectively, 
* provision of more reliable process characterisation for pilot plant and production engineers, 
risk free exploration of a large number of process alternatives and operating and limiting conditions 
within the complete process sequence, 
identification of critical parameters not apparent from the laboratory or pilot scale work, 
9 aid trouble shooting in existing operations and study safety problems, 
* support control system design. 
It has been proposed that these potential benefits may be directed towards supporting decisions in: 
9 planning of experiments and data collection, 
* process feasibility and safety investigations, robust scale-up and technology transfer, 
sensitivity analysis and determining the limits of the process to support process validation, 
optimisation of process operation considering and trading between econorMc, environmental and/or 
risk factors. 
It is hoped that the introduction of systematic model-based techniques will increase the probability of 
obtaining good quality processes before application to the regulatory authorities beyond which 
opportunities to instil process changes are limited. Consequentially, this should also reduce the need to 
introduce radical process changes due to unpredicted poor performance and problems at later stages, 
resulting in considerable loss of time and resource during reapplication to the authorities. Some industrial 
attitudes and potential limitations regarding the use of process modelling are also acknowledged: 
0 models are only developed in the event of development problems (trouble shooting) or they are 
considered to add value to the process, 
most knowledge is empirical or based on experience where there is little understanding of the 
underlying mechanisms and for which modelling from first principles is not generally applicable (e. g. 
solids processing -crystallisation, filtration, drying), 
implementation must not have an adverse impact on the efficiency of current work methods and there 
must be some positive quantifiable return for any additional effort, 
the limitation of modelling is that it will only solve a fraction of the problems typically observed due to 
the unique nature of problems and because some processes are not typical engineering applications and 
are not conducive to current modelling technologies, 
0 short term objectives of reaching deadlines may conflict with and override 
long term objectives for 
improved process development, 
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* models need to be relevant and accurate over realistic ranges of values for the parameters used for 
scale-up which is more dependent on the experience and expertise of the individual than in the ability 
of the tools used to solve the mathematical problems, 
9 models may be unreliable and the results inaccurate due to the number of unmeasurable external 
influences and the limitations of models applied for scale-up must be realised by the scientists, 
* the inability to accurately model certain process aspects, such as physical properties and in particular 
processes involving solids are major problems, 
* on the whole the level of process modelling is low with the exception that the chemistry and reaction 
stoichiometry is generally well defined though rigorous kinetic reaction models are usually unjustified 
(for short-lived small-volume products) with operation often based on conversion, 
and views towards process optimisation: 
9 it is largely left to manufacturing due to time constraints, the difficulty in getting a feasible process to 
begin with and the risk associated with each project, 
it is only considered when there is a basis for a workable and scaleable process and is rarely afforded, 
* model-based numerical optimisation solutions may not be suitably sensitive to real life safety issues. 
Some interesting and valid issues covering a range of viewpoints have been raised here. While the vision 
is worthwhile, the implementation of process modelling techniques appears to be limited by the current 
technologies available for modelling and/or current working practices (and current skills base). Some of 
the current advances in this field are discussed in the next section. The accuracy of model predictions, in 
particular for physical properties, may be viewed as questionable but the industrial perception of the 
current status of modelling technologies may be lower than it should be. 
2.3.1 Some current advances in process modelling for batch processes 
Some new ideas and approaches proposed in the literature concerning model-based support for systematic 
process development are discussed. This is followed by some published examples where the use of 
process modelling does appear to have made a difference. 
Barrera and Evans (1984) introduced a comprehensive approach to the optimal design and operation of 
multi-product batch process plants using existing equipment. They consider a hierarchical solution 
approach in recognition of the computational intensity of the optimisation problem for the complete batch 
process design. The upper level selects the equipment sizes and storage policy from a given inventory, 
where combinatorial optimisation strategies are proposed. The ntiddle level distributes the horizon time 
between the products and the lower level selects the operating times and conditions for the individual 
product processes posed as an NLP problem. An example for the lower level sub-problem demonstrated 
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the advantages of considering the integrated process sequence through the trade-offs determined with the Zý t, 
shifting of process load between operations and with the productivity and operating costs 
The concepts of a comprehensive modelling approach for entire pharmaceutical process sequences are 
explored by Basu et al. (1999). They concluded that changes to current process development practices are 
essential and advocate that integration with process modelling is one new approach to bring this change 
about. Allgor et al. (1996) demonstrated the application of systems process modelling for integrated batch 
process development and optimisation. In their methodology rigorous mechanistic process models are 
constructed, validated and used in conjunction with laboratory experimentation and pilot plant data. A 
first step determines a feasible base case process design (seen as the most challenging aspect) based on 
these models given a plant superstructure derived from a state task network (STN) representation. This 
describes the tasks involved in transforming raw materials from one thermodynamic state into the desired 
products and wastes in other states. Secondly, systematic optimisation of the base case follows according 
to some economic criteria. Some of the problems recognised by Samsatli and Shah (1996) in their work 
regarding multi-stage biochemical processes are also applicable to synthetic pharmaceutical processes. 
They used integrated design procedures which aim to capture the key interacting effects between unit 
operation models within the optimisation. 
The use of process modelling and simulation as a tool to support pharmaceutical process validation is 
promoted by Wright and Bramfitt (1997). They endorsed the use of dynamic mass and energy balances to 
provide a detailed description of the intrinsic chemistry, kinetics and thermodynamics with a complete 
operational specification in the equipment model. Their article refers to illustrating examples for two 
industrial reaction processes (Wright, 1984 and Bollyn et al., 1995), discussed in the next section. 
Shah et al. (1999) questioned the current working practices and also advocate the advanced role of 
process systems engineering in process design and development, within the specifications of the Britest 
project (Batch Route Innovative Technology, Evaluation and Selection Techniques). The aim is to 
improve process efficiency by defining the process In terms of its physicochemical properties and 
understanding how external conditions affect these in order to determine the best conditions outside the 
firrutations of existing equipment or unit operations. Here model building and model validation purposes 
drive experimentation and the models are used to determine the process design. 
Stephanopoulos et al. (1999) discussed some of the methodologies proposed to support the different 
phases of batch process development and the need for further progress. The emphasis is on the conceptual 
design of batch processes using an operating plan approach but also encompasses production route 
planning and materials selection among others, within the confines of the 'BatchDesign-Kit' software. 
A new batch process modelling approach is introduced by Martinez (2000) where reactor models are 
developed driving and making effective use of incoming experimental data. With an uncertain model a 
sequential experiment design strategy is proposed to locate the optimum operating conditions in a 
'learning by doing' manner. The modelling and process optimisation are integrated within an experimental L- C- t:, 
data collection loop. 
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There is a limited number of published examples (possibly due to industrial confidentiality) where process 
modelling has proved beneficial in real process development. It should be noted that virtually all of these 
concern reaction processes. 
Wright (1984) provide an example where process modelling was applied in conjunction with an industrial 
pilot process for an equilibrium controlled aqueous phase reaction process (the Williamson Synthesis) 
operated in semi-batch mode. The aim was to develop a combined kinetic, reactor and controller model 
(based on very limited kinetic data) in order to determine an operating policy which maintained the 
primary reaction while minimising the secondary reaction. A reasonable agreement between the model 
and the limited experimental data was achieved and simulation experiments were able to indicate the 
possibility for improved yield and reduced reagent loads. However, this article exemplified one of the 
inherent risks in expending modelling effort during the process development stage in the pharmaceutical 
industry, in that the process was abandoned by the company. 
The multi-step batch reaction and distillation sequence example given by Allgor et al. (1996) provides a 
useful view of the type of information available in the development of an industrial process for a speciality 
chemical. It is shown that the use of an integrated process modelling and development methodology 
allowed the modification of a laboratory operating policy to a feasible one in the plant scale equipment. 
This required the use of physical property estimation methods and rigorous process models which 
captured the limitations imposed by the equipment. They justify the need for a systems approach through 
the determination of optimal inter-unit trade-offs between the key reaction process and downstream 
separations. 
Concerning the development of reaction kinetics, there seems to be some significant advances. Once the 
reaction kinetics have been ascertained they can be incorporated into a process model and be used to 
accelerate scale-up and determine the best operating policy. Bollyn et al. (1995) provide one industrial 
example where reaction calorimetry data was used to determine between four proposed reaction 
mechanisms and kinetic schemes for a multi-step catalysed oxidation reaction. They developed a process 
model and validated the best operating policies determined from model simulations with pilot plant data, 
identified parameter sensitivities which were not obvious from the laboratory experiment and modified 
and validated the model with respect to the manufacturing equipment. It was claimed that this combined 
process modelling approach allowed fast scale-up for a safe and economic process with only a few pilot 
plant runs. Sano et al. (1998) provide a similar account in the development of a reaction process model for 
a pharmaceutical intermediate. They used this model to determine the optimum operating policy 
accounting for the limited cooling capacity of the plant vessel. 
2.4 A future vision 
it is widely agreed that a new approach to process development is required in order to reduce development 
times and resources, improve the quality of processes and would ultimately determine the success of 
competing companies in the future (Basu et al., 1999, Shah et al., 1999, Stephanopoulos et al., 1999). 
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Invariably such an approach would focus on a long term vision for cost-effective process development 
involving improved interactions between chemists and chemical engineers and/or the use of systematic 
methods to improve the fundamental understanding of the process for more efficient scale-up and process Z__ 
optimisation. 
The perception of a model-based approach in one such vision from within the pharmaceutical industry is 
summarised. Basu et al. (1999) proposed the use of a process vision in which all the requirements of a 
good quality process are met and one that is applicable to the efforts of all the stakeholders. They envisage 
that the integration of computational techniques (process synthesis and process modelling) with the 
necessary experimental methods would improve the both the efficiency of the process development and 
the quality of the processes in a more systematic approach. The development of models describing the 
entire process would be conducted after the embodiment of the process vision and identification of the 
optimum process from the synthesis. The process modelling application steps involve: 
" determining the experimental data required to substantiate the model, 
" running the experiments to collect the data, fit the model parameters to the data, 
" improving the model, 
" validating the model by laboratory and kilogram scale experiments and pilot plant runs, 
" coupling the model with pilot and manufacturing plant equipment specifications and operating 
policies, 
validation and sensitivity analysis of the equipment model to support technology transfer into the 
manufacturing plant. 
These cycles are compatible with the systematic model building procedure presented by Hangos and 
Cameron (2001) shown in Figure 2.2, where the data required to improve and validate the model can be 
collected from the necessary scale-up runs and additional experiments. In addition, the data collected from 
failed runs should be used to rigorously validate the model. The structural characteristics, accuracy and 
reliability of the models depends on the quality of the data and assumptions upon which they are based. 
The development of a tool based on a reliable model of the entire system based on the physico-chemical 
phenomena and equipment specifications aims to support the answers to some of the process conundrums 
posed by the complex interactions between upstream and downstream operations, make scale-up more 
robust and assist in technology transfer and process validation in both the pilot and manufacturing plants. 
This is a new approach which would require a significant shift in current attitudes and efforts towards 
process development. Yet the potential benefits are recognised to be very worthwhile. This view (and that 
of others) is essentially a long term one, waiting for the development of the tools suitable to the needs of 
the stakeholders and one which may require the reallocation or introduction of a skills base in model 
development techniques if such expertise is not already present in the current workforce. 
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Figure 2.2. A systematic approach to model building (Hangos and Cameron, 2001). 
2.5 Conclusions 
In this chapter the background and main challenges and implications associated with process development 
in the pharmaceutical industry have been discussed. It is clear that there are many unique pressures which 
shape the current culture of process development. A brief review of some of the current applications of 
modelling approaches observed in development was made. From the literature it appears that actual 
implementation of process modelling approaches are mainly limited to reaction and distillation processes. 
This may be due to the poor perception that industry has of the current status of modelling and the quality 
of predictions, for example in models predicting physical properties and solid phase processes. 
The advance of reaction calorimetry techniques now permits the construction of detailed mechanistically 
derived dynamic equations to describe reaction kinetics. With this understanding it should be possible to 
use process models to accelerate the scale-up of reactions, reduce scale-up failures and optimise the 
process with reduced number of pilot plant runs. 
An ambitious future vision for the integration of model-based techniques with experimental effort is cited 
is envisaged. This vision is dependent on the available in which modelling of the entire process II modelling 
technologies, software tools and current attitudes. The aim of the work presented in this thesis is to 
substantiate the use of a model-based approach which may be appropriate within such a vision with the 
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explicit consideration and management of model uncertainty, so far not encountered for complete 
pharmaceutical process sequences. 
In the next chapters the expression and analysis of model uncertainty are investigated and a review of the 
main techniques available for optimisation under uncertainty follow. 
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CHAPTER 3 
SOME ASPECTS CONCERNING UNCERTAINTY IN MODELS 
3.1 Introduction 
In the previous chapter some of the current issues in process development in the pharmaceutical industries 
were discussed. Views towards the potential benefits that process modelling could bring to this field 
indicate their worth but there remain some limiting factors to practical implementation. However, some 
industrial examples of combined modelling and process development success have been highlighted, 
though these appear only to concern reaction processes and not complete process sequences. Some recent 
approaches promoting the use of model-based support in batch process development were identified and a 
future vision for pharmaceutical process development was made in which process modelling provides a 
major contribution. 
In any decision making process where the data or information available upon which decisions are based 
may be uncertain and where the entailing course of action involves a risk of significant consequence then 
quantitative risk assessment studies provide a valuable support tool (Haimes et al., 1994). In this chapter 
uncertainty in process model systems is considered. With the consensus that systems process modelling 
can significantly benefit the process development and since the models represent the current knowledge of 
the process in mathematical form, it becomes clear that assessment of the effects that this uncertainty in 
the process knowledge may have on the performance should not be overlooked. 
The problem under uncertainty is defined in Section 3.2. Possible sources and characteristics of 
uncertainty are discussed in Section 3.3. Quantitative methods to deal with uncertainty in a stochastic 
process model system framework are examined. These techniques form the basis for Uncertainty and 
Sensitivity Analyses in a Risk Analysis type approach (Section 3.3 and Section 3.4). The entailing 
information provides a platform for the management of uncertainty (or risk management). Some past 
applications of these methods are discussed, in particular those relating to chem=ical engineering 
applications (Section 3.5). The capacity of different techniques in satisfying the identified important 
properties are compared and the approach and techniques deemed most applicable to the types of 
problems concerning this thesis are discussed in Section 3.6. 
3.2 Defining the problem under uncertainty 
The framework for the stochastic system considered in this work consists of a process which in this work 
is represented by a deterministic model of the chemical process with uncertain parameters. Three 
assumptions define the Uncertainty Analysis problem considered in this work: 
0 the deterministic model is not structurally incorrect, 
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0 process knowledge uncertainty represented by uncertainty in the parameters of the deterministic model 
is more important than natural system variability, 
the uncertainties are random as opposed to systematic. 
Models are only imperfect mathematical representations of observed reality and model parameter 
uncertainties arise from a lack of firm theoretical basis, simplifications and assumptions and/or poor 
quality modelling data. Uncertainty associated with errors in the model structures are not explicitly 
considered in this work. To a limited extent uncertainties in the model parameters may be assumed to 
account for structural errors (Pinto, 1998). In this work the analyses assume parametric errors. 
In the context of chemical engineering process systems, Pistikopoulos (1995) classified parametric 
uncertainties in process engineering into four types: 
" model-inherent, including kinetic constants, physical properties, transfer coefficients, 
" process- inherent, including flowrates, temperatures, stream qualities, 
" external, including feed stream availability, product demand, prices, environmental conditions, 
" discrete, equipment availability and failures. 
This thesis is concerned with parameter uncertainties associated with the first two types where the 
operation of the process to obtain a desired product is of interest. Within the confines of the process 
model, the model inherent uncertainties range from parameters describing physical properties, intrinsic 
phenomena, extrinsic phenomena and to those factors assumed to describe the possible effects of 
phenomena which are not explicitly described in the models due to a complete lack of data or 
understanding (i. e. in a black box approach). These provide the uncertain inputs to the stochastic system 
considered in this work. The latter two types are associated with the planning and scheduling of multi- 
product or multi-purpose plants and equipment reliability aspects. 
A distinction should be made between uncertainty and variability. The former is due to a lack of 
fundamental knowledge in the process phenomena or property and can be reduced by increasing the 
knowledge. This is commonly termed as subjective uncertainty and is a property that is determined by the 
understanding of the analysts and the level of modelling permitted. The latter is an inherent property of the 
system and cannot usually be reduced. This is commonly termed as stochastic uncertainty. It is not 
generally possible to totally separate them. With the emphasis on the management of incomplete process 
knowledge contained in process models, model parameter uncertainty is the relevant property to which 
efforts can be made to reduce the uncertainty in the system (by improving the knowledge). In a rigorous 
stochastic description of the process system both parameter uncertainties and system variabilities (if 
present and can be realistically characterised) should be considered simultaneously to determine the 
combined influences and the relative worth of management actions aimed towards reducing the parameter 
uncertainties. 
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Computational and time resource may exert limits on the accuracy which can be obtained with some 
Uncertainty and Sensitivity Analysis methods. In this work the emphasis is not on extremely large 
computationally intensive models (as may be observed in nuclear, geophysical, environmental or business 
model applications which may take hours to solve a single realisation) but rather on integrated sequences 
of deterministic models in a process systems engineering framework for which a single simulation is 
expected to take the order of seconds to solve. The individual models need to capture the key process 
behaviour without extreme complexity. This permits a little more relaxation and flexibility in the analysis 
techniques available, compared to the experimental designs formulated for physical experiments and 
intense computational models. 
3.2.1 Relation between data and model parameter uncertainty 
The quality and quantity of the data available to build process models obviously has a large influence on ZD 
the uncertainty associated with the parameters of the resulting models. Experimental and plant data may 
contain systematic errors, erroneous data and outliers. While this work does not specifically consider 
systematic errors, the effect of limited or erroneous data or data outliers contained in the experimental or 
plant measurements is discussed. 
The presence of erroneous data and outliers are associated with the model parameter estimation problem 
within the model building process (see Figure 2.2, Section 2.4). Their presence in model parameter 
regressions are passed as uncertainty estimates in the optimal parameter values. They can provide a 
significant source in the uncertainty estimate, quantified according to the methods employed to estimate 
parameter confidence intervals and regions (discussed in Section 3.3.3.1). Weighted regression methods 
can allow for identifiable data outliers. If only limited data is available and the regression is based on only 
a few data points then it becomes harder to confidently identify and accordingly weight outliers and so a 
greater degree of uncertainty is likely to be apparent in the resulting parameter estimates. Alternatively, if 
only a single data point or observation is available from which a model parameter value is assumed then it 
is clear that error in this data will have a considerable effect on the assumed value. In this case the 
associated parameter uncertainty is subjective to the analyst and the possible error should be accounted for 
accordingly. 
Since conventional estimation methods assume stable probability distributions (often normal or uniform) 
for parameter uncertainties then the problem of extreme data points is negated concerning the 
implementation of Uncertainty Analysis techniques (which place observations based on the 
characterisation of input probability distributions). Only in the case where input uncertainty distributions 
are directly developed from raw measurement data, for example some process inherent influences such as 
feed quality, will the problem of data outliers and associated unstable distributions directly affect the 
implementation of certain Uncertainty Analysis techniques. Some of the techniques discussed in the 
following section account for considering extreme parts of input distributions. 
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3.3 Uncertainty Analysis methods 
Conventional error analysis methods can be applied to evaluate the propagation of error and uncertainty in 
measurement data and parameters to the dependent variables In simple relationships. Specific formulas are 
available and these may be compounded for more complicated situations. However, with increasing 
complexity of relationships and time dependent models, large numbers of uncertain parameters and an 
even larger number of dependent variables the practical application of these formulas are limited. To 
derive more information about the propagation effects of the uncertainties to the performance variables 
more flexible and comprehensive methods in the guise of Uncertainty Analyses are discussed. 
Uncertainty Analysis aims to provide a quantification of the uncertainty contained in a stochastic system 
in terms of the output or performance response distribution to the distributions of the inputs (subjective 
and/or stochastic). Haimes et al. (1994) advocate the use of probability distributions to express a lack of 
knowledge in Risk Analysis and to provide information to the decision maker. With this information it can 
be decided whether the observed uncertainty is large enough to affect any subsequent decision and 
whether this uncertainty is too large to make any meaningful decision in the first instance. 
Risk Analysis approaches requires typically involves a number of steps: 
* screening, 
* definition of measures for the quantification of uncertainty, 
0 definition of uncertainty space based on the available data, 
approximation of the uncertainty quantification measures within the uncertainty space, 
* Sensitivity Analysis measuring contributions of input uncertainty factors. 
These steps and associated methods concerning Uncertainty Analysis are discussed in the sub-sections of 
Section 3.3, with the exception of Sensitivity Analysis which is discussed in Section 3.4. 
3.3.1 Screening 
Screening is a method which precedes the Uncertainty and Sensitivity Analyses. If there are a large 
number of potentially uncertain factors in the system (more than a desired number of simulation runs) then 
it becomes desirable to determine those which may have a significant effect on the system response. A 
variety of methods are available to accomplish the screening. 
Perturbation Analysis is a simple technique in which deviations in the factors are systematically 
introduced to the deterministic model in turn. This can be used when the number of 
factors is not too great 
and the simulation model is not too big. Importance sampling can be used if it is desired to include of high 
consequence but low probability input scenarios in the screening. 
The entire input uncertainty space is 
split into non-overlapping regions (strata) and one observation sampled 
from each and is weighted by 
the probability of each stratum. With a large number of factors group screening techniques are often used. t: I tr 
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These are based on the principle of aggregation such that individual factors are combined into groups and Cý 
are then assessed as individuals. Low-order polynomials are used to approximate the simulation model in 
a black box manner. This simplifies the system but does not exploit the structure of the actual model as is 
done in the perturbation and importance sampling methods. Kleijnen (1997) discussed sequential 
bifurcation (SB) as a novel and efficient group screening technique which proceeds sequentiaHy, splitting 
the aggregated factors until the most important factors are identified and their effects estimated. The 
factors identified in the screening procedure may then be incorporated in more rigorous Uncertainty and 
Sensitivity Analysis methods where a larger sample can be used effectively and more insight obtained. 
In this work the Perturbation Analysis approach is considered sufficient since the problem considered is 
unlikely to contain hundreds of potential factors. 
3.3.2 Quantification of uncertainty 
In the Risk Analysis approach, to quantify the uncertainty in the performance criteria of the stochastic 
process system, the uncertain inputs need to be quantified and characterised. The uncertainty in these 
inputs are modelled by treating them as random variables. In some cases the uncertain inputs are directly 
based on physical measurement data from which a sample distribution is developed to approximate the 
population distribution. Here Bayesian techniques can be used to combine prior subjective information on 
the probability distribution function with new measured data (Draper, 1995). In this work uncertain inputs 
encompass mainly model parameter uncertainties (as defined in Section 3.2) and are not the measurement 
data sample distributions. Depending on the information available, the nature of the parameter and the 
experience of the model developer, normal or uniform distributions are often assumed for model 
parameter uncertainties. Different distributions may be apparent for other stochastic input properties 
which are directly based on physical measurements. In order to obtain relevant results to support decisions 
under uncertainty, a reasonable characterisation which represents the state of knowledge of the input 
uncertainties is an essential element of any Risk Analysis approach. This topic is discussed in detail by 
Haimes et al. (1994) in the context of practical risk assessment for decision makers. 
Particular measures in the distributed output performance criteria predicted by the stochastic system 
constitute the risk associated with a process sequence. The general function for a stochastic output 
criterion measure may be stated in terms of an expected value, E, in some function, f, for a deterministic 
output performance criterion, (D. This is expressed analytically in the probability integral given in 
Equation 3.1. This is integrated with respect to the cumulative probability distribution of the output 
criterion, CDF((D), and where 0 is the uncertain parameter. The integral in Equation 3.2 is equivalent since 
the output probability distribution function, PDF((D), is equal to the derivative of the CDF((D) with respect 
to the output, 
Elf (ý>(O))j = fol f 
((D(O))dCDF((D) (3.1) 
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f ((D(O))PDF(a))d(D (3.2) 
Alternatively, since the exact forms of the output CDF((D) and PDF((D) are both unknown, E can be 
expressed as the multi-dimensional integral over the joint probability distribution function of the 
stochastic inputs, PDF(O), 
Elf (0(0))j f 
oc, q 
f ((D(O))PDF(OPO (3.3) 
where E) is the total uncertainty space and PDF(O) is estimated from experimental data or assumed from 
conventional distributions. The two most common measures characterising a distribution are the mean 
(location) and variance (spread) parameters. The probability integral for the mean or expected value of a 
performance criterion is given by, 
Ej(D(O)j = fo,: e 
(D(O)PDF(O)dO (3.4) 
The variance is a common measure for the variability or spread of a distribution about its mean. The 
probability integral for variance is given by, 
Varj(D(O)j f 
': - 
EI(l)(0)1)2 PDF(OýO 
0 ze 
(0(0) 
(3.5) 
Variance can be strongly influenced by the presence of outliers. If outliers are assumed not to be so 
important then the width of a desired confidence interval or between lower and upper fractiles (e. g. 5% 
and 95%) can be used as a measure to quantify the uncertainty in only the bulk of the distribution. 
The square root of the variance is the standard deviation. This is another measure of variability. It may be 
interpreted as a measure according to Chebyshev's rule for any random variable and any distributi tD III ion: at 
least I- I/k 2 of the distribution or observations will fall within k standard deviations (CY) of the mean (i. e. 
pý> - k(y,,,, pýo + kcyo) for any number of k greater than 1. 
Taguchi's quality loss function is an established measure for quality in production engineering. It 
measures the cost of a loss in quality proportionally to the squared deviation in quality from a desired 
target relative to the square of the quality deviation at which point the cost is incurred (Taguchi et al., 
1988), 
L((D) =a 
(D 
- (D th 
) 
where a is the Taguchi loss proportionality constant, Z' 
(3.6) 
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C 
Tag 3 
A2 
(). 7) 
and A is the permitted tolerance in the performance from the desired threshold val ue, Oth , 
before a cost, 
CT,,., is incurred for the loss in qualit . 0y 
A variety of other stochastic criteria may also have application in Uncertainty Analysis. They can include 
deviation functions from a desired value other than quadratic. These can be linear or one-sided when only 
uncertainty above a particular threshold is important. Samsatli et al. (1998) recognised a use for one-sided 
robustness metrics in chemical processes for instances when only the violation either above or below a 
particular chemical process plant performance threshold is important and any deviations on the opposite 
side are not important. They introduced a general deviation function from which both one-sided and two- 
sided performance criteria under uncertainty can be derived. A probability of violation, Pr, i,,,, of a 
(minimum) constraint threshold or desired target, Vh, was stated, 
Prvio, t«P th - (D(O» > 01 =f:, 9 
ß«D(0»PDF(OýO 
0 
where P is a binary variable, 
(3.8) 
Iif (D th _ (D(o) ý:. 0 
10 
i q) th _ (D(o) <0 
(3.9) 
f 
and a new metric was introduced to measure the average linear extent to which a (minimum) threshold is 
violated, Evi,,,, 
Evio, 
f«Dth 
_ gb(0» > 01 = 
flg"q ß(4>lh 
- 4)(0»PDF(OýO (3.10) 
One-sided effects can also incorporated into Taguchi's quality loss function as shown by Bernardo et al. 
(1999a) where the proportionality constant (a) in Equation 3.6 may be preceded by a binary variable, P. 
3.3.3 Construction of uncertainty space 
Characterisation of the stochastic inputs to the uncertain model system form the uncertainty space from 
which the system output response is generated. This comprises of probability distribution functions t:, 
contained within confidence intervals (truncation limits) or joint confidence regions. 
The methods discussed in the next sub-section assume the availability of data with which to estimate a 
characterisation for a particular parameter or set of parameters. In the absence of sufficient data with 
which to use mathematical methods to estimate parameter uncertainty distributions, then Haimes et al. 
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(1994) recommend using expert judgement and Bounding Analysis (consideration of sensible values for 
the limits and the importance of the analytical form of the distribution). This assuming method Is 
employed in this thesis where either normal or uniform distributions are assumed. The effect of different 
input distributions may be investigated in a Robustness Analysis (Kleljnen, 1997). 
3.3.3.1 Limits for parameter uncertainties 
If parameters are estimated or assumed independently of each other, the joint sampling space may be 
described as a hyper-rectangle where each dimension represents one uncertain input bounded by its In 
respective upper and lower confidence limits. 
The sampling space for independent uniformly distributed inputs are typically characterised by upper and 
lower confidence intervals around the nominal value. If no data is available for model parameter 
estimation, confidence limits around the assumed nominal values are assumed as some percentage of the 
nominal. For uncertainty in independent parameters of assumed nominal values, desired to be 
characterised by normal distributions, the standard deviation is assumed at some percentage of the 
norYUnal value. Confidence limits around the nominal value can be assumed at some number of standard 
deviations (typically two or three deviations for approximately 95 or 99.9% probability of containment 
according to Chebyshev's rule). 
It is a common assumption that model parameter uncertainties arising from parameter estimation 
procedures based on measurement data, are normally distributed. Least squares regression is a commonly 
used parameter estimation method for which confidence intervals can be simply stated. For a model linear 
in its parameters exact confidence intervals around the least squares optimum values of individual 
parameters, 0*, may be defined as, 
<s 
(j T fpp (3.11) 
where subscript p is the index of the input uncertainty (0), s is the square root of the estimated residual 
variance computed from the residual sum of squares (RSS) between the regression model predictions, 
at the optimum parameter estimates and the measurement data, (D, 
RSS(O*) 
(3.12) 
N- P) 
F( 
RSS(O*) =1 
«Dn 
- (ýn 
(0*» (3.13) 
n=I 
and J is the Jacobian matrix of the model predictions with respect to its P parameters and the values of the 
confidence limits are defined where the value of t is taken from the Student's t-test distribution with N-P 
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degrees of freedom (number of regression data points, N, and number of parameters, P, in the regression 
model), assuming a desired level of confidence, I-a. For a model non-linear in its parameters, individual 
confidence intervals can be approximated assuming a linearisation of the model about its optimal 
estimated parameter values, 
I 10 2 
_ 
0*1 :5 
(ý )2 
pp Pp tN-P, I-"' 
2 
(3.14) 
where Vpp is the ppth element of the covariance matrix, V, and is the variance estimate of the pth model 
parameter (input uncertainty). 
In a multi-parameter model where the parameters are estimated simultaneously, a joint confidence region 
provides a more appropriate measure of the (normally distributed) uncertainty space than would a hyper- 
rectangle comprising the individual confidence intervals. For a linear model, a hyper-ellipsoidal joint 
confidence region is defined, 
of jTj(0 _ 0*): 5 S2 PFN, N-P, 1-a (3.15) 
where 0 is a vector of the model parameters and the value of F is taken from the F distribution. This is the 
distribution of a random variable, F, defined as the ratio of two independent chi-squared random variables 
divided by their respective degrees of freedom. It is commonly used in standard tests of hypotheses in 
regression. For a non-linear model a hyper-ellipsoidal confidence region is approximated by, 
PFN, N-P, 1-a (3.16) 
assuming linearisation of the model about the optimal parameter values. Parameter correlations are 
contained in the approximation to the covariance matrix. 
The likelihood method is another approximate method for confidence intervals and regions. Here the 
intervals and regions are constructed from contours of constant likelihood which may be expected to 
provide coverage of the actual confidence intervals or regions more accurately than the linearisation based 
methods. The problem with this method is the increased computational time in determining a contour of 
constant likelihood in the model responses and the difficulty in characterising the contour once it has been 
obtained (Donaldson and Schnabel, 1987). 
An exact approach for joint confidence regions is the lack-of-fit method. Donaldson and Schnabel (1987) 
state that the same disadvantages faced by the likelihood method are present in this method with a further 
increase in computation requirement in producing a contour based on both the model response and the 
Jacobian matrix. 
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Donaldson and Schnabel (1987) conclude from their general study on regression parameter confidence 
regions that the linearisation methods provide the most concise representation of information required to 
construct confidence intervals and regions, though not the most accurate. In their work on statistical 
measures of Ooint) parameter estimates from models fitted to respiratory impedance data, Lutchen and 
Jackson (1986) claim that as a first level of statistical information, the linear approximation methods for 
confidence intervals and regions can be assumed to be sufficient in capturing the main aspects of the 
parameter error. This assumption has also been made in chemical engineering applications where 
linearisation methods have used for confidence intervals and regions. For example Ma et al. (1999) used 
hyper-ellipsiodal confidence regions for their study of worst case batch process performance as did 
Rooney and Biegler (1999) In their work on optimal design under uncertainty. In this thesis it is assumed 
that linearisation methods for confidence intervals and regions are sufficient for parameter uncertainty 
estimates from least squares parameter estimations. 
3.3.3.2 Estimation of the parameter covariance matrix 
Linearisation methods for the estimation of confidence intervals and regions require the estimation of the 
parameter covariance matrix (as shown in Section 3.3.3.1). There are three common methods used to 
approximate the parameter covariance matrix. Donaldson and Schnabel (1987) state that the most 
common and easily computed estimate for the covariance matrix is, 
ý=s 2(j(o* )T J(O*))-' (3.17) 
where J(o*) is the Jacobian matrix of the model predictions at the optimal parameter estimates (0), 
estimated numerically using the first order Taylor's approximation and s is defined in Equation 3.12. The 
other linearisation methods require more information, 
ý=2 H(O .) -1 (3.18) 
ý=s2 H(O* 
)-I( 
J(O*)T J(O*) H(O*)-l 
where H is the Hessian matrix of the residual sum of squares at 0*. 
Donaldson and Schnabel (1987) conclude from their study that the linearisation method for confidence 
regions (see Section 3.3.3.1) should be constructed from the covariance matrix approximated by Equation 
3.17 since it is the simplest, most numerically stable and at least as accurate as the other two Hessian 
based variants (Equation 3.18 and 3.19). The approximation of the covariance matrix by Equation 3.17 for 
multi-parameter models is assumed in this thesis. 
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3.3.3.3 Computation of uncertainty space 
The uncertain inputs to a system may be characterised by probability distribution functions, as mentioned 
in Section 3.3. Consideration of a general range of inputs associated with individual process operation 
models integrated into a single process sequence model can result in a combination of independent 
distribution functions and a number of multi-variate distributions which may contain correlation 
structures. Depending on the exact technique used to approximate the system, these distribution functions 
are either considered independently and the correlation structures implemented after this consideration, or 
all the distribution functions are combined in a single multivariate function and the corresponding non- 
zero and zero (independent parameters) correlations combined into a single structure. These issues are 
further discussed in the following sections. 
3.3.4 Approximation methods for performance under uncertainty 
Given some definition of the space in the uncertain system inputs, in terms of limits and distribution 
character between the limits, it is necessary to quantify the propagated output performance criteria of the 
uncertain system. Due to the common use of highly non-linear input probability distributions (i. e. normal), 
complex (deterministic) model equations and threshold constraints it is often very difficult or impossible 
to determine the system output probability distribution function or non-linear probability integral 
measures (see Section 3.3.2) analytically. Instead approximation methods are used. 
For computationally demanding deterministic models within the probability integral (see Equation 3.3), 
approximation of the actual model can be used. Tatang et al. (1997) proposed a probabilistic collocation 
method which uses this approach for Uncertainty Analysis of complex geophysical models. The response 
surface of the actual model is approximated using orthogonal polynomial functions of specified order of 
the input uncertainties. A sampling technique is then used to approximate the output distribution through 
simulation of the polynomials. The response surface needs to be well approximated by a low order 
polynomial expansion and may produce errors if the actual model contains discontinuities. In addition, 
this method relies on the uncertain inputs being independent. 
Alternatively, f((D(o)) can be computed directly in scenario based approaches to the multi-dimensional 
integral approximation. These approximation approaches typically locate observations within the input 
uncertainty distribution space at which the actual deterministic model is solved. They may be classified 
into sampling techniques based on either pseudo-random or low discrepancy number generators or on 
numerical integration approximation formulas. 4-1 
Different approximation methods for output performance and the main advantages and disadvantages with 
respect to the issues stated above are discussed next. The different Uncertainty Analysis approaches are 
surnmarised in Table 3.1. 
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Table 3.1. Summary of propagated uncertainty quantification methods for Uncertainty Analysis. 
Method Key features 
Differential analysis Estimation of local uncertainty using Taylor series expansion requiring partial 
derivatives. E and Var approximated using variance propagation techniques. 
Response surface Approximate model of the response surface based on a simulated experimental 
methodology design to place parameter observations. E and Var approximated from the 
response surface model. 
Monte Carlo sampling Based on pseudo-random number sequence to estimate E and Var. Requires many 
(MCS) observations to converge but this number is independent of the dimension. 
Latin hyper-cube Variance reducing stratification approach ensuring full coverage of input 
sampling (LHS) distributions to give better performance than MCS. May have poor uniformity 
properties with increasing dimensions. 
Harnmersley sequence Based on low discrepancy (high uniformity) quasi-random number sequence. 
sampling (HSS) More efficient than MCS but is dependent on the dimension. 
Equal probability Stratified approach based on sampling from level sets of equal probability in 
sampling (EPS) parameter space. More accurate confidence regions for highly correlated 
parameters. 
Quadrature numerical Numerical approximation technique based on solving Legendre polynomials. High 
integration accuracy but number of collocation points is exponentially dependent on the 
dimension. 
Cubature numerical As for quadrature with reduced accuracy but significantly more efficient requiring 
integration fewer collocation points for certain situations (e. g. normal probability 
distributions, < 10 dimensions). 
Fourier amplitude Transforms multi-dimensional uncertainty space into single dimensional Fourier s- 
sensitivity test (FAST) space. Fourier transform pattern search covers s-space for the approximation of E 
and Var. Increased efficiency and coverage due to integration over one dimension 
in s-space but not applicable for correlated parameters. 
3.3.4.1 Differential analysis 
Differential analysis Is a method used to quantify the local uncertainty about a nominal set of parameter 
values based on a Taylor series expansion. The effects of perturbations are often approximated with first 
order terms, 
d 
1: 
f (0*), 
ýo 
P=j 
dOp P 
(3.20) 
where (P is the output performance, 0* is the vector of nominal values of the uncertainties, 
AO is the vector 
of perturbations in 0 and p is the index of the uncertain factors. Higher order expansions are possible if the 
necessary partial derivatives can be reasonably obtained. Variance propagation techniques can 
be used to 
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estimate the expected performance value, E((D), and the variance, Var((D). For first order Taylor series 
expansion terms, these estimators are given by, 
d(f (0*»- 
E(AOP) 1 
dop 
p 
a(f (0*»- 
2pp- 
d(f (0*» - d(f (0*»- 
Var«D) Var 0 +2y ,y 
(3.22) 
p=I 
d0 p) dOp dor 
Cov(op 90r) 
p p=I r=p+I 
where Cov is the covariance. 
3.3.4.2 Response surface methodology 
An approximation to the response surface of the model in the space of the uncertainties can be developed 
for use in Uncertainty and Sensitivity Analyses. An experimental design is used to obtain input parameter 
scenarios at which points the original model is simulated. Kleijnen (1997) discussed the use of factorial 
and fractional factorial designs of simulation experiments to determine which factor combinations are 
required to maximise the accuracy of the factor effects when the simulation time for large deterministic 
models is limiting. A surface response is constructed from these simulation results, usually based on least 
squares techniques. A response surface based on first order terms is given by, 
p 
b, + jbPOP 
P=l 
(3.23) 
More complex response surfaces involving higher orders, cross-products or based on polynomial fits can 
be used. Equations estimating the expected value and variance are based on the response surface model. 
Based on the first order response surface the expected value and variance can be estimated, 
p 
E((D) = b, + bp E(OP) (3.24) 
P=j 
ppp 
Va r «D) = 2: b2 Var(OP) +22: bb 101) 
(3-25) 2: 
rCOV p, p (OP 
P=l p=lr=p+I 
Alternatively, a sampling technique can be used to place scenarios in the response surface (Equation 3.23) 
and E and Var can be obtained from the sample estimations. This provides an estimate 
for the distribution 
in (D at little computational cost but requires a good approximation of the true response surface. 
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3.3-4.3 Sampling based techniques 
Sampling based techniques allow the performance response to be estimated over the entire space of the 
uncertainties. The selection of successive inputs to obtain the information on the stochastic output is very 
important when it is desired to keep the number of observations low for computational efficiency reasons. 
Whatever the sampling technique, the deterministic model is simulated at the observed values of the 
stochastic inputs located by the sampling strategy. This placement is based on the distribution 
characteristics of the input uncertainties. Sample based measures are used to approximate the integral 
quantities defined in Section 3.3.2. Common statistical measures may be applied to quantify different 
aspects of the generated sample output distribution, such as the sample expected value and variance 
(sample estimates for the probability integrals given in Equations 3.4 and 3.5, respectively), 
m 
EI(D(0)1=-' j(D(O,, ) 
m 
M=l (3.26) 
Varl(D(O)l =Ij 
((D(O,, EI(D(O,,, )1)2 
mI 
M=l (3.27) 
The sampling based techniques are flexible to the estimation the probability of performance threshold 
violation and expected extent of (minimum) threshold violation (see Equations 3.8 and 3.10, respectively), 
Prvio, goth - tv ol= 
iM 
(3.28) (0» >-1ß. «D , 
(0» 
m m=I 
m 
Evio, eth _«)(, 9»>01= 
1 Y, ßm (e 
m 
(0»«p th 
_ (p m 
(0» (3.29) l( Mm=l 
where the binary variable, P, is defined in Equation 3.9. 
Monte Carlo, Latin Hyper-cube, Hammersley and Equal Probability Sampling strategies are discussed. 
These methods differ in the properties of the number sequences generated. There are basically two 
important properties: randomness and uniforrnity. Diwekar and Kalagnanam (1997) state that since the 
error of approximating an integral with a finite sample depends on the equidistant properties and the fact 
that there is usually no physical significance between successive sample observations in real applications, 
the uniformity of a sample is more critical than the randomness in the approximation of a uniform 
distribution. Discrepancy or dispersion is a measure of sequence density and quantifies the deviation of a 
number sequence from a uniform distribution (Lambert, 1988). Quasi-random sequences provide low 
discrepancy (good uniformity) and provide more accurate integration approximations than pseudo-random 
sequences for a specified number of observations. 
The most well known and commonly applied sampling technique is based on Monte Carlo pseudo-random 
number generation methods (MCS). A pseudo-random number sequence s Lgenerated to approximate 
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uniform coverage over a P-dimensional unit hyper-cube. These observations are inverted over the 
cumulative distribution functions of the input uncertainties. Typically a large number of observations are 
required to converge to a reasonable accuracy and on average the number of observations, M, required to 
maintain a probabilistic integral approximation error within E, is proportional to E-2 (Wozniakowksi, 
1991). This is independent of the number dimensions, P. 
Latin hyper-cube sampling, LHS (McKay et al., 1979) is a more thorough stratified approach than 
importance sampling (previously discussed as a screening method in Section 3.3.1). In LHS full coverage 
of the range of each input uncertainty is ensured. The probability distribution of each stochastic input is 
split into equal intervals of probability from which one input value is chosen at random and is weighted by 
the distribution. These weights replace the M and M-1 reciprocal weights in the sample mean and variance 
estimations (Equations 3.26 to 3.29). Values from one distribution are randomly paired with values from 
the others and once selected they are not replaced. In this way M-P tuplets of input observations are made. 
During this selection it is assumed that each input is independent and any correlation structures are 
implemented afterwards. Median LHS is a similar approach except the input values are not selected 
randomly from each interval but are the median values. There is no theoretical error bound for stratified 
methods but studies have shown LHS to be significantly more efficient than MCS (McKay et al., 1979, 
Diwekar and Kalagnanam, 1997). 
The Hammersley sequence sampling (HSS) scheme, introduced by Diwekar and Kalagnanam (1996 and 
1997) is based on a variant of the low discrepancy Hammersley sequence. HSS is a quasi-random Monte 
Carlo scheme which constructs a quasi-random sequence which performs better than pseudo-random 
Monte Carlo. They present an algorithm which generates the Hammersley points which place M points of 
coverage inside a P-dimensional unit hyper-cube in a low discrepancy design. This design has better 
uniformity properties in P-dimensions than MCS, LHS or median LHS. A disadvantage is that the 
convergence accuracy is also dependent on P but in general it is more efficient with the minimal number 
of samples (M) required to guarantee an average case error (F-) is of the order F--'[Iog(F, -)](P-')2 
(Wozniakowksi, 1991). This relationship for HSS is compared to the MCS for values of P (in HSS) at 2,5 
and 20, shown in Figure 3.1. 
Iman and Conover (1982) introduced a rank correlation technique to induce desired correlation structures 
between independently generated inputs from sampling based techniques. The advantages of this 
technique is that it is independent of the types of input distributions, simple to implement and the values of 
the original (uncorrelated) sample observations are retained so that the structure of the sample is 
unaffected. This is important for stratified sampling procedures such as LHS. The technique is based on 
the reordering of independently generated input samples according to the ranking order of a transformed 
matrix of arbitrary scores which is assumed to have a rank correlation matrix close to the user supplied 
target correlation matrix. Iman and Conover (1982) applied this to LHS using an arbitrary matrix of van 
der Waerden scores. Diwekar and Kalagnanam (1997) implemented this technique in the FISS with an 
arbitrary matrix of Hammersley points. 
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Figure 3.1. Comparison between orders of error for HSS and MCS sampling. 
Key: -= MCS . ..... = HSS (P = 2), ---- = HSS (P = 5), = HSS (P = 20). 
Vasquez et al. (1999) introduced a new Equal Probability Sampling (EPS) technique for non-linear 
models. EPS combines a random sampling technique with the generation of level sets of probability 
(closed hyper-surfaces) in the stratified parameter space, such that each point on a set is equally likely. 
More accurate confidence regions can be produced than those based only on the covariance matrix, when 
the parameters are highly correlated. The probability distribution of the parameter estimation regression 
objective function, the residual sum of squares (RSS), is stratified into intervals of equal probability which 
are inversed to form the level sets in the parameter space. The EPS method randomly places sample points 
in each level set to approximate the RSS probability distribution. 
3.3.4.4 Numerical integration techniques 
Numerical integration techniques can also be used when the distribution function is known or can be 
approximated. These are not based on the random or low discrepancy generation of input scenarios of 
equal weighting. The scenarios are simultaneously located and weighted according to the satisfaction of 
some particular condition. Gaussian quadrature and cubature methods are discussed. 
Gaussian quadrature is a common numerical approximation method for multi -di mens ional integrals. It has 
been applied in optimal cherrucal process design under uncertainty approaches by Straub and Grossman 
(1990,1992,1993), Pistikopoulos and lerapetritou (1995) and Terwiesch et al. (1998). Quadrature points 
are located in the [-1,1] interval at the roots of the relevant order Legendre polynomial (based on the 
desired number of points). These points are then transformed into the actual space given the bounds. Each 
point is assigned a weight according to its location and Legendre polynomial solution. The deterministic 
model is simulated at each weighted quadrature point in the input space and an output is determined to 
estimate the desired probability integral, E, for some function (possibly a deviation), f, of the output 
performance criterion, (D. The product Gauss integration formula with the transformation into the 
uncertainty space is given by, 
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P oUB - oLB 
m 
Elf ((D(Op,,, ))l fl ppIw,, (D[O(V,, )]PDF[O(v,, )] 
P=j 
2 
M= I 
(3.3 0) 
where M is the total number of quadrature points, w is weight, v is the location in uncertainty space, P is 
the total number of input uncertainties of index p, PDF is a joint probability distribution function 
characterising the input uncertainties, 0, and OUB and ()LB are the upper and lower bounds. The quadrature 
approximation can be highly accurate and efficient for low dimensional problems. 
Bernardo et al. (1999b) present specialised integration formulas for product Gauss and cubature which 
can be used to increase the efficiency and accuracy of numerical integration over the multi-dimensional 
probability distribution if the input uncertainties are normally distributed. They are constructed to 
integrate over the entire input uncertainty space irrespective of design feasibility constraints. Here 
cubature is defined as a numerical integration technique which generalises the principles of one- 
dimensional quadratures to multi-dimensional integration. Cubature formulas can be more efficient than 
product Gauss but have a reduced accuracy. Specialised formulas are specifically constructed to integrate 
over multi-dimensional space and are not the products of one-dimensional quadrature and require a lower 
number of points than the product Gauss formula. 
The definition of the multi-variate normal probability distribution function incorporates the correlation 
structure via the covariance matrix, 
[_ 1 (0 
_ M)T 
ý(0 
_ M)] N exp - 
(det 2 (27r) 2 
(3-31) 
where det V is the determinant of the covariance matrix, 0 is the matrix of uncertain input observations 
(the collocation points in the uncertainty space) and g is the vector of nominal values. 
3.3.4.5 FAST method 
The Fourier amplitude sensitivity test (FAST) procedure introduced by Cukier et al. (1973) was 
developed to approximate specific criteria such as the performance mean and variance criteria and global 
sensitivity coefficients. The Uncertainty Analysis aspect is discussed here (mean and variance) and the 
FAST sensitivity indices are discussed later in Section 3.4.3.3. The FAST method is based on the 
transformation of the P-dimensional integral over the joint probability distribution characterising the input 
eved by us' uncertainty space into a one-dimensional integral over Fourier s-space. This is achi ing an 
appropriate Fourier transformation function, G, for each input factor, Op, 
Op = Gp 
(sin cops) (3.32) 
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where (o is the angular frequency, and s Ei (-n, 71) is a scalar. This allows the estimation of the output mean 
and variance from integrals over a single dimension in s. 
7r 
EJ(Dj ff (s)ds (3.3 3) 
27r 
-7r 
7r 
Varfd)l ff 2(+S - 
[EI(DI] 2 (3.34) 27r 
- 7r 
-2 A2+B 2) (3.35) Y( ii 
j=l 
where f(s) is a function of the G, and A and B are the Fourier coefficients which are integrals in one- 
dimensional s-space. Application of the FAST method for the Uncertainty Analysis requires the 
simulation of the deterministic model over a sample of observations in s-space for the numerical 
integration of the Fourier coefficients. The range in s is discretised into equally spaced points for a set of s 
observations which are transformed to the actual input factor values via each Fourier transform G 
(Equation 3.32). This is a pattern search method as opposed to a random Monte Carlo type placement. 
The deterministic model is simulated at each input factor co-ordinate. The choice of the Fourier 
transformation function determines the search curve which aims to sample the input. factor space 
according to the probability distribution of the input. The magnitude of the frequency determines the 
uniformity and density of the coverage obtained in the input uncertainty space. 
A range of techniques for the approximate quantification of performance uncertainty under input 
parameter uncertainty have been addressed in this section. Related to these Uncertainty Analysis 
techniques is the application of a variety of methods and measures by which contributions towards the 
propagated output uncertainty may be identified and quantified, in Sensitivity Analysis. Therefore before 
the selection as to the most appropriate Uncertainty Analysis approach to the problem considered in this 
thesis is made, the Sensitivity Analysis techniques are reviewed. The applicability, advantages and 
disadvantages of the combined analyses are identified in the discussion (Section 3.6). 
3.4 Sensitivity Analysis methods 
Sensitivity Analysis aims to identify the major contributions to the observed uncertainty in the output 
predictions as an alternative to the subjective examination of multiple sets of scatter plots. With regard to 
the contributions of the uncertain inputs to the stochastic system, Sensitivity Analysis provides 
quantitative measures of the strength of certain relationships between the uncertain parameters to the 
predicted output variables. There are many different methods for global Sensitivity Analysis (see Saltelli 
et al., 2000a and 2000b) and these measures are mainly classes of the variance-based methods. Table 3.2 
provides a summary of the sensitivity measures. These are defined and discussed in the following sub- 
sections. 
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Table 3.2. Summary of Sensitivity Analysis methods and measures. 
Method Key features 
Ceretis paribus Informal approach based on introducing independent deviations in turn to measure 
(one at a time) (first order) effect on output. 
Differential analysis Partial derivatives provide a normalised local sensitivity coefficient and an 
estimate of the fractional contribution of a parameter to the output variance. Often 
difficult to obtain the partial derivatives. 
Response surface Normalised coefficients of the response surface model provide first order factor 
methodology sensitivities. Accuracy depends on how well the response surface predicts reality. 
Correlation coefficient Sample based measure for linear relationships. Simple to compute but susceptible 
(CC) to spurious correlations. 
Standardised regression Sample based linear measure of the 'standardised global influence' of an input. It 
coefficient (SRQ is not susceptible to spurious correlations. 
Partial correlation Sample based linear measure of input factor importance excluding the effects of 
coefficient (PCC) other factors. 
Rank transformation Transformation for sample based measures which negates the strong influence of 
outliers and resulting first order measures are applicable for non-linear but 
monotonic relationships. 
Correlation ratio Variance based importance measure for global sensitivity analysis. Measures 
(CR) contribution in non-linear and non-monotonic relationships. 
Sobol' index Variance based importance measure for global sensitivity analysis. Amenable to 
(So) computation of total effect indices. 
Fourier amplitude Transforms multi-dimensional uncertainty space into single dimensional Fourier s- 
sensitivity test space. Fourier transform pattern search covers s-space for the approximation of E 
(FAST) and Var. Increased efficiency due to integration over one dimension but not 
applicable for correlated parameters. 
3.4.1 Some sensitivity measure definitions 
3.4.1.1 Informal sensitivity coefficient 
Measurement of the effect on the deterministic model performance criteria under individual perturbations 
in each uncertain parameter from its nonunal value while the others parameters are 
fixed at their nominal 
or mean values is also known as the ceteris paribus or one at a time approach. As previously stated this 
approach has also found application as screening process for the Uncertainty Analysis 
(see Section 3.3.1). 
and these effects may be also considered as first order sensitivity measures. 
This sensitivity or 
perturbation coefficient, PC, may be estimated as a relative change in performance, (D, 
for a fixed 
deviation in a particular uncertain input, AOP, 
/ D' 
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Pcp = 
O(Op* + AOP) - 10(0p*) 
0(0*) 
3.4.1.2 Differential analysis coefficients 
(3.36) 
The terms computed in the differential analysis approach for Uncertainty Analysis (Section 3.3.4.1) can be 
used to compute Sensitivity Analysis measures. The partial derivatives from the first order truncation of 
the Taylor's series, af(O*)/aOp (see Equation 3.20), may be used to form a normallsed sensitivity or 
differential coefficient, DC, 
DC --`: 
df (0 *) op* 
p dOp 4D(O*) 
(3.37) 
The DC measures the effect on the performance due to a perturbation in an input parameter from its 
nominal value. Additionally, for a first order Taylor series approximation the fractional contribution to the 
output variance, FCV, of an input uncertainty, Op, may be estimated, 
df (0*) Var(OP) 
FCVP =-- (3.38) dOp Var((D) 
3.4.1.3 Response surface coefficient 
Response surface parameter sensitivities, RSC, may be obtained from normallsation of the coefficients of 
the response surface (Equation 3.23), 
RSCP = 
bp E(Op) 
E((D) 
(3.39) 
which are analogous to the differential coefficients given in Equation 3.37. The RSC measures the 
importance of each 0 with respect to equal sized perturbations from the nominal. 
3.4.1.4 Correlation coefficient 
Correlation coefficients (CC) provide linear measures of the Input contributions. The square of the CC 
represents the fraction of the variability in the output explained by the total variability in an input. The 
sensitivity interpretation is lost if the inputs are correlated and accordintgly they are susceptible to spurious 
correlations which may be present in a limited sample over multiple dimensions. The Pearson product 
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moment sample correlation coefficient (CC) is estimated from the covariance between the output sample 
and the input, divided by the corresponding standard deviations, 
ccp 
SSaep 
ss'Dasso 
POP 
(3.40) 
where subscript p is the index of the uncertain inputs, SSpe is the sum of products of the distances of the 
performance, (D, and input uncertainty, 0, values from their means, SS(I), p and SSO() are the sum of squares 
of the distances from the means of (D and 0, respectively. 
3.4.1.5 Standardised regression coefficient 
Standardised regression coefficients (SRC) can be estimated in the presence of correlated inputs and may 
be compared to the CCs to avoid misleading interpretations due to spurious correlations. In contrast to 
CCs, the square of the SRC represents the fraction of the output variability which is explained by the 
variability in the input not due to any of the other inputs. SRCs are first order sensitivity measures and 
may be interpreted as linear measures of the 'standardised global influence' of each input on the output, 
Hofer (1999). The benefit of standardising the data is the provision of a measure which is independent of 
the subjective input probability distributions and the values can be directly compared with each other. 
SRCs are the coefficients of the multi-linear regression problem minimising the sum of squared errors 
between the standardised output data and the regression model output. They are derived from the 
regression coefficients, b, determined from the following multi-linear regression, 
p 
(D m= 
bo +I bp Op, + Em 
P=j 
(3.41) 
where (ý is the regression model output prediction, F, is the residual error (from the actual outputs, (D) due 
to the linear regression model approximation and subscripts m and p are the indices for the observation 
number and the uncertain factor. Given b, then the regression model can be expressed in standardised 
form, 
p 
(D std, m 
I SRCP op, std, m 
P=j 
where 
SRCp = 
bpso 
p 
S4) 
op'm - OP 
Op, 
sid, m - SO 
p 
(1) m- (1) sid, m - S, v 
(3.42) 
(3.43) 
(3.44) 
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0 and (D are the sample means of 0 and (D ,s is the sample standard deviation and the subscript std 
represents a standardised value. 
3.4.1.6 Partial correlation coefficient 
The partial correlation coefficient (PCC) measures the strength of the correlation between the output, (D, 
and a given input, Op. after adjustment for any effect due to correlation between Op and 0, r#p. The 
largest PCC is associated with the input whose contribution to the multi-linear regression model is least 
adequately accounted for by the remaining inputs when it is excluded. The PCC can be determined from 
its relationship with the SRC, 
2 
(PCC )2 
= 
(SRCp) 21 
Rý, 
p2 I- Rý 
(3.45) 
where Rj' 
p 
is the coefficient of determination of the multi-linear regression of Op on (D and the 0, r=1, 
2,... P with r#p, and R2 is the coefficient of determination of the multi-linear regression of (D on the 0, r 4) 
= 1,2,... P. 
3.4.1.7 Coefficient of determination 
The coefficient of determination, R 2, is not a sensitivity measure but represents the fraction of variability 
in the sample output which can be explained in a linear function. It is a measure (between 0-1) of how 
much confidence should be taken from sensitivity measures which assume near linear relationships (CC, 
SRC, PCC). R2 is the square of the multiple correlation coefficient between the multi-linear regression 
model output and the observed sample output, 
2 RSS R=I- (3.46) 
TSS 
mm-1 
TSS «Dm - (D) (D2 -M 
«D) (3.47') 
m 
m=I 
mm 2: (D2 _bTeT(I) (3.48) RSS =1 
«Dm 
- gý m) ý.. j m 
m=I m=I 
b= 
(OTO)-IoTq) (3.49) 
where RSS is the residual sum of squares between the vector of deterministic model output observations, 
(1), and the vector of regression model outputs, (1) TSS is the total sum of squares of the distances 
between (D and the mean value, (D - Subscript m, denotes a sample observation in (D of total number M, b 
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is vector of the least squares point estimates for the multi-linear regression coefficients (which may 
computed analytically from Equation 3.49), 0 is the matrix of uncertain input observations. 
3.4.1.8 Stepwise regression analysis 
Stepwise regression allows the building of a regression model which does not include all the possible 
input uncertainties so as to avoid over-fitting problems (where the regression model attempts to fit the 
predictions of observations rather than the trends). By stepwise addition of the most important inputs as 
identified in a prior correlation analysis, the regression model is sequentially increased. Each additional 
input has the largest correlation with the uncertainty in the dependent variable (output) that is not included 
in the current regression model parameters. The change in the coefficient of determination, AR 2, with each 
parameter addition is an immediate measure of the total fraction of output uncertainty which is accounted 
for by the added parameter uncertainty. To terminate the addition of inputs, a F-test or t-test of 
significance is used to determine the probability that the additional regression coefficient has an absolute 
value larger than a value which would be obtained if there was no relationship at all between the 
additional parameter and the output. The SRC values for the final regression model can then be compared 
for contribution ranking. 
3.4.2 Rank transformation 
Rank transformation of sample observations aims to remove the effect that outliers and/or strongly skewed 
distributions may have on contributor measures, and in particular those based on regression models (Iman 
and Conover, 1979). The transformation replaces data values with their ordinal numbers and the ordinal 
(rank) data is used in the subsequent calculations and regressions. This allows the estimates for some of 
the sampling based sensitivity measures measuring the strength of linear relationships (e. g. CC, SRC, 
PCQ to be more dependent on the bulk of the sample values and less dependent on the presence of a 
small number of outliers. The rank equivalent linear measures (CRR, SRRC, PRCQ, are based on the 
strength of monotonic relationships rather than linear relationships and works with non-linear relationships 
between the input and output variables if they are monotonic. Non-monotonic non-linear relationships 
require more sophisticated techniques. 
3.4.3 Measures of importance 
Since linear relationships may not satisfactorily explain the output variability an alternative measure can 
be estimated. Measures of importance are global varlance-based sensitivity measures which are model 
independent, being able to measure non-linear and non-monotonic relationships. They can be used to 
provide measures of global importance which are not based on regression or correlation analysis and are 
able to avoid the 'curse of dimensionality' for the estimation of total effect Indices (exponential increase 
in number of interaction terms with number of factors). They can be used in conjunction with sampling 
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based coverage methods. Three measures are discussed: the approximate correlation ratio (CR), the Sobol' 
index (So) and the FAST index. 
3.4.3.1 Correlation ratio 
The correlation ratio, CR, is based on the notion that if an input uncertainty is fixed at its nominal value 
then it is an important influence if the predicted output variance is reduced by a large amount relative to 
the output variance when the input is not fixed. The square of the CR is the fraction of the output 
variability explained only by the variability In a particular Input. Analysis of variance components 
methods to estimate the CR tend to be computationally expensive (Saltelli et al., 2000), requiring many 
model evaluations. Hofer (1999) approximated the first order CR for a particular input by splitting the 
input sample set into a number of disjoint intervals which each contain an equal number of observations. 
In this way the conditional means of the outputs at given values of the inputs can be approximated, 
2= 
Vare, JEJ(DIOP 11 Eo, IVarl(DIOP 11 
CRP - VarflDj - Varf(Dj 
(3.50) 
where (D is the vector of deterministic model performance outputs, 0 is the vector of observations in the P 
pth uncertain input, Vare 
P 
and Ee 
P 
and are the variance and expectation conditioned on OPI A total effect 
CR index can be estimated by leaving all the OPundetermined and conditioning on all the 0, where r# p. 
3.4.3.2 Sobol" index 
The approach of Sobol' (1993) is based on a decomposition of the model output function into orthogonal 
summands of increasing dimensionality. Each index, So, is a ratio of the partial variance (computed from 
integration over the required decomposition terms), Dp, to the total variance, D, 
sopl,.. 
-, ps :- 
Dpl,..., Ps 
D 
for 1! ý p, <... < ps !ý 
for S sensitivity measures and P uncertain inputs. D and Dp can be approximated from simulation sample 
observations using an appropriate sampling strategy for the inputs. All the So indices sum to I and a first tý 
order sensitivity index measures the fractional contribution of each input to the variance of the output (i. e. 
the fractional contribution of OP to the variance in the output, f(O)). A second order index measures the 
interaction effect between the inputs (i. e. the part of the variation in f(O) due to Op and Or that cannot be 
explained by the sum of the individual effects of Op and Or). 
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A total sensitivity index (TSI) which measures the total contribution of a single input factor to the output 
variance can be estimated given the partial variance due to all the factors not involving the input. The TSI 
is more reliable than the first order So Index in the assessment of the overall effect of each sIngle factor. 
3.4.3.3 FAST index 
As discussed in Section 3.3.4.5, the Fourier amplitude sensitivity test (FAST) procedure of Cukier et al. 
(1973) can be used for Uncertainty and Sensitivity Analyses. FAST Sensitivity Analysis is another 
variance based approach and the global FAST indices estimate the contribution of individual factors to the 
output variance. These work for both monotonic and non-monotonic input-output relationships. The 
Fourier series representation of the original model can be decomposed to obtain these fractional 
contributions. The partial variance contribution of input factor p, DwP , requires the simulation of the 
deterministic model at each discrete value in s-space and then computation of the Fourier coefficients, A 
and B. The first order FAST indices, SFAST, is the partial variance relative to the total variance, 
D,,, 
p 
= 21 
(A 2+B2p (3.53) jw, jto 
j=l 
FAST D,,, p 
pD FAST (3.54) 
FAST i providing the angular frequencies, 4, are integers and the total variance estimate, D, is given in 
Equation 3.35. The total FAST indices (Saltelli et al., 1999) include the additional higher order effect of 
an input due to any interactions with the other inputs. 
3.5 Some past applications 
The use of Risk Analysis methods to deal with uncertainty in model systems in a quantitative manner is 
prevalent in a wide range of applications where models play an important role in structuring the available 
data into relevant information for the decision maker. 
A large amount of the literature concerning Uncertainty and Sensitivity Analysis associates methodologies 
orientated towards the use of large scale continuous or discrete time event models which contain hundreds 
of possible uncertain factors and for which a single simulation can take a significant amount of computer 
time (refer to reviews by Helton, 1993, Kleijnen, 1997, Hofer, 1999, Saltelli et al., 2000a). Methods have 
been applied to large scale models arising from a variety of applications including the fields of nuclear 
physics (Helton, 1993), geophysics (Tatang et al., 1997), environmental (Crosetto et al., 2000) and 
business and logistics (McKay et al., 1999). V 
In chemical engineering, Risk Analysis approaches involving uncertainty and sensitivity methods of the 
type discussed have gained some attention for the simulation assessment of continuous processes and in 
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particular those unit operations employing thermodynamic models and chemical reaction kinetic models 
subject to physical property and kinetic parameter uncertainties 
Diwekar and Rubin (1991) investigated a complex gasification flowsheet usincy a sample based (Monte 
Carlo and Latin hyper-cube) stochastic modelling capability in a continuous chemical process flowsheet 
simulator (ASPEN). They showed that the consideration of internal and external uncertainties in chemical 
plants was useful for a range of applications. These included performance and economic assessment, risk 
analysis, feasibility studies and for the comparison between alternative technologies. Frey and Rubin 
(1992) consolidated these views towards process development involving new technologies, emphasising 
the importance of uncertainty and stochastic modelling (using MCS) in providing information for research 
and development decisions. 
Several articles have investigated uncertainties in rigorous physical properties in chemical engineering 
applications. Nelson et al. (1983) tested the sensitivities of distillation column designs to variations in the 
predicted phase equilibrium behaviour through one at a time deviations in the average relative volatilities. 
Kubic and Stein (1986) used a fuzzy set approach for uncertainty in thermodynamic models, which was 
associated more with structural errors. Macchietto et al. (1986) measured first order sensitivities of a VLE 
flash, a superfractionation column and a multi-stage integrated flowsheet to uncertainties in the relevant 
thermodynarruc parameters and function models. They based this on Taylor series expansion and gradient 
chain-ruling. A LHS based approach is implemented by Whiting et al. (1993) and Vasquez and Whiting 
(1998) for the analysis of the combined effect of thermodynamic model parameter uncertainties 
(correlated binary interaction parameters, accentric factors, critical temperatures and pressures) on the key 
duties of a distillation column and in the predicted phase equilibria behaviour in liquid-liquid extractions. 
They used the first order SRC, PCC and the rank equivalent measures to investigate the meaning of the 
results. In a further study concerning thermodynamic uncertainties, Vasquez and Whiting (1999) 
incorporate both systematic and random experimental data errors in a MCS based approach. Here, 
systematic errors are induced into a data set through the random generation of pseudo-expert mental data 
points. The original data set are shifted to within the bias limits (defined from comparison with literature, 
standard values and from the experimental conditions) according to a representative uniform probability 
distribution. Random errors are induced from the parameter regressions based on sets of randomly 
observed experimental data points whose probability distributions are based on instrument statistics and 
any other information. The authors found that systematic errors can have a significant role in 
Uncertainty 
Analysis of thermodynamic applications and the information can support decision making in experimental 
data measurement and design. Xin and Whiting (2000) and Vasquez and 
Whiting (2000) applied a new 
equal probability sampling (EPS) technique (see Section 3.3.4.3 
for details) to analyse uncertainty in 
thermodynamic models. The former work investigated cryogenic air separation and methanol 
dehydration 
process flowsheets and the design of a runaway reaction pressure-relief system under 
thermodynamic BIP 
uncertainties. SRC, PCC and rank equivalents were used to identify sensitivity contributions. 
The latter 
work investigated thermodynamic models for liquid-liquid systems. 
Maranas (1997) a method 
for the quantitative assessment of physical property prediction uncertainty in optimal molecular 
design 
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problems under group contribution parameter uncertainties. Chance constrained programming was used to 
transform the stochastic optimisation problem to an equivalent deterministic one, bypassing the need for 
integration under the input PDF. This is discussed in more detail in Chapter 4. It was noted how important 
property prediction uncertainties were in influencing the optimal designs. Tayal and Diwekar (2001) 
considered the same problem using Hammersley sequence sampling. 
To examine the dynamic propagation of uncertainty, McRae et al. (1982) implemented the FAST 
approach to study the uncertainty in the kinetic parameters and operating conditions of a non-isothermal 
autocatalytic reaction. The method is used to attribute partial variances of each factor to the total variance 
in the product concentration as a function of reaction time. Torvi and Hertzberg (1997) introduced an 
orthogonal polynomial expansion technique for the approximation of evolving probability distribution 
functions in uncertain dynamic processes. They applied this to a non-isothermal batch reactor with 
uncertain kinetic parameters to observe the propagation of uncertainty (distribution moments and fractiles) 
in the product concentration with time. This method is limited to small numbers of uncertain factors due to 
the use of quadrature for the integration under the multi-variate distribution function. 
3.6 Discussion 
The problem considered in this thesis concerns the analysis of integrated sequences of batch and 
continuous deterministic models which maybe subject to model-inherent and process- inherent parameter 
uncertainties (defined in Section 3.2). This can result in a reasonably large deterministic process model 
but not excessively so (since distributed systems are not considered) and not one which requires a 
individual simulation time greater than the order of seconds or tens of seconds. This allows some more 
flexibility in the methods available than may be apparent for larger scale models. However, the number of 
uncertain inputs may also be quite large, in the order of tens but below probably below fifty. This means 
that although more scenario evaluations may be permitted, the dependence of the number of evaluations 
required for convergence accuracy should not be strongly dependent on the number of uncertain 
parameters for application in this work. Regarding the sensitivity techniques, flexibility of application to a 
range of different contribution measures would be useful, since the physico-chemical system maybe 
strongly non-linear in its parameters. 
A number of properties are important in the consideration between the various Uncertainty and Sensitivity 
Analysis methods and measures that have been defined in the previous sections. For the Uncertainty 
Analysis these include: 
e conceptual simplicity, flexibility and ease of implementation for different analysis situations, 
9 proper coverage of the full range of the candidate uncertainties, 
* dependence of the estimated distribution accuracy to the number of observations (deterministic model 
evaluations), 
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dependence of the number of required deterministic model evaluations to the number of input factors, 
capacity to capture the significance of outliers and erroneous data. 
The differential analysis approach has two major disadvantages. The first is that it provides only local 
information on the effect of uncertainty from the nominal point of the analysis. If the relationship between 
the inputs and outputs are highly non-linear and contains discontinuities then differential analysis will not 
be useful. No information concerning the distributions of the inputs are conveyed in the results. Also, the 
calculation of partial derivatives required for the Taylor series can be very difficult, although 
approximations can be used. These derivatives can be used directly as local measures of sensitivity. 
The response surface approach may be straightforward once the surface approximation has been 
constructed but a number of disadvantages are apparent. These are the difficulty in developing an 
appropriate experimental design if many input uncertainties are present, the difficulty in detecting non- 
linearities and discontinuities between the inputs and outputs and the difficulty in including input 
correlations. Any results from the ensuing analyses are only as good as the approximation of the response 
surface, for which an adequate construction may be difficult. The response surface approach can also give 
direct information concerning the sensitivity towards factors. 
If there is more flexibility with the number of simulations permitted for the analyses then direct sampling 
based techniques exhibit a number of desirable advantages for Uncertainty and Sensitivity Analysis. Not 
only are they conceptually simple but are also flexible to manipulation for specific situations such as the 
estimation of different statistical measures (not just the mean and variance but also one-sided deviation 
functions), they exploit the full range of the input uncertainties and the output performance distributions 
can be estimated without the use of intermediate models (allowing the direct implementation of sequences 
of models, as observed by Helton, 1993). In addition, the scenario simulation results are readily applicable 
to the direct estimation of sampling based sensitivity measures such as the CC, SRC, PCC, AR 2 and their 
rank equivalents. 
An important advantage of sampling techniques based on pseudo-random number sequences is that they 
do not always require more sample observations as the problem dimension (number of uncertainties) 
increases. In compromise, a large number (greater than 100) of observations may be needed in the first 
instance to achieve a reasonable degree of accuracy in the approximation of the integral. The pseudo- 
random number based approach of MCS is simple to implement, samples from the full range in each 
input, has a retaining nature (additional observations can be added one at a time to the current sample with 
disturbing the sample) and the number of observations to reach a reasonable accuracy is more or less 
independent of the number of uncertainties. The major disadvantages are the large number of observations 
required to obtain this accuracy and the lack of unifornuty which may be apparent in the sample. The 
stratified approach of LHS is recommended as a variance reduction technique (McKay et al. 1979) and 
compared to conventional MCS, less variability between samples is expected and a better approximation 
of the output distribution is obtained for the same number of samples. Diwekar and Kalagnanam (1997) 
state that the main drawback with LHS is that the stratification (uniformity) is one-dimensional and does 
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not necessarily provide good uniformity properties on a P-dimensional unit hyper-cube, because the 
extension to further dimensions is on a random basis. In addition, it is not a retaining method. Similar to 
MCS, the retaining nature of the Hammersley points in the HSS permits the incorporation of additional 
input scenarios without disturbance of the original observations. Kalagnanarn and Diwekar (1997) show 
that the convergence rate of samples propagated through different functions are claimed to be between 3 
and 100 times faster for HSS than the MCS, LHS and median LHS techniques, for the range of linear and 
non-linear functions and correlations structures they imposed. A disadvantage may be that the imposition 
of a correlation structure on the sample appears to change the uniformity properties of the low discrepancy 
design. The advantages of the EPS method is that it can provide more accurate Uncertainty Analysis 
predictions when parameters are highly correlated, due to better estimation of the confidence region. z: 1 
However, it is only applicable in the case when the model parameters have been obtained from the 
regression of experimental data and the residual sum of squares is available. Since the probability 
distribution of the regression objective function is required in EPS, it does not appear applicable to the 
case when subjective characterisations of probability distributions in model parameter values are assumed 
when there is no available data for parameter regression. 
Torvi and Hertzberg (1998) showed that for a given number of observations the convergence accuracy of 
a stochastic simulation of a batch distillation column, the gaussian quadrature method was better than the 
median LHS and the Halton sequence methods with MCS being the least accurate. However, the major 
disadvantage of the quadrature technique is the logarithrruc dependency of the sample number with 
problem dimension (number of input uncertainties). This makes it unsuitable for stochastic systems with a 
large number (greater than five or six) of uncertainor variable inputs. Bernardo et al. (1999) conclude that 
when the number of stochastic inputs is less than ten and are normally distributed, specialised cubature 
formulas can be obtained which are more efficient that HSS and product Gauss formulas. However, since 
the choice of the most suitable integration formula needs to be selected according to the particular 
uncertainty problem this is not conducive to a general approach. In addition, application of any of the 
discussed sensitivity measures would require the re-simulation of new scenarios. 
Helton (1993) claim that although the FAST approach allows the full range of each input to be sampled 
and the original model is simulated without modification (as for the sampling based methods), the main 
disadvantages are that many observations along the space-filling curve may be required, the underlying 
mathematical complexity (such as the use of specialised formulas to estimate statistical measures 
involving Fourier coefficients) renders it inflexible to different analysis situations and it is not possible to 
specify correlations between the inputs. 
A number of sensitivity measures have been identified in Section 3.4. Important considerations regarding 
the Sensitivity Analysis methods include: 
9 efficient estimation of sensitivity measures (dependence of the number of required deterministic model 
evaluations required and dependence on the number of input factors), 
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dependence of the sensitivity method accuracy on the additive, linear or monotonic behaviour between 
the uncertain inputs and outputs of the model, 
* capacity to capture the significance of outliers and erroneous data, 
0 capacity to measure sensitivities of main factor effect and total factor effect. 
The limitations of the ceretis paribus (one at a time), differential analysis and response surface approach 
sensitivity measures have already been identified due to the inherent problems discussed regarding the 
Uncertainty Analyses. 
Use of a sampling based technique allows a range of linear-based sensitivity measures (CC, SRC, PCC, 
AR 2 and their rank equivalents) to be estimated directly from the results of the Uncertainty Analysis 
without the need for any further simulations. These measures provide first order information on the 
combined influence of the uncertainties over the entire space. It is important to compare ranking priority 
of the contributors predicted by the CCs with those predicted by the SRCs. While the SRCs provide more 
precise information regarding the individual contributions of the uncertainty sources and are not 
susceptible to spurious correlations, the multi-linear regression from which they are derived, may be 
susceptible to over-fitting if a large number of inputs are considered. In this case the SRC contributions 
may be misleading, but careful stepwise regression can be used to avoid over-fitting problems. PCCs can 
give rmsleading of input contribution ranking importance since they measure the strength of linear 
relationships between inputs and the output after corrections have been made for the effects of other inputs 
(Saltelli et al., 2000). A factor exhibiting a large PCC does not necessarily make a large contribution to 
the output uncertainty. Hofer (1999) explains the reason is because the PCC is a quotient of parts of the 
variability in the output explained by the multi-linear regression model, as opposed to fractions of the 
variability. This means that the relation to the total variability in the output is lost and may make the PCC 
a less suitable measure for sensitivity ranking. The main limitation of these indices (CC, SRC, PCC and 
their rank equivalents) is the reliance on the assumption of near linear or near monotonic relationships 
between the inputs and outputs. 
The variance based indices of CR, Sobol' and FAST methods are not limited to near linear or near 
monotonic relationships. They are global measures of the main effect contribution of each input factor (the 
fractional contribution of the input factor to the output variance). The first order Sobol' and FAST indices 
are equivalent to the CR. The total effect indices of Sobol' and FAST provide a more accurate measure of 
individual factor contribution since they account for effects due to interactions of the considered input 
with the other inputs (i. e. higher than first order). A disadvantage of the Sobol' sensitivity indices is that a 
separate integral requiring a new sample set needs to be estimated for any measured effect (first order or 
higher), which is not required in the FAST method. The Sobol' method requires ni(2P+l) deterministic 
model simulations to calculate the first and total sensitivity indices, where ni is the sample size required to 
solve each individual variance integral and P is the total number of factors. Unless P is low and the 
Imulation time for each deterministic model is relativek low, computational resource and time could si 
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limit the use of the approach. FAST is a more efficient method for sensitivity than Sobol' indices since it 
permits the estimation of the first order and higher order sensitivity indices using the same sample- set of 
deterministic model simulations. In contrast to the Sobol' approach, the number of simulations required to 
calculate the first and total sensitivity indices is less at P(n1+1). 
Of the range of Uncertainty and Sensitivity Analysis approaches discussed, the sampling based methods 
are preferred in this thesis. In particular Monte Carlo and Latin hyper-cube strategies have been 
implemented in past chemical engineering applications (see Section 3.5). This is largely due to the 
flexibility they entail in adaptation to different analysis situations and the more informative analysis they 
permit in terms of the examination of the complete characterisation of the input uncertainty space. The 
computational effort required to achieve a sufficient accuracy depends directly on the number of 
deterministic model simulations and so an efficient sampling method is required. Of the sampling based 
methods, the Hammersley Sequence Sampling (HSS) that Diwekar and Kalagnanam (1997) implemented 
for the off-line optimal quality control of chemical process under parameter uncertainty appears to be the 
most efficient (compared to MCS and LHS) over the range of (linear and non-linear) functions verified in 
their work. In addition, the authors have already applied HSS successfully to chemical engineering 
applications (batch distillation, CSTR). Other advantages are the retaining nature of HSS, it remains 
efficient for a large number of input uncertainty factors and can be used in conjunction with the 
correlation inducement technique of Iman and Conovor (1982). The disadvantage that as a sampling based 
approach a reasonable number of observations may still need to be required to attain a reasonable 
accuracy may be acceptable due to the relatively large number of factors (greater than 5) likely to be 
employed in the complete process sequence. This makes the use of the numerical integration methods 
discussed impractical. Regarding sampling based Sensitivity Analysis measures, for essentially linear 
contributor input-output relationships, the correlation coefficient (CC) and standard regression coefficient 
(SRC) are proposed. For non-linear but monotonic relationships and to negate the effect of erroneous data 
and outliers in the input samples, the rank equivalents (RCC and SRCQ are suggested. For strongly non- 
linear or non-monotonic relationships then the approximate correlation ratio (CR) is suggested since this 
can also be estimated directly from the sample simulation results of the Uncertainty Analysis. While a 
limitation is that the sensitivity methods used to compute these measures do not encompass the 
computation of total effect indices, the essential criterion that the key contributors are identified remains 
satisfied. 
3.7 Conclusions 
In this chapter the problem of uncertainty considered in this thesis, is defined as concerning subjective 
model parameter uncertainties as opposed to stochastic variability or model structure errors. This provides 
emphasis towards the analysis and improvement of the available models. A variety of different approaches 
for risk assessment are defined and discussed in this chapter. These encompass both Uncertainty Analysis 
and Sensitivity Analysis techniques with the aim of quantifying the output performance uncertainty 
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propagated from the inputs and identifying the main contributors to this uncertainty. These tools provide 
more informed support to decisions than would single solution points and provide a basis for the 
management of uncertainty. Some of these methods have found application in the chemical process 
literature and in particular regarding the consideration of uncertainty in thermodynamic models for 
physical property prediction and in reaction kinetics. There appears to be no literature at present 
concerning the large amounts of uncertainty which may be associated with integrated process sequences 
such as those found in the pharmaceutical industry. 
A sampling based approach using the Hammersley sequence sampling strategy is selected for Uncertainty 
Analysis in this thesis. This is because of the flexibility in adaptation to different analysis situations 
(estimation of different measures associated with uncertainty) that sampling methods permit and in 
particular the improved efficiency that HammersleY sequence sampling (HSS) appears to show over 
Monte Carlo (MCS) and Latin hyper-cube (LHS) sampling methods. The sampling based approach allows 
a range of sampling based sensitivity measures to be estimated according to different input-output 
uncertainty propagation effects, without the need for any additional deterministic model evaluations other 
than those determined in the Uncertainty Analysis. 
In the next chapter optimisation methods under uncertainty are discussed. These provide a form of 
management response to the process uncertainty. The aim is to provide a more desirable response in the 
process system performance under uncertainty through the determination of new operating policies or 
process designs. 
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CHAPTER 4 
SOME ASPECTS OF OPTIMISATION UNDER UNCERTAINTY 
4.1 Introduction 
In the previous chapter a range of mathematical methods were discussed concerning the role of parameter 
uncertainties in a stochastic modelling environment. These were associated with Uncertainty and 
Sensitivity Analyses in relation to internal and external parameter uncertainties in deterministic models. 
These tools allow the quantification of uncertainty propagated in models and the identification of the main 
contributors to the observed uncertainty in the performance variables. It was concluded that an efficient 
sampling based approach would be desirable due to its flexibility for adaptation to different analysis 
situations. 
The analysis approaches discussed in Chapter 3 form the basis of a model based risk assessment to model 
uncertainty. The next logical step is risk management where actions are considered based on uncertainty 
information obtained from prior analyses. In this chapter some different approaches to optirMsation under 
uncertainty are reviewed. These may be viewed as a form of management under uncertainty which either 
consider decisions at the equipment design stage or at the operating stage or both simultaneously. For 
clarification, this thesis is more concerned with the design of the process in terms of its operating policy 
and is less concerned with the design of the actual equipment used in the process. This is because in the 
pharmaceutical industry and particularly in process development it is common to use existing multi- 
purpose equipment. However, a large proportion of the chemical engineering literature referring to 
optimisation under uncertainty is concerned with simultaneous equipment design and control variable 
optimisation. This distinction between design and control variables becomes important with the 
assumption that the latter can be adjusted for any possible realisations of the uncertainty. The assumption 
of perfect control adjustment is implicit in optimistic 'wait and see' approaches. The extent of the validity 
of this assumption depends on the ability to detect the feedback information (from on-line process 
measurements) and the quality of that information made available for closed loop control adjustment of 
certain process variables. When design and control variables are considered equivalent only a single 
operating policy is obtained in a conservative 'here and now' strategy. Since methods proposed for the 
simultaneous optimisation of equipment design and process operation under uncertainty are characteristic 
of the evolution of a significant proportion of the problem formulations for optimisation under 
uncertainty, these are included in the discussion in this chapter. 
Similar to the Uncertainty Analysis methods many OPtirnisation under uncertainty approaches involve the 
evaluation of a deterministic model of the process at particular scenarios (input sets of uncertain parameter 
values determined from specific observations in the uncertainty space). To reiterate, the 
deterministic 
process considered in this thesis consists of a sequence of integrated process models of which the general 
characteristics are: dynarruc or steady-state, lumped parameter and in general non-linear and semi- 
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empirical. The prime concern of this thesis are the uncertainties contained in the model inherent 
parameters since improvement of the fundamental process knowledge associated with the mechanisms for 
production and separation is a key objective. However, extension to the consideration of uncertainty in 
process inherent such as feed stream properties and operating conditions is also important since in some 
cases these factors may also be influential with regard to the overall process system. 
4.2 Response to uncertainty 
Traditionally, in response to uncertainty, the chemical processing industries have incorporated design 
margins and/or used one at a time Sensitivity Analyses over specified operating ranges. The latter is 
implemented in the pharmaceutical industries where it is common to use existing equipment designs and 
specification of the operating variables is of key importance. 
Empirical over-design factors are typically applied to a nominal optimal design obtained from the 
assumption of a completely deterministic system with nominal parameter values and a single operating 
condition with the hope to improve operability characteristics. This use of design margins does avoid the 
complexity of explicitly considering variations, however inadequacies of this convention are: 
* lack of a firm rational basis, 
41 usually not possible to either guarantee optimality or feasible operation for conditions other than the 
nominal ones, 
achieves a conservatively designed system, but without any way to quantify the degree of conservatism CI 1-1) 
associated with the design. 
With the level of computing technology now available, variations and uncertainty in process design can be 
incorporated in more systematic manners than the use of crude empirical over-design factors. This Is 
apparent in the large amount of chemical engineering literature available concerning uncertainty. Some of 
reviews on the optimisation of process design and operation under uncertainty are introduced next. 
Grossmann et al. (1983) reviewed optimisation strategies for flexible design for steady-state processes 
under parameter uncertainty. Here, flexibility is defined as the ability of a design to maintain feasible 
regions of operation under different variations of its parameters. These variations may be due to either 
parameter uncertainty or multi-product operations. The problem formulations considered in this review 
focus on minimum cost design with a fixed degree of flexibility and those with an optimal degree of 
flexibility, quantified via a flexibility index. Rippin (1993) briefly discussed the importance of flexibility 
and uncertainty in a review of batch process systems engineering. Terwiesch et al. (1994) presented the 
011 er uncertainty. 
They results of an industrial survey concerning batch unit modelling and operation und 
recognised the significant uncertainty which may be apparent in batch reactor process models and 
reviewed the state of industrial batch reactor practice with respect to design objectives, modelling, 
instrumentation and operation. Model uncertainty is discussed with respect to off-line (open-loop) control 
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profile optimisation under uncertainty (probabilistic and set membership approaches) and in particular 
regarding optimisation of on-line (closed-loop) feedback control. The former is of interest in this thesis. 
Pistikopoulos (1995) discussed combined design and operation of this class of problem and provides a 
classification of uncertainty (model- inherent, process- i nh erent, external and discrete) upon which a 
general mathematical formulation for optimisation under uncertainty is given. This formulation is used to 
address related problems including the value of perfect information (Raiffa, 1968), flexibility, 
controllability and reliability. From a non-chemical engineering specific perspective, Wets (1996) 
identified challenges in stochastic programming associated with the design of models for making optimal 
decisions under uncertainty. This is a general overview but many of the issues are relevant to chemical 
engineering problems (e. g. maintaining computational tractability while giving probabilistic descriptions 
of uncertainty, modelling chance constraints, value of information). 
The next section surnmarises some of the key aspects of the approaches discussed in the reviews listed 
above for management of uncertainty in design and/or operation of chemical processes. 
4.3 Optimal design and/or operation under uncertainty methods 
Grossmann et al. (1983) state the general form of the problem of design under uncertainty for minimum 
cost, C, as given by, 
minC(d, z, x, O) d, z 
S. t. h(d, z, x, O)= 0 
(d, x, 0): 5 0 (4.1) 
where d, z, x and 0 are vectors of design, control, state and uncertain parameters, and h and g are vectors 
of the equalities and inequalities. The problem may be stated as selecting d to Minimise C while ensuring 
an optimum level of feasible operation with the manipulation of z. If only optimal process operation is 
considered and d is already fixed then the problem complexity is reduced since only decisions in z are 
made. Many of the methods which have been proposed to solve the type of problem shown in Equation 
4.1 are associated with determining the limits of the feasible region in some manner. Other methods 
permit some infeasibility in the optimum process without explicitly defining the feasible region. 
Under the parameter uncertainties the evaluation of the objective requires the multiple integration under 
the multi-variate probability distribution, as shown for the stochastic quantities defined in Section 3.3.2. 
Different methods have been used to approximate this multiple integral and solve the optimisation under 
uncertainty problem. The problem can be solved directly through the use of sampling based approaches 
such as Monte Carlo, Latin hyper-cube or Hammersley sampling (as discussed in Section 3.3.4.3) which 
explicitly discretise the uncertainty space. Alternatively, scenario based optimisation approaches can be 
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used based on implicit discretisation using numerical integration techniques (see Section 3.3-4-4). 
Sometimes the scenarios are expressed with pre-assigned probabilities of occurrence. 
The choice of parameter uncertainty characterisation is a key assumption which strongly influences the 
way in which many methods for design under uncertainty have developed, 
e parameter uncertainty within bounded ranges of values where the problem may be transformed to a 
deterministic one, 
* knowledge or prediction of the uncertain parameter probability distributions and the expected value 
objective is optimised in a stochastic optimisation. 
The discussion in the following sub-sections covers methods which include optimal design and/or 
operation under uncertainty which are either associated with: 
(i) scenario-based methods which determine a feasible region under parameter uncertainty characterised 
only by bounded ranges, 
(ii) stochastic methods which deternune the feasible region under probabilistic characterisations of 
parameter uncertainty, 
(Iii) stochastic methods which permit partial feasibility without explicitly determining the limits of the 
feasible region (robust approaches). 
Another sub-section discusses the concept of operational windows for integrated batch processes where 
ranges of control variables are determined for feasible operation. 
4.3.1 Flexible plant design and operation 
Flexibility analysis is a tool which has been commonly applied to design under uncertainty problems in 
chemical engineering in the past. Here, design specifically means the selection of the equipment design 
variables. Grossmann et al. (1983) discussed two types of generic problem: 
9 design for a fixed degree of flexibility, where the plant is designed for optimal economics while 
maintaining operational feasibility over a pre-specified range of parameter uncertainties, 
design for an optimal degree of flexibility, where a design is optimised for both economics and 
flexibility and the degree of flexibility is quantified using a flexibility index. 
The former class of problems is also associated with the deterministic multi-period optimisation problem 
in which a plant is optimally designed to operate under a fixed set of sequential operating conditions 
for 
multi-product or multi-purpose type plants (e. g. oil refining, pharmaceuticals). 
The parameter uncertainty 
problem can be reduced to the general form of the deterministic multi-period problem with 
discretisation 
of the parameter uncertainty space to a set of alternate scenarios 
for which the control variables are 
independently adjustable. 
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The difference between design and control variables is implied from the common assumption that 
flexibility permits the (perfect) adjustment of control variables according to particular realisations -of the 
uncertainty whereas the design variables remain fixed. This assumption corresponds to the 'wait and see' 
operating strategy. Conversely, the 'here and now' operating strategy treats the operating variables as 
equivalent to design variables which are not subject to adjustment at particular realisations. This 
assumption has important implications on the solution the design and operation optimisation problem. A 
two-stage programming formulation has been considered very effective in characterising optimum 
chemical plant design under uncertainty assuming perfect control manipulation. For a cost objective, C, 
the general two-stage problem is given as: 
Design Stage, 
min EOR(d) ýC(d, 0)1 (4.2) d 
Operating Stage, 
C(d, 0) = min C(d, z, 0) (4.3) 
Z 
S. t. f (d, 1-, 0) <0 
and the feasible region R associated with design d is given by, 
R(d) = 
101 V0 c- R3z: f (d, z, 0): 5 01 (4.4) 
The design is selected in the design stage and the operating stage aims to ensure design feasibility through 
control variable manipulation. This formulation poses a difficult problem and a variety of techniques have 
been proposed to solve it which are included in the discussion in the following sections. 
4.3.2 Bounded range uncertainty feasible region approaches 
The methods discussed in this section are associated with guaranteeing the existence of a hyper-cube (or 
rectangle) description of a feasible region inside bounded ranges of uncertain parameters. A summary of 
optimal design and/or operation methods based on this approach to uncertainty is given in Table 4.1. 
Two-stage design and operation approaches to optimisation for the consideration of the dependence of the 
control on the design have been investigated extensively for the case of (deterministic) parameter 
uncertainties characterised by bounded ranges. Nishida et al. (1974) used a minimax strategy for process 
synthesis in which the best value of the objective function is determined at the worst parameter value in 
the bounded range. The continuous design parameters are chosen once the flowsheet structure parameters 
have been modified. The problem with the rninimax approach is that the design is only optimal for the 
worst case set of parameter values which may not be very representative and may not be feasible at other 
parameter values. 
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Table 4.1. Summary of work concerning chemical process design and operation defining a feasible 
region under bounded parameter (deterministic) uncertainty. 
Author Key features 
Nishida et al. (1974) Minimax optimal design for worst case parameter scenario. 
Grossmann and Sargent (1978) Two-stage multi-period design stage and operating stage assuming 
vertex critical parameter points based on local gradients. 
Halemane and Grossmann (1983) Design for fixed degree of flexibility using two-stage multi-period 
design stage and operating stage feasibility test assuming vertex 
solutions for critical parameters. 
Swaney and Grossmann (1985a and Deterministic flexibility index definition for design for optimal degree 
1985b) of flexibility, improved implicit vertex enumeration search. 
Grossmann and Floudas (1987) Feasibility test and design for optimal flexibility problems for linear 
and non-linear systems, using an active constraint strategy not 
assumýing vertex solutions. 
Chacon-Mondragon and Hirnmelblau New definition of flexibility index in the space of the control variables, 
(1988) exact solution for linear systems or approximate solutions for non- 
linear systems. 
Pistikopoulos and Grossmann Optimal retrofit design for increased flexibility of linear systems with 
(1988a) an analytical expression for the flexibility index. 
Pistikopoulos and Grossmann Optimal retrofit design for fixed degree and optimal degree of 
(1989a, 1989b) flexibility of non-linear systems. 
Varvarezos et al. (1995) Design for optimal degree of flexibility of linear systems, using 
sensitivity analysis to identify critical points for flexibility index 
evaluation. 
Dimitnadis and Pistikopoulos (1995) Feasibility test and flexibility index problems for dynamic systems. 
Ostrovsky et al. (1994,1997,1999 Efficient bounding procedures for feasibility test and flexibility index 
and 2002) problems. 
Mohideen et al. (1996) Integrated process and control systems design under time-varying 
Barisal et al. (2000a) parametric uncertainty. 
Bahri et al. (1997) Integration of flexibility and controllability for synthesis of process 
structures and control systerns. 
Kuhlmann et al. (1998) Multi-period optimal control problem, iteratively adds critical 
parameter scenarios to determine a robust control policy. 
Ma et al. (1999) Analytical method to analyse the effect of worst case optimal batch 
control profiles. 
Rooney and Biegler (1999 Optimal design for fixed degree of flexibility, using critical parameter 
and 2001) scenarios based on joint confidence region vertices. 
Barisal el al. (2000b) Solution of deterministic flexibility analyses of linear systems with 
explicit dependence of the flexibility index on the design variables. 
Raspanti et al. (2000) Simplified reformulations of feasibility test and flexibility index 
problems for design optin-ýsation. 
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Grossmann and Sargent (1978) introduced a two stage formulation which aims to guarantee design 
feasibility (equivalent to an infinite penalty for infeasibility). The design and operating variables are I L_ I 
selected by a multi-period optimisation of the expected performance comprising of a discrete set of 
parameter scenarios. This is subject to maximising each individual inequality constraint with respect to the 
uncertain parameters. This does not guarantee feasibility for all parameter values si ince the selection of the 
parameter scenarios in the constraint maximisations are based on local gradient signs from which the 
extreme (bounding) values are assumed. A stochastic programming approach of Malik and Hughes (1979) 
used a two stage approach for flexible design and operation based on Monte Carlo sampling. Halemane et 
al. (1983) claim that the disadvantages with this method is there is no guarantee that the design will be 
feasible under the parameter uncertainties and the MCS requires considerable computational effort. 
A two-stage formulation which does guarantee design feasibility over bounded ranges of parameter 
uncertainties, from which many later approaches are based, was proposed by Halemane and Grossmann 
(1983). This formulation aims to solve the design under uncertainty problem for a fixed degree of 
flexibility, as discussed by Grossmann et al. (1983). A multi-period (or multi-stage) optimisation is solved 
in the design stage, 
M 
max Pft = f, (d) +w -M, 0M) d, z,, 
fm fm (d, 
M=1 
S. t. f (d, zm, Om)! ý 0 for Vm 
0T= 1010LB < 0: ýý OUB (4.5) 
where Pft is a multi-period profit function, f,, is a function for the fixed costs, index m represents a period 
or scenario and wf is a weight factor corresponding to the discrete probability of each period. The original 
equalities, h, and inequalities, g, of Equation (4.1) are reformulated into a new vector of inequalities, f, 
which express the implicit elimination of the state variables (x) from the problem. A key assumption is 
that the vector of uncertain parameters (0) are of the deterministic type, characterised by bounded values, 
()UB and ()LB, in a region T, which contains all possible values of the parameters. Grossman and Sargent 
(1978), Varvarezos et al. (1992), Paules and Floudas (1992) and Subrahmanyam. et al. (1994) have 
presented methods to solve multi-period design optimisation problems in applications for design 
feasibility under uncertainty, multi-period multi-product batch plants, distillation sequence synthesis and 
scheduling under uncertainty. 
The optimal design, d*, obtained from the design stage, which is guaranteed to be feasible only at the 
specified periods, is subjected to a feasibility test which aims to select for every realisation of 0cTa 
vector of operating variables which is both optimal and feasible. The assumption is that with knowledge of 
the exact realisations of the parameters perfect control can be achieved. Halemane and Grossmann (1983) 
showed that the feasibility test is equivalent to the sub-problem, 
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max min max fdz, O ! 50 (4.6) OcT z jEj 
where J is the number of reformulated inequality constraints. This constraint states that if for a given 
design, d*, a control, z, can be selected to satisfy the critical parameter scenario, Oc, which gives the 
maximum violation of the worst constraint (maximum valued constraint for given d, z, 0), then X(d) :50 
for all 0 (=- T and the feasibility test is passed for design d*. This sub-problem allows the possibility of 
circumventing an infinite number of inequality constraints. 
The problem is to select a finite number (M) of discrete periods for the multi-period design problem such 
that the assurance of operational feasibility at these points also ensures feasibility at all the other possible 
points which are not considered. Determination of the critical points (parameter scenarios which violate 
the constraints the most) using the feasibility test aims to find these periods. A limitation is that in the case 
where the uncertain parameters represent parameterisations of physico-chemical phenomena models the 
assumption that exact knowledge of the uncertain parameters at a particular time can be determined is 
unlikely to be valid even with on-line measurement of the dependent variables. 
A range of methods have been proposed for the feasibility test problem. Halemane and Grossmann (1983), 
Swaney and Grossmann (1985a and 1985b) and Ostrovksy et al. (1994) suggested vertex search methods 
(explicit and implicit branch and bound enumeration techniques) assuming deterministic uncertain 
parameters for which the critical points are located at vertices of the hyper-rectangle. This may not be true 
for non-convex constraints. Swaney and Grossmann (1985a and 1985b) introduced a flexibility index in 
response to the design for optimal flexibility problem under deterministic uncertainty. They quantify this 
index, F, as the maximum fractional deviation, 5, from the nominal parameter value, ()N, in any of the 
uncertain parameter dimensions within which a hyper-rectangle feasible region can be inscribed, 
max, 5 
maxminmaxf d*, z, O)<O OeT z jEJ 
T(S) = 
jol(ON 0:: ýý 
(ON 
+ 5+Ao+ )I 
where 
(4.7) 
_ON 
ON -0 op 
+p , (5p =p-p 
for Vp = 1,..., P (4.8) 
p ý0ý A Op- 
and AO is the deviation from the upper or lower uncertainty bound to the nominal value. 
Sirmlarly, the 
solution was based on vertex points and does not guarantee correct solutions in the presence of non- 
convex constraints which result in non-vertex critical points. 
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In an attempt to overcome this problem and avoid the enumeration of all vertices Grossmann and Floudas 
(1987) suggested an active constraint set strategy (ACS) based on the a prl'ori Identification of potential 
active constraints (from the stationary conditions) which limit flexibility. This does not rely on the 
assumption that critical points rely on vertices. The feasible region is projected into the space of the 
feasibility functions (functions of d and 0) of which one function is associated with each potential active 
set. They take advantage of the fact that the feasibility function is a piecewlse continuous function and 
general mixed integer formulations are provided for both the design for fixed degree of flexibility and 
flexibility index problems. For the case of linear constraints the problem either reduces to a mixed integer 
linear programming problem (MILP) which may be solved by branch and bound enumeration approaches 
or to a series of linear programming problems (LP) using the ACS. For the case of non-linear constraints 
the ACS decomposes the mixed integer non-linear programming problem (MINLP) into non-linear 
programming (NLP) sub-problems but the possibility of a large number of active sets requires the solution 
of many NLPs. Global solutions can be guaranteed for non-linear constraints quasi-concave in the 
uncertain parameters. To improve the computational efficiency and extend the globality of solutions for 
different problem classes, Ostrovsky et al. (1994,1997,1999 and 2002) proposed different bounding 
methods for the solution the deterministic flexibility analysis chemical process design problems. Raspantl 
et al. (2000) present reformulations which simplify the feasibility test and flexibility index problem 
formulations of Halemane and Grossmann (1983), Swaney and Grossmann (1985a and 1985b) and 
Grossman and Floudas (1987). This is achieved by aggregating inequality constraints or using smoothing 
functions which simplify the optimality conditions. 
Cabano (1987) identified that plant retrofit is inherently associated with uncertainty and flexibility. 
Pistikopoulos and Grossmann (1988a) formally considered the retrofit design of a linear plant for a 
specified degree of flexibility using ACS. They defined the retrofit problem as determining the parameter 
and/or structural changes which are required in an existing process so as to increase its flexibility with the 
least investment cost. They exploited the linear properties to provide an analytical expression for the 
deterministic flexibility index which allows the identification of all the critical parameter points and the 
inclusion of an explicit inequality constraint on the design flexibility. While this allows a more compact 
and efficient representation a disadvantage is that this approach still requires the a priori identification of 
all the active sets which despite systematic enumeration procedures can still involve the solution of a large 
number of MILPs. To overcome this problem Varvarezos et al. (1995) used sensitivity information (of the 
feasibility function) to identify all the critical points that limit flexibility (i. e. the non-redundant active 
sets) associated with a linear design. They used this information to evaluate the flexibility index for the 
optimal design of linear systems under fixed degree of flexibility without the enumeration of all the 
possible active sets. Pistikopoulos and Grossmann (1989a) extended their previous work to the retrofit 
design of non-linear systems and an efficient strategy is proposed for special classes (linear in the design 
variables and bi-linear in the uncertain parameters and control variables, i. e. where the state variables have 
been eliminated to give a reformulated set of linear inequalities). Pistikopoulos and 
Grossmann (1989b) 
extended their work on optimal retrofit under fixed degree of flexibility to optimum 
flexibility in non- tlý 
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linear systems. Their approximation of the two-stage design and operating problem (Equation 4.1) 
involved solving the economic cost/profit optimisation and the design feasibility separately. An iterative 
parametric analysis is performed under two sub-problems. The first is a trade-off between the retrofit cost 
and the deterministic flexibility index and the second computes the expected revenue over the hyper-cube 
definition of the feasible region for each of the retrofit redesigns. The optimal degree of flexibility is not 
necessarily the largest value of flexibility but that which optimises the difference between the expected 
revenue and the retrofit cost. However, the expected revenue is likely to be under estimated since the 
hyper-cube is an over conservative definition. 
Chacon-Mondragon and Himmelblau (1988) provided an alternative definition of the flexibility index. In 
this work the maximum hyper-rectangle is inscribed inside the feasible region defined in the space of the 
control variables and not the uncertain parameters. They claimed it is easier to compute than the index of 
Swaney and Grossmann (1985a and 1985b) but the exact measure can only be computed for systems 
linear in the control variables otherwise a linearisation approximation is required. 
Soroush and Kravaris (1993) and Dimitriadis and Pistikopoulos (1995) have considered flexibility in the 
optimal design and operation of dynarync batch systems. The former work defined flexibility with the 
assumption that the controller is always able to force the design independent operating conditions to 
follow their nominal optimal profiles. This may be conservative as it does not account for any operating 
conditions which may be more appropriate under uncertainty than the nominal set. DiM]triadis and 
Pistikopoulos (1995) extended the feasibility test and flexibility analyses problems of Halemane and 
Grossmann (1983) and Swaney and Grossmann (1985a and 1985b) to application with dynamic systems 
under time varying deterministic uncertainties. The dynamic feasibility test is stated as the problem of 
being able to establish if there is at least one control variable profile which satisfies the feasibility 
constraints over the entire time horizon for every possible dynamic profile of the uncertainties. The 
dynamic flexibility index is the largest scaled deviation of the uncertain parameter profile that the design 
can tolerate while remaining feasible over the entire time horizon. They utilise dynamic optimisation 
techniques to solve the proposed two-stage formulations for these problems. One limitation is the large 
size of the optimisation problems for even small systems. The index problem also assumes that the 
direction in parameter space for the location of the critical point is known or is at one of the vertices in the 
dynamic hyper-rectangle. 
The parametric programming approach provides a systematic method for the analysis of parameter 
uncertainty on the optimal solution in linear programming problems. The parametric solution is a function 
of the uncertain parameters and provides a map of the optimal decisions over the uncertainty space. 
Barisal et al. (2000b) solved both deterministic and stochastic flexibility analyses for linear systems using 
parametric prouramming. The use of parametric programming provides the explicit 
dependence of the 
deterministic feasibility test measure and the flexibility index on the design variables so reducing the size 
of the test and index problems (similar to the approach of Varvarezos et al. 
(1995), for a fixed degree of 
flexibility in linear systems). In the case of stochastic parameters the approach reduces the size of the 
analysis problems and allows the explicit expression of the system cost as a 
function of a target flexibility 
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index and also the dependence of the flexibility on the design variables. Parametric programming has 
found more extensive application to MILP and MINLP process synthesis problems under uncertainty 
(Pertsinidis et al., 1998, Acevedo and Pistikopoulos, 1996 and 1997, Dua et al., 1999, Hene et al., 2002). 
One of the underlying assumptions in the two-stage design and operation methods for optimal design for 
fixed degree of flexibility is that the parameter uncertainties are characterised by bounded ranges or 
individual confidence intervals. This may lead to overly conservative estimates of the influence the 
uncertainties have on the design since the resulting hyper-rectangle may be a poor estimate of the actual 
parameter uncertainty space. Rooney and Biegler (1999) recognised this problem with particular concern 
regarding correlated model parameters. To overcome this they incorporated elliptical joint confidence 
region information into the two stage multi-period design formulation. They selected the two extremums 
along the longest axis of the joint confidence region of the parameters as the initial periods for the multi- 
period design optimisation. The feasibility test is then solved (using the active constraint strategy) to find 
additional critical scenarios to add to the design stage. The design optimisations contained far fewer 
periods than otherwise obtained in the hyper-rectangle approach, and converged more rapidly. Limitations 
are the requirement of the parameter covariance matrix usually from the regression of experimental data, 
the reliability on the non-global feasibility test and the computational expense in determining the 
confidence region extremums for large problems. To determine critical scenarios from confidence regions 
not well approximated by hyper-ellipsoids (due to highly non-linear models), Rooney and Biegler (2001) 
modified their prior approach by using a likelihood ratio test to derive non-linear parameter confidence 
regions. 
Model parameter uncertainty has also received attention in the design and control of chemical plants and 
process operation. Bahri et al. (1997) discussed a systematic approach to consider controllability and 
flexibility of a plant. Flexibility is introduced into the plant using the concept of back-off as a measure of 
flexibility (ensuring feasible operation by moving the optimum point to a point inside the feasible region 
where the worst disturbance set will not cause constraint violation). In a two-stage dynamic optimisation 
approach, the outer loop computes the best flowsheet design and/or control structures with the 
combination of disturbances which gives the most constraint violation (deternuned from the inner loop). 
Mohideen et al. (1996) introduced a framework for optimal integrated process design and control system 
design under parametric uncertainty and process disturbances. This aimed to provide an optimum design 
and control scheme at minimum annualised cost over the entire time horizon under the specified 
uncertainty. A multi-period design sub-problem is solved for the process and control structure and design 
to which critical scenarios are added iteratively following the solution of a dynamic feasibility test. The 
resulting MINLP problems were very large for even relatively small scale systems and were limited to the 
consideration of multi-loop proportional integral (PI) controllers and continuous decisions. Barisal et al. 
(2000a) provided a more efficient approach for the solution of a similar type of problem but for discrete 
and continuous decisions. It does not guarantee global solutions. Iterative addition of critical scenarios in 
a two-stage multi-period problem is also used by Kuhlmann et al. (1998) for the optimal control of fed- 
batch fermenters. They determine the critical scenario inside bounded ranges of parameter uncertainty 
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from a constraint maximising sub-problem and amend the current set of scenarios in the optimal control 
problem used to determine the robust control profile providing feasible operation under the uncertainty. 
Ma et al. (1999) provided an alternative approach to quantify the effect of uncertainty in model parameter 
and control implementation on the performance of optimal open-loop control policies for batch chemical 
processes. Instead of attempting to estimate the integral quantities denoted in Equations 3.1 to 3.10, they 
used an analytical method to measure the sensitivity of both the optimal control policy and the 
performance objective deviations from their nominal values at an estimate of the worst case uncertain 
parameter scenario. 
4.3.3 Probabilistic uncertainty feasible region methods 
The methods discussed in this section are associated with the attempt to determine the feasible region 
more accurately than the hyper-rectangle definition. These methods are typically associated with 
probabilistic definitions of the uncertainty and are summarised in Table 4.2. Stochastic or probabilistic 
uncertainty characterisation incorporates a greater level of knowledge regarding the uncertainty (through 
Table 4.2. Summary of work concerning chemical process design and operation defining the feasible 
region under probabilistic parameter (stochastic) uncertainty. 
Author Key features 
Kubic and Stein (1988) Design reliability (probability of feasible design operation) assuming 
no control variables. 
Pistikopoulos and Grossmann Retrofit design for optimal degree of flexibility in linear systems. 
(1988b) 
Pistikopoulos and Mazzuchi (1990) Evaluation of stochastic flexibility for linear systems under normally 
distfibuted uncertainty. 
Straub and Grossmann (1990) Stochastic flexibility index for flexible and reliable linear systems 
subject to combined discrete and continuous parameter uncertainties. 
Straub and Grossmann (1992) Evaluation and optimisation of expected flexibility for flexible and 
reliable multi-product batch plants. 
Straub and Grossmann (1993) Extension of stochastic flexibility analysis and design optimisation to 
convex non-linear models with convex non-linear feasible regions. 
Pistikopoulos and lerapetritou (1995) Simultaneous design feasibility and econornic optinusation approach 
for convex non-linear systems under stochastic parameter uncertainty. 
Barisal el al. (1998) Analytical methods for stochastic flexibility analysis of linear dynamic 
systems under normally disthbuted uncertain parameters. 
Terwiesch et al. (1998) Optimisation of probabilistic success measures for robust dynamic 
semi-batch process operating policies. 
Barisal et al. (2000b) Solution of stochastic flexibility analyses of linear systems with 
explicit dependence of the flexibility index on the design variables. 
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probability distribution functions) than is posed in bounded range deterministic uncertainty approaches. 
As mentioned in Section 4.3.1, stochastic parameters are usually associated with the design objective for II 1ý I 
optimal degree of flexibility, where economic trade-offs with flexibility (quantified through a stochastic 
flexibility index) are explored. Flexibility is associated with the size of the feasible region and accurate 
determination of the feasible region is a key element of many approaches. 
Stochastic flexibility analyses are concerned with the probability of feasible operation of a process subject 
to uncertainties which are described by probability distributions and for which perfect control is assumed. 
Kubic and Stein (1988) used a stochastic flexibility measure based on the integration of the probability 
distribution function of the uncertainty over the feasible region. They called this design reliability, i. e. the 
likelihood that a design will operate, and was based on random and fuzzy uncertainties. The concept of 
fuzzy set theory was used for non-random parameter uncertainties for which distinct bounds are not 
known. Membership functions define the fuzzy set used to describe the possible reallsations of the 
uncertain parameters. However, the explicit consideration of degrees of freedom (decisions) was not 
possible in their work. Pistikopoulos and Grossmann extended their work on optimal retrofit under fixed 
degree of flexibility (bounded ranges of uncertainty) for linear systems (1988a) to optimum flexibility in 
linear systems under stochastic uncertainty (1988b). A two-phase retrofit cost-flexibility-expected revenue 
trade-off approach as used for non-linear systems (1989b) and previously described in Section 4.3.2, is 
implemented with the difference being that the stochastic flexibility index (1988b) provides a more 
accurate estimation of the feasible region than the hyper-cube index definition (1989b). 
Pistikopoulos and Mazzuchi (1990) introduced a systematic approach for the evaluation of a flexibility 
index for process systems under normally distributed uncertainties. The advantages are that the 
transformation of the feasible region into the space of only the uncertain parameters explicitly accounts for 
the perfect adjustment of the degrees of freedom and that large numbers of correlated uncertain 
parameters can be handled. However, their approach is restricted to linear systems and normal parameter 
distributions. Straub and Grossmann (1990) introduced a stochastic flexibility index (probability of 
feasible operation) for linear systems subject to combined discrete and continuous parameter uncertainties. 
The work combines flexibility with reliability into an expected stochastic flexibility which is the sum of 
products of the probability for each discrete state and the associated stochastic flexibility under the 
continuous uncertainties (which may be correlated and characterised by a range of distributions). The 
application to linear models allows an effective analytical scheme for the quadrature integration of the 
distribution function. It is limited to a modest number of constraints and it is not easily extended to design 
optimisation. Straub and Grossmann (1992) similarly combine flexibility and reliability 
for the evaluation 
and optimisation of expected flexibility in multi-product batch plants under normally 
distributed 
uncertainty in demand and discrete uncertainty in equipment availability. 
They show how parametric 
optimisation can be used to trade-off between optimal flexibility or expected profit against cost. 
The 
assumption of normal distributions and the fact that the time 
horizon constraint is linear in demand 
uncertainty allows simplified problem formulations which would otherwise not 
be possible. 
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The extension of stochastic flexibility analysis to non-linear models was made by Straub and Grossmann 
(1993). They presented an approach to evaluate the stochastic flexibility of a non-linear feasible region 
under perfect control which can be extended to design optimisation. The stochastic flexibility index, SF, 
for a non-linear feasible region in a total of P uncertain parameter dimensions is defined as, 
OUB011B(ol) 011B 
12p 
(01,0, 
-, ---191, -1) 
SF =ff... f PDF(OýOp ... 
dO2dOl 
oLB oLB OLB 
12 
(01) 
p 
(01 
10,1 ... 
OP-1 
(4.9) 
where PDF is the truncated joint probability distribution function of the uncertain parameters (which may 
be correlated), 0, and ()UB and ()LB are the upper and lower bounds of the feasible region. As proposed by 
Straub and Grossmann (1990) gaussian quadrature is used to accurately approximate the multi- 
dimensional integral by determining the bounds of the feasible region in each dimension in turn and then 
locating the collocation points inside. The determination of these bounds assumes perfect control and a 
convex feasible region. A non-convex region will be incorrectly defined unless the region is one- 
dimensional convex in each uncertain parameter. As discussed in Section 3.3.4.4, any approach which 
uses gaussian quadrature to approximate integrals is limited by the number of uncertain parameters which 
can be reasonably handled given the exponential increase in the size of the problem with the number of 
dimensions. The extension to design optimisation involves iterating between a design (master problem) 
and an operating stage (sub-problem) by applying Benders decomposition. The authors showed that the 
SF metric is superior to Taguchi's quadratic quality loss metric (defined in Section 3.3.2) since the latter 
designs may produce designs which ignore the effect of hard inequality constraints, whereas the SF 
produces feasible designs but which may exhibit larger quadratic loss. 
Pistikopoulos and lerapetritou (1995) guarantee design feasibility in their simultaneous design feasibility 
and economic optimisation approach for convex non-linear systems under stochastic parameter 
uncertainty. This does not require a priori discretisation of the uncertainty and implements the sequential 
quadrature technique of Straub and Grossmann (1993) to determine and integrate over the feasible region. 
The two-stage Benders decomposition algorithm used in this work has also been used for the stochastic 
optimisation of process planning problems (lerapetritou and Pistikopoulos, 1994). The approach is 
restricted by the number of uncertain parameters perrrutted due to the exponential increase in the number 
of operational feasibility sub-problems. In addition, it may not find the global optimum for non-convex 
problems. Ahmed et al. (2000) avoid the problem of entrapment in local solutions and the solution of the 
feasibility test sub-problems in a reformulated algorithm for optimal planning under uncertainty. 
Barisal et al. (1998) applied stochastic flexibility analysis to linear dynamic systems under normally 
distributed uncertain parameters. They presented a procedure for the evaluation of stochastic flexibility 
over time and a framework for design optimisation which are both analytical. A single stage design 
problem is posed to determine the optimal design that meets a desired stochastic flexibility target over the 
entire time horizon. While Barisal et al. (1998) determined the dynamic feasible region throughout the 
process time for linear systems Terwiesch et al. (1998) determined the feasible region for non-linear batch 
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processes in terms of the desired endpoint performance criteria for an optimal robust operating policý'. 
They recognised the importance of utilising robust objectives and their approach permitted a ý'ariety of 
risk objectives and inequality constraints to be expressed (maximum probability of feasible product, 
threshold level of risk, expected value, variance). To evaluate the probabilistic measure of success they 
applied the gaussian quadrature integration approximation of Straub and Grossmann (1993) to determine 
the size of the feasible region for the dynamic system under constant (correlated) stochastic parameter 
uncertainties without assuming perfect control. Results from tightly controlled experiments were shown to 
qualitatively confirm the improved success rate with an operating policy determined by the probabilistic 
method over the nominal and heuristical operating policies. The limitation is associated with the size of 
the problem depending on the number of uncertain parameters due to reliance on gaussian quadrature. 
Only simple operating policies can be optimised with their algorithm but this is stated to be no great 
drawback given the industrial techniques in batch process operation. 
In the consideration of both deterministic and stochastic parameter uncertainties the vector of uncertain 
parameters in the general problem (Equation 4.1) is partitioned into two subsets of deterministic and 
stochastic parameter uncertainties. This results in a combined multi-period and stochastic programming 
problem to which Pistikopoulos (1995) and lerapetritou et al. (1996) provided a general formulation. The 
design selected in the design stage is passed to the operating stage which aims to identify an optimal 
vector of control variables for all reallsations of the stochastic uncertainties and for every period in the 
deterministic uncertainties. This can result in a particularly large optimisation problem. 
4.3.4 Robust partial feasibility approaches 
In this section methods are discussed for which the solutions do not guarantee feasibility over a defined 
feasible region but rather permit partial feasibility by evaluating the entire uncertainty space. Robust 
approaches are often based on the concept of quality management and robust design and operation, 
introduced by Taguchi (1986). In this theory every departure of the measurable performance quality from 
the nominal value causes some economic loss according to a quadratic penalty ftinction (see Equation 3.6, 
Section 3.3.2). 
A stochastic constraint is defined as a constraint on a stochastic variable. The constraint may be treated as 
either hard (either it cannot be violated or is violated but with severe consequences) or soft (for which the 
decision maker permits some violation at the expense of a finite penalty). Robust approaches allow for 
partial feasibility of processes in certain inequality constraints under uncertainty by applying soft 
stochastic inequality constraints to allow for a limited degree of failure in certain variables. Such 
approaches differ from flexibility analyses which treat all constraints as hard and attempt to guarantee 
feasibility within the uncertainty space assuming perfect control in the face of the uncertainties. In this 
respect robust approaches tend to lead to less conservative solutions than 
flexibility analysis approaches 
but at the expense of some level of failure. On the other hand, perfect 'wait and see' control is not always 
assumed. A summary of literature concerning robust approaches is given 
in Table 4.3. 
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Table 4.3. Summary of work concerning robust (partial feasibility) chemical process design and 
operation. 
Author Key features 
Charries and Cooper (1959,1962, Application of probabilistic constraints on inequality constraint failure 
1963) using chance constrained programming technique, for problems with 
Maranas (1997) uncertain parameters linear in the inequality constraints. 
Petkov and Maranas (1997,1998) 
Weisman and Holzman (1972) Unconstrained process optimisation where the probabilistic constraint 
violations are expressed as penalty functions in the objective. 
Pai and Hughes (1987) Two-stage plant design with finite penalty functions for infeasibility in 
the operating stage. 
Ruppen et al. (1995) Optimal control profile formulation over the entire space of stochastic 
parametric uncertainty, with stochastic performance constraints. 
Diwekar and Kalagnanam (1996, Stochastic optimisation using Hammersley sequence sampling for a 
1997) robust 'here and now' design and operating policy. 
Kalagnanam and Diwekar (1997) 
Bhatia and Biegler (1997) Feedback correction policy for dynamic processes in simultaneous 
batch design and scheduling under process model uncertainty. 
Sarnsath et al. (1998) Soft one-sided stochastic constraint functions in a multi-scenario 
Uesbeck et al. (1998) dynamic stochastic optimisation approach for a robust operating policy. 
Bernardo and Saraiva (1998) Robust design and operating policy optimisation with uncertainty in 
model parameters and operating policy implementation. 
Darlington et al. (1999) Mean-variance objective optirnýisation problems for non-linear systems 
with soft stochastic constraints. 
Michel et al. (1999) A robust design approach which analyses the propagation of Taguchi's 
quality loss function through the process unit sequence. 
Abel and Marquardt (2000) Dynamic process operation optimisation for time varying uncertainty in 
hybrid systems. 
Bernardo et al. (I 999a and 200 1) Incorporation of Taguchi's penalty functions into a single level design 
and operating policy stochastic optirnýisation. 
Berriardo et al. (2000) Optimal reduction of model parameter uncertainties for economic 
objective, in a two-stage design formulation. 
Early optimisation under uncertainty approaches treated design and operating variables equivalently. The 
stochastic approach of Weisman and Holzman (1972) optimised an unconstrained problem where the 
expected value of the cost objective function incorporated penalty functions 
for the probability of 
violation for individual constraints. A drawback is that this formulation does not rigorously ensure a 
lower 
lirnit on the probability of constraint failure. The stochastic chance-constrained programming approach of 
Charnes and Cooper (1959,1962,1963) does guarantee a lower lin-ut on the probablIlty of fall ure in 
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inequality constraints in an alternative approach to the use of penalty functions. A chance constraint is of 
the following general type, 
Pr[g(x, 0): 5 0] ýý a (4.10) 
where the probability, Pr, that the uncertain constraint, g, which is a function of the uncertain parameters, 
0, and the variables, x (which may include the decision variables), is satisfied by some probability, (X. 
Chance-constrained optimisation is one method of stochastic programming which reconciles the 
optimisation over uncertain constraints. If the probability distribution function of 0 is known and is stable 
then the probabilistic constraint given in Equation 4.10 can be reformulated as a deterministic equivalent 
(i. e. one which is not a function of 0). The form of the original constraint (g) defines the difficulty in 
reformulating a deterministic equivalent. Chance constraints linear in the uncertain parameters can be 
readily reformulated. If the uncertain parameters follow stable two parameter probability distributions 
(such as the normal distribution), then g is rearranged into the standard normal form by subtracting the 
mean and dividing by the square root of the variance of g(x, 0). Since 0 follows a stable distribution then 
the chance-constraint is replaced by applying the standardised normal cumulative distribution function 
(SNCDF) to the standardised g, 
SNCDF 
0- p[g(X, O)l 
>a (4.11) 
,, 
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Inverting the SNCDF and rearranging leads to the deterministic equivalent, 
I 
, u[g(x, 
O)] + SNCDF- I alVar[g(x, O)]l 
2 <0 (4.12) 
where the mean and variance terms of g are represented using the mean (po), variance (E[O-ý4f ) and 
covariance (E[Op-ý4p](0, -Vej) terms for 0 combined with explicit evaluations of g as a 
function of x only 
(i. e. g(x)). 
The advantage of chance-constrained programming is that this results in a convex programming problem 
and avoids the multi-variate integration which defines the problem size in other stochastic programming 
approaches. Chance-constrained prograrruning is limited by the requirement that the uncertain parameters 
are linear in the uncertain constraints and that their probability distribution functions are stable. However, 
it does allows the incorporation of a high number of correlated parameters. In chemical engineering 
applications this approach has been implemented by Maranas (1997) for the optimal molecular design and 
Petkov and Maranas (1997 and 1998) for the planning and scheduling of multi-product batch plants under 
demand uncertainty. 
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The two-stage design and optimisation approach of Pai and Hughes (1987) under deterministic parameter 
uncertainty acknowledged that it is not always desirable to always guarantee feasibility. Permanent 
feasibility is not required but rather a finite cost penalty is introduced into the operating stage objective 
function. This penalises the realisations of uncertainties in designs for which no feasible solution of the 
operating stage is apparent. 
Ruppen et al. (1995) discuss the computational aspects of dynamic optimisation of 'here and now' batch 
reactor operating policies under parameter uncertainty. They formulate the problem by discretising the 
entire uncertainty space to create a deterministic multi-scenario model equivalent of the stochastic 
problem. An objective function of an expectation operator of a deterministic performance quality and 
stochastic inequality constraints are applied in the multi-scenario optimisation. 
Instead of creating a deterirunistic equivalent to the stochastic model, Diwekar and Kalagnanam (1996, 
1997) and Kalagnanam and Diwekar (1997) used a stochastic optinýiisation algorithm to determine robust 
'here and now' design and operating policies under uncertainty in model parameters and the operating 
variables. As discussed in Section 3.3.4.3 they introduced a Hammersley number sequence based 
sampling strategy (HSS) to efficiently sample the entire uncertainty space. Direct solution of the stochastic 
model places the sampling sub-routine inside the optimisation loop and scenarios are placed until some 
convergence criterion is met. Bernardo and Saraiva (1998) also used stochastic optimisation based on 
HSS for the simultaneous robust design and operating policy under uncertainty in model parameters and 
operating policy implementation. The operating policy decisions are 'here and now' in the parameter 
uncertainty space (single stage optimisation problem) but are themselves subject to error. These errors are 
expressed as operating regions characterised by *the relative error (standard deviation divided by the 
mean). The economic objective penalises narrow operating regions as control costs and explores 
interactions between quality robustness (Taguchi loss function) design, operating and control costs. 
Uesbeck et al. (1998) introduced a robust multi-scenario dynamic optin-u'sation formulation (for 
fermentation processes) which provides an operating policy which attempts to maintain good performance 
in the nominal (no uncertainty) case while constraining product quality to a high extent of satisfaction 
under the uncertainties. They discretised the parameter space a priori (to the implementation of the 
optimisation algorithm) to provide a deterministic equivalent to the stochastic model. A one-sided 
maximum expected violation soft constraint is imposed by introducing constraint violation variables 
which are properly expressed using a switching technique. This comprised of one additional degree of 
freedom (a deviation variable) and two additional inequality constraints (one determining the deviation 
variable and the other forcing the deviation variable to be either greater or smaller than zero) per scenario. 
The drawback is that the size of the model is increased as a result. Samsatli et al. (1998) solved a similar 
problem in a more comprehensive formulation. They provided a general function 
for robustness metrics 
applicable to any one-sided or conventional two-sided stochastic constraints. 
Instead of using additional 
constraints to handle one-sided deviation quantities (Bhatia and Biegler, 1997, 
Uesbeck et al. 1998) they 
used a hyperbolic smoothing function to approximate binary variables. 
Gaussian quadrature is used to 
evaluate the expectation form of the integral under the joint parameter PDF and the operating poli Z:, II icy can 
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be either 'here and now' (scenario independent) or 'wait and see' at each collocation point. As mentioned 
in Section 3.3, the number of points that quadrature schemes require, grows exponentially with the number 
of uncertain parameters. They state that despite the non-convexity of the smoothing functions most 
industrially relevant dynamic models are highly non-convex such that entrapment in local optimum 
solutions would be a problem anyway. 
A multi-scenario robust optimisation approach incorporating Taguchi quadratic loss penalty function and 
robustness metrics (mean, variance, quantiles) was introduced by Bernardo et al. (1999a and 2001). They 
transformed the two-stage design and operating policy optimisation into a single level optimisation using 
cubature integration to place parameter scenarios and allowing the operating policy (but not the design 
variables) to vary with each scenario. They used the same approach as Uesbeck et al. (1998) to account 
for asymmetric loss functions. The efficiency of the cubature integration under the entire uncertainty space 
may be limiting for problems with many uncertainties and requires they all be normally distributed. 
As an alternative to multi-scenario methods to approximate the uncertainty space, Darlington et al. (1999) 
used Taylor series expansion to approximate mean-variance objectives in their optimisation approach for 
robust process operation. Penalty functions are used to allow partial feasibility in non-linear stochastic 
constraints. Michel et al. (1999) optimised the design and operation of process flowsheets using factorial 
designs in the uncertain parameters and the decisions. They decomposed the flowsheet into sub-systems. 
The system is optimised minimising the deviations in each sub-system output quality variable 
(interconnecting stream variable) from its nominal value via a Taguchi quadratic loss function. A measure 
of the relative contribution of the quality loss penalty associated with each sub-system to the final product 
penalty is provided. 
Bernardo et al. (2000) differentiated between inherent system variabilities and model parameter 
uncertainties. They incorporated information R&D costs for the optimal reduction of key model parameter 
uncertainties into a two-stage process robust design optimisation problem under uncertainty. The 
uncertainty space is redefined with each optimisation iteration of new decisions concerning the magnitude 
of the standard deviations in the reducible and significant parameter uncertainties. A strategy allows for 
the fact that the true mean of the reduced uncertainties may not be known. In addition to the pros and cons 
of using the cubature integration technique, it could be difficult to provide a realistic R&D cost to levels 
of uncertainty reduction. Pinto (1998 and 2001) also considered the cost of parameter uncertainties 
assuming linear Taylor series expansion of uncertainty around the nominal parameters and the nominal 
optimal decision variables. An econorrUc value was assigned to parameter uncertainties and used for 
process optimisation. It represents the total average cost which may be expected for not knowing actual 
optimum operating conditions due to the uncertainties. Sensitivity Analysis is used to identify which 
parameter uncertainties strongly influence the objective. This information is used to support decisions in 
sequential experimental design, providing the objective can be well defined. The economic cost function 
is proposed as the experimental design criterion used to determine experimental design procedures based 
on an expectation of how experimentally regressed parameter variances change when additional data is 
added to the prior set (Bard, 1974). 
81 
Integrated design under uncertatntyfor phannaceutical processes 
Some approaches take into account the fact that process knowledge becomes available during operation 
through measurements and can be used to reduce the effect of the uncertainty in the remaining duration of 
the process. Solutions based on operating policies implemented with feedback control determined under 
model uncertainty provide a more realistic compromise between the optimistic 'wait and see' solutions 
and the conservative 'here and now' solutions, discussed in the introduction to this chapter (Section 4.1). 
Terwiesch et al. (1994) discussed on-line feedback control optimisation methods under uncertainty based 
on knowledge of current states. They state that the lack of on-line measurements limits practical 
implementation in industrial practice. Dynamic optimisation using feedback correction policies under 
model parameter uncertainty was implemented by Bhatia and Biegler (1997) for simultaneous operating 
policy and planning of batch plants. They assumed a small number of a priori known instances of 
parameter uncertainties in a multi-period formulation, with the acknowledgement of the computational 
problem with increasing scenarios. Pinto (2001) incorporated the evolutionary operation procedures 
(EVOP) to optimise a continuous plant during operation. This rectifies the over-estimation of the cost of 
parameter uncertainty by evaluating the partial recovery of the losses which were introduced during the 
design phase due to uncertainties. 
While most of the discussed approaches only considered static uncertainties, Abel and Marquardt (2000) 
incorporate time varying uncertainties into the robust optin-fisation of operating policies for dynamic 
hybrid (discrete-continuous) systems. Optimisation approaches are formulated for uncertainty in the model 
parameters but also in the process model structure (e. g. implementation of safety systems) resulting in 
either single-level or bi-level scenano- integrated optimisation problems. These provide solutions 
comprising of different control profiles for the various switching times (at which point the model structure 
and uncertainties may change). Limitations are the complexity of the problem and the associated 
application of current numerical solution techniques. 
4.3.5 Operational windows 
Although the concept of operational windows is not an approach which necessarily directly implements 
uncertainty knowledge, they are particularly useful for batch processes since they recognise that in real life 
these are never run only at one set of operating conditions and some flexibility should be allowed. The 
idea is to combine the knowledge contained in process models with operational windows in the control 
variables so that any co-ordinate of control values inside the window results in feasible operation in 
meeting the constraints and any desired product qualities. This is similar to the notion of 
feasibility under 
uncertainty except here the feasible region is expressed in the space of the control parameters and 
uncertainties are not considered. 
Woodley and Titchener-Hooker (1996) used successive model simulations to construct (non-linear) 
feasible operational windows in multi-step biochemical engineering processes. In addition, they built 
trade-off windows for varying constraints on the process criteria. They used these to indicate the optimal 
balance between operational flexibility and process quality while accounting for Interactions between 
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process stages. Zhou et al. (1997) attempted to formulate operational windows through the correct 
selection of control variables and understanding the dependence of the process constraints on them. They 
visualised complex bioprocess problems by plotting windows at different design stages, from conceptual 
design (based on heuristics) to detailed process design (where specific correlations are known), and used 
them as a tool for Sensitivity Analysis to assess interactions and changes in operating variables. Sarnsath 
et al. (1999 and 2001) adapted the multi-period method of Halemane and Grossmann (1983) to maximise 
the volume of a hyper-rectangle characterisation of the feasible control space. Critical scenarios in the 
control variable space are iteratively added to the problem but one difference is that this volume is not 
centred on a nominal point since this may already be on the edge of the feasible region. They applied this 
to sequenced operations so that trade-offs between control variables in different stages can be made. As 
previously discussed concerning robust approaches, Bernardo and Saraiva (1998) solved process design 
and control optimisation problems combining parameter uncertainty with windows of control variable 
tolerance to account for errors in implementation. They optimised the size of the control tolerance 
windows by attaching a cost for narrow windows. 
4.4 Discussion 
The robust approaches which explore the entire space of the uncertainties are considered the most 
applicable to the type of problem posed in this thesis. The robust approaches discussed In Section 4.3.4 
have been successfully applied to one or two step batch process examples though not to complete 
integrated batch/continuous process sequences. While the guarantee of a defined feasible region is an 
important issue in some conceptual problems it is also important to contemplate the effect that regions of 
non-feasibility may have on the process as considered in the robust approaches. The assumption of fixed 
plant equipment design bypasses the need for the design and operating two-stage optimisation strategies 
employed in many of the feasible region approaches. An approach which can provide optimal decisions 
under all the uncertainty while capturing the dynamic/continuous and non-linear effects modelled in the 
system of integrated processes appears to be most satisfied by the robust approaches discussed. 
It is desirable that a general optimisation framework has the capacity to provide optimal decisions for a 
complete pharmaceutical process accounting for the following properties: 
9 capacity to implement a range of different uncertainty distribution models, 
* capacity to implement a range of different deterministic process models In an integrated sequence, 
capacity to implement a range of different robustness metrics/stochastic inequality constraints, 4ý 
capacity to implement a number of uncertain input factors (reaching the order of tens), 
capacity to implement different conceptual optimisation opportunities (decision variable application to 
operating policies, operating windows/tolerance, parameter uncertainty reductions). 
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The first four issues have already been portrayed in the context of Uncertainty Analysis (see Section 3.6) 
and remain relevant in the extension to optimisation under uncertainty problems. The last Issue Is 
important for a generic approach. A robust stochastic optimisation approach based on the direct solution 
of the general optimisation problem under uncertainty using an efficient sampling based approach is one tý, 
method which can allow the provision for the issues posed above which limits the eventuality of excessive 
problem sizes and computational requirements. The capacity to directly implement the knowledge 
structures provided in the Uncertainty Analysis allows the decisions to be determined by the optirrusation 
algorithm without the enforced loss of any of the information contained. It is proposed that such an 
approach within a general optirnisation under uncertainty framework will produce solutions which are 
meaningful in the context of pharmaceutical systems. 
4.5 Conclusions 
In this chapter, the use of optimisation under uncertainty methods to determine better solutions in the 
desired decision space of deterministic process models subject to parameter and external process 
uncertainty, is postulated as a management response too] to the specified uncertainty. A range of methods 
under parameter uncertainty are discussed. These included formulations constructed to determine 
equipment design assuming perfect control, not assuming perfect control and those only concerning 
operating policies. The discussion was split between methods which determine hyper-rectangle feasible 
regions in bounded ranges of uncertain parameter space, those which deternune feasible regions in 
uncertainty space characterised by stochastic probability distributions, robust approaches which consider 
the entire uncertainty space and assess partial feasibility, and windows of operation which consider 
feasible regions in the control variable space (without specifically accounting for model uncertainty). 
A robust approach was selected as being the most suitable for the type of problem considered with the 
assumption that the equipment design is fixed given the allocation of pre-existing plant equipment and 
emphasis is placed on determining robust operating policies. A sampling based approach (using an 
efficient sampling technique) for the direct solution of stochastic optimisation problems is considered for 
the following key reasons: it is able to capture the non-linear and dynanuc behaviours of integrated 
dynamic/continuous process sequences, permits the incorporation of a reasonably large number of 
uncertain factors (more than ten) into the optimisation without exponentially increasing the problem size 
and provides a framework which is flexible to the implementation of different robustness metrics and 
conceptual optimisation objectives. 
The next chapter defines both the problem considered in this thesis for integrated pharmaceutical process 
design under uncertainty and the methodology proposed to solve it. The associated mathematical 
techniques implemented in the methodology are described in detail. 
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CHAPTER 5 
AN APPROACH FOR INTEGRATED DESIGN UNDER UNCERTAINTY 
5.1 Introduction 
Various methods to deal with uncertainty in models and in the optimisation of uncertain process models 
have been discussed in Chapter 3 and Chapter 4, respectively. The range of optimisation methods under 
uncertainty, discussed in Chapter 4, originated from deterministic and stochastic programming problem 
viewpoints. As would be expected, the interpretation of the problem under uncertainty is important in 
defining the context to which the results may be useful in supporting process design and development 
decisions. 
In Section 5.2 the conceptual problem is posed and objectives of this work are clarified in Section 5.3. In 
Section 5.4 an approach is presented where Risk Analysis methods associated with a stochastic 
representation of the uncertain process system are integrated within systematic model development 
procedures. This approach aims to quantify the process response to uncertainty in the current 
understanding of the system resulting from incomplete process knowledge characterised by model 
parameter uncertainties. In doing so, this aims to focus effort towards those parts of the system which have 
the greatest effect on the response. In Section 5.5 four stochastic optimisation problems are formulated to 
address the problems of determining (1) the required stochastic input parameter uncertainty reductions to 
meet desired levels of uncertainty in the response, (2) optimal operating policy decisions for the uncertain 
system, (3) the value of perfect information regarding potential certainty in measurable properties and (4) 
permitted tolerances to errors or uncertainty in the implementation of operating policies. 
5.2 Conceptual problem for uncertainty in models 
The objective of this work is to introduce a systematic model-based approach to support the process 
development of pharmaceutical processes, with the specific aim of accounting for the large amounts of 
uncertainty in the process knowledge. Given a conceptual process design, a lack of understanding in the 
underlying physico-chemical mechanisms is transcribed to uncertainty in the imperfect models used to 
describe the operations of the integrated process sequence. As mentioned in Section 3.2, this work does 
not aim to indicate what a better model structure should be but rather where parameter uncertainties in a 
current set of models appear to be relatively important. Pinto (1998) suggests that the presence of 
significant structural inadequacies might be inferred from these uncertainties. An important distinction 
becomes apparent when independent data is available for model validation purposes. Both the location of 
the distribution of a predicted output performance variable relative to the data point(s) and its spread are 
important aspects. The quantification of the spread and sensitivity to the spread are the main 
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considerations of the model-based Risk Analyses proposed in this thesis. However, the model structure 
may be more relevant than parameter uncertainty to the relative location of the distribution to the data. 
5.3 Integrated design objectives 
This work aims to introduce some form of management of the uncertainty associated with the model 
representations of the current process knowledge. In the face of large amounts of uncertainty predicted in 
the important process output criteria, three management responses are considered: 
(1) reduction of the uncertainty by improving current models/parameter estimations associated with the 
key contributing uncertainty factors identified, 
(Ii) manipulation of the available process decisions (operating policy) to improve process robustness to 
model uncertainty, 
(111) consideration of process altematives. 
Response (1) concerns the gathering of additional information for systematic model development for more 
reliable models. Response (ii) and (111) concern the optimisation and comparison of uncertain but complete 
processes sequences. In order to formulate a framework to allow the implementation of the above 
management responses, methods are provided which couple the use of a model-based approach under 
uncertainty with the vision of complete integrated sequences of pharmaceutical processes. The following 
issues are considered regarding the explicit consideration of uncertainty in systematic model development: 
quantification of the effect of model uncertainty on the important output predictions, 
9 identification of the key process sub-sequences and key contributors to the observed effects under 
model uncertainty, 
9 identification of required reductions in key input uncertainties to meet desired limits on output 
prediction uncertainty, 
* the capacity to incorporate new information. 
The issues addressed for the optimisation of integrated process flowsheets under uncertainty are: 
quantification of the effect of model uncertainty on the objective function and constraints, 
9 optimisation of uncertain process performance criteria with manipulation of operating policy variables, 
9 the value of potential measurements on exterrial process inherent uncertainty sources, 
the maximum process operating policy variable error tolerance permitted to meet 
desired limits on the 
uncertainty in output performance predictions. 
A schematic linking the different parts of the methodology used to address these 
issues is shown in Figure t) 
5.1. The individual aspects are examined in more detail in the following sections of this chapter. 
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------------------------------------------------- ---- 
Information 
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Figure 5.1. Management of uncertainty in a model-based approach to integrated design under uncertainty 
for pharmaceutical processes. 
5.3.1 Assumptions 
The assumptions associated with the problem to which the objectives of this methodology are directed are 
reiterated: 
* status of conceptual pharmaceutical process 
conceptual process (including feed materials) is already specified, 
- equipment (of fixed design) is already allocated, 
* deterministic process model 
integrated sequence of individual process models (representing the unit operations specified In the 
conceptual process), 
- linear and/or non-linear models, 
- time-dependent and/or steady-state models, 
lumped parameter and not distributed systems, 
40 stochastic system 
- uncertainty in the parameters of the 
deterministic process model system and no specific 
consideration of natural variability or structural uncertainty, 
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model inherent parameter uncertainty (including kinetic constants, transfer coefficients, 
thermodynamic and physical property parameters), 
process inherent parameter uncertaInty (measurable propertles of external feed streams), 
parameter uncertainties are static in time unless associated with an external action, 
model parameter uncertainties may be characterised by uniform, normal or other types of stable 
probability distributions (stability is assumed since parameter distributions are either regressed or 
assumed due to a lack of data and are not directly estimated from distributions of raw data points), 
uncertain parameters may be correlated, 
* optimisation under uncertainty 
decisions (degrees of freedom) are determined simultaneously for the integrated flowsheet, 
equipment design parameters are not degrees of freedom but take fixed values according to the 
available equipment allocated in the conceptual design, 
- decisions are determined without recourse knowledge of the uncertain properties except that their 
values are assumed to reside somewhere in the defined uncertainty space (i. e. scenario independent), 
controller operation is perfect giving instantaneous application of the desired operating conditi I-- IIi ions 
(i. e. controller design is not considered). 
5.4 Combined Risk Analysis and model development approach 
The technical Risk Analysis approach comprises of methods to quantify the uncertainty contained in a 
stochastic representation of the process model system (Uncertainty Analysis) and to identify and rank the 
most important contributors to the uncertainty in the system response (Sensitivity Analysis). In this 
methodology elements of the Risk Analysis approach (see Chapter 3) are combined with systematic model 
development procedures (see Figure 2.2, Section 2.4), so that the most important ranked parameters to the 
uncertain (but structured) system can be identified. The suggestion is that this information can be used to 
drive the general direction for data collection to improve the models and reduce the uncertainty. As more 
data becomes available the methodology allows the tracking of the effect of increased knowledge in 
individual process models and the effect on the complete uncertain system, in an iterative manner. 
A schematic of the combined approach is shown in Figure 5.2. The steps within the dashed line box in 
F gure 5.2 comprise the Uncertainty Analysis. The stochastic characterisation of the system is defined by iC) III 
the assumptions stated previously in Section 5.3.1. The steps of the proposed model 
development scheme 
are discussed next. The mathematical methods are stated for those steps specifically associated with the 
Risk Analysis approach. Less emphasis is placed on the steps associated with conventional model 
development procedures. The reader is referred to Hangos and Cameron (2001) for further details of steps 
specifically concerning procedures in the systematic approach to model 
development. 
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The first six steps are general to all conventional process model development problems. These six steps 
are applied in turn for the development of process models of individual operations comprising a sequence. 
In Step I the modelling problem is defined regarding the desired complexity, range, accuracy, time 
characteristics and spatial distribution. In Step 2 the proposed controlling mechanisms and characteristics 
of the process believed to be important to the problem definition are selected. The type, amount and 
quality of the data available to support the problem definition and desired model characteristics is 
evaluated in Step 3. The problem definition may be revised accordingly. The equations for the assumed 
physico-chemical phenomena, physical property models with the equipment model and any significant 
external actions (operating policy) are assimilated in Step 4 and a deterministic model of the process is 
constructed in Step 5. The model may be mechanistic (white box), semi-empirical (grey box) or empirical 
(black box). Ideally the model-based process development approach should be aiming towards the 
derivation of mechanistic models for which a good underlying understanding of the process is displayed 
(but may require an unrealistic amount of effort). The viability of this aim depends on the complexity of 
the process and underlying mechanisms (of particular concern in pharmaceutical processes) as well as the 
data which can be reasonably obtained. 
If no quantitative data is immediately available concerning a particular process operation then the 
methodology assumes the formulation of a simple mass balance model in Step 5, as a minimum pre- 
requisite level of model complexity. Recognition of this inadequacy is an acknowledgement that there is a 
need to obtain data to improve the process understanding required to develop a more accurate model 
structure if justified. Unit operation models and material specific physical property, thermodynamic, 
kinetic and/or transfer models may be available from engineering literature, for which parameter values 
need to be fitted. Physical property data banks may contain estimates of the required parameter values for 
the more common components. However, in the case of pharmaceutical processes for new synthetic 
chemicals, data concerning the active pharmaceutical chemicals will not be available from existing data 
banks and it is necessary either to conduct further experiments or assume the properties of substitute 
materials, for those process models requiring property knowledge. 
With the available data or observations and the assumed model structure, values for the parameters of the 
individual unit operation models are estimated (Step 6a) or assumed (Step 6b). Non-linear least squares Is 
a common method for parameter estimation when experimental or process data is available for parameter 
fitting. Different forms of least squares regression can be utilised according to different situations. 
Z-1 I ion Weighted or robust regressions are useful in the presence of outlying 
data points. In addition, examinati 
of the profile predictions compared to the trends in the data points can indicate the presence of errors in 
the assumed model structure. If quantitative data is not available then engineering 
judgement must be used 
which may be based on qualitative observations to define simple mass 
balances. The resulting model of 
each process operation are integrated to form a deterministic model of the complete sequence. 
In Step 7a Perturbation Analysis (one at a time approach, see Section 3.3.1) is used as an initial screening 
procedure to determine which of the parameter uncertainties in the complete sequence may 
be potentially 
significant in the integrated system. 
Positive and negative deviations from the nominal parameter 
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estimates, based on the judgement of the developer (for example these could be the approximate precision 
ranges for different types of model parameters as suggested by Hangos and Cameron, 2001), In all the Z: ý 
parameters of the process sequence model are simulated in turn. The parameters whose deviations return 
significant responses in the important process output criteria are selected to characterise the stochastic 
system to the Uncertainty Analysis. A significant response is considered to be a deviation in any of the 
important performance criteria greater than 1% from its nominal value. 
In Step 8 the approach used for the quantitative estimation of the uncertainties in these parameters is 
determined by the data available for parameter estimation. The development of parameter uncertainty 
estimations can be based on three different information sources: 
9 analysis of the performance of the model building based on experimental measurement data (Step 8a), 
allows the estimation of uncertainty in the optimum parameter estimates using confidence intervals or 
regions from least squares regression (or other parameter fitting methods), often assuming normal 
probability distributions in the parameter distributions, 
e expert technical judgement is needed when quantitative data is not available for systematic model 
building and models are assumed whose parameter values are instead based on observations and/or 
assumptions and associated confidence intervals and probability distributions need to be assumed 
(Step 8b), for which conservative estimates may be elicited given the lack of data, 
9 published information either quantitatively specifying parameter uncertainties or from which 
judgements can be inferred (Step 8a or 8b). 
Step 9 completely defines the stochastic system considered in this problem and the sampling procedure is 
invoked in Step 10. The sampling procedure is discussed in more detail with regard to the schematic given 
in Figure 5.3, where the step numbers relate to those in Figure 5.2. 
If model parameters are estimated simultaneously in multi-parameter models (Step 6a), correlations 
between the parameters may be apparent. The stochastic system is approximated using an efficient 
sampling scheme over the defined uncertainty space which may include correlated uncertain parameter 
space. Approximate correlation structures can be obtained from the estimation of the parameter 
covariance matrix. In this methodology, estimation of the covariance matrix in 
Step 10b, ý, is based on 
the first order Taylor's linearisation, as discussed in Section 3.3-3.2, 
ý= 2( j(o* 
)T J(O*)) (5.1) 
where J is the Jacobian matrix of the output (D(O) at the optimal parameter values, 
0*, (i. e. the NxP 
matrix with the (n, p)th element estimated by 
af(x,,, 0)/aOp at 0% for N data points and P parameters) and s2 
is the estimated residual variance, previously defined in Equation 
3.12 (Section 3.3.3.1). J is estimated by 
introducing deviations into each optimal parameter value in turn and re-evaluating 
the change in the 
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predicted dependent variable at each data point (Step 10a). Given the covariance matrix it is 
straightforward to determine the correlation matrix, ý (Step 10c), 
P12(3'19'- pIper117p Pl 2 «' Pl P 
2 
ý= P21a2(TI CF2 ... P2P'72(YP 
=> C= 
P21 
*o **' P2P (5.2) 
2 
-PP1aP(yl 
PP2(TP(T2 **' C7P 
- -PPI 
PP2 ... 1-0- 
where p is the correlation coefficient and cy is the parameter standard deviation (determined from the 
square root of the parameter variances, C72, in the leading diagonal of the covariance matrix). In Step l0e a 
unit hyper-rectangle of dimension P is sampled using the quasi-Monte Carlo Hammersley sequence 
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sampling scheme (HSS) of Diwekar and Kalagnanam (1997). This scheme is selected since the significant Z: ' 
improvement in efficiency which can be obtained has been verified for stochastic chemical processes in 
previous work (Diwekar and Kalagnanam, 1997, Kalagnanam and Diwekar, 1997). In addition, the quasi- 
Monte Carlo nature of the Hammersley points means that the number of observations required to get a 
reasonable convergence of the output performance variance (e. g. 1(7( of the true value) was shown to be 
less strongly related to the number of input uncertainties than a stratified technique such as LHS- Their 
results showed the decrease in the required observations for a given number of uncertainty factors was of 
the order of 2-200 between HSS and LHS for the linear and non-linear functions employed. The HSS and 
the sample correlation inducement techniques are described in the following paragraphs. 
Diwekar and Kalagnanam (1997) define the M points of the HammersleY sequence variant, ep(m) in a P- 
dimensional hyper-cube as, 
ep (m) =I- cp (m) (5.3) 
ni 
c PH m, 
(PR, (M), (PR, (M), (PRp- 
I 
(M for in = 1,2.... M (5.4) 
where integer in is written in radix-R notation, resulting in the expansion of integer in into (radix) base R 
scale with integer coefficients, ak, 
ma va, -,,... a -, a I ao 
(0: 5 ak <R P) 
(5.5) 
ao +ajR I p +aR 
2... 
+avRv 
-pp 
0:! ý ak <R P) 
(5.6) 
and R1, R21-, Rp-1 are the first P-1 prime numbers (integers) and V 109RM -": [(In m)/(In R)] which is 
rounded down to the nearest integer. The inverse radix number, (p (a unique fraction between 0 and 1), for 
the mth observation and pth factor, is constructed by reversing the order of the digits of m (integers ak) 
around the decimal point, 
(111) =. aoala a, 
(0:! ý ak < RP) (5.7) 
=aOR-11 +ajR -2 +... +avR-v-l 0:! ý ak <R 
(5.8) 
p- p- P-I P) 
For example, to place the first six points in the second dimension of a unit 
hyper-cube (p=2), then the 
binary scale is used (first prime number RI=2) and the Inverse radical numbers, (PAM), are obtained 
from, 
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In In 92(M) 92 (M) 
Decimal Binary Binary Decimal 
I 1 0.1 0-5 
2 10 0.01 0.25 
3 11 0.11 0.75 
4 100 0.001 0.125 
5 101 0.101 0.625 
6 110 0.011 0.375 
(5.9) 
and so on for M points, where the decimal scale value for (PAM) is determined from Equation 5.8. It is 
clear from Equation 5.8 that the addition of points does not disturb the positions of those already placed. 
To generate the Hammersley points Diwekar and Kalagnanam (1997) presented an algorithm, shown in 
Figure 5.4, which is implemented in this thesis. The sub-routine (invradix) used in this thesis for the 
generation of the inverse radix notation for (pR(M) is based on long division and is valid for any magnitude 
of P assuming P is less than M. Since a large number M is defined a priori to the sampling routine, such 
that the convergence criterion on the output is met for an observation number (m) less than M, then the 
first dimension (p=1) associated with the first column of cp(m) in Equation 5.4 (m/M) will not be covered 
for the range between m/M and M. To avoid this the first column of the Hammersley sequence denoted in 
Equation 5.3 is not used in the sampling routine employed in this methodology. 
As mentioned in Section 3.3.4.3, Diwekar and Kalagnanam (1997) used the rank correlation technique of 
Iman and Conover (1982) to induce any correlation structures between independently generated inputs 
which may be apparent due to the simultaneous estimation of parameters. This approach is implemented in 
this methodology as depicted in Step 10f of the sampling scheme (Figure 5.3). The basis of this approach 
assumes that rank correlation coefficients are a meaningful way to describe dependencies between 
stochastic inputs. The desired rank correlation matrix, C*, of a matrix of independently generated sample 
input (column) vectors, X, is set as equal to C (the desired correlation matrix of X). The elements of the 
columns of X are rearranged so that the desired rank correlation structure results between the inputs. This 
rearrangement is achieved by defining a new matrix in Step l0e, K, which has the same dimension as X 
but is independent of X. Iman and Conover (1982) used random permutations of the van der Waerden 
scores for each column in K which were found to give a correlation matrix close to the identity. Diwekar 
and Kalagnanam (1997) used the Hammersley points which is likewise implemented in this methodology. 
These are inverted over the standard normal cumulative distribution (mean and standard deviation equal to 
one) and the elements in K are rearranged to obtain the correlation structure defined by C, to c,, ive a 
matrix, K*. Since C is positive definite (i. e. xTCx >0 for any non-zero vector x) Cholesky factorisation is 
used to obtain a lower triangular matrix, L, such that, 
LL 
is multiplied by LT to give a matrix, K*, 
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KI! 
If the correlation matrix for K, E, is the identity matrix (i. e. zero correlations between the columns of K) 
then K* has a correlation matrix which is C. Not only is it necessary that the correlation matrix of K is 
close to the identity matrix but also the correlation and rank correlation matrices of K* should be close to 
each other. If these two conditions are met then the desired correlation structure can be induced into X by 
rearranging each column vector of X into the same rank order as the vectors of K* to give the desired 
input matrix X*. In this way, the sample rank correlation structure of X* will be the same as that for K* and 
Figure 5.4. Algorithm for the generation of Harnmersley points (Diwekar and Kalagnanam, 1997). C- Cl I 
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approximates C to the same extent that the rank correlation matrix for K* approximates C. Iman and 
Conover (1982) provide a correction for the situation when E is not close to the identity matrix, 
E=QQT (5.12) 
K* = K(Q-1 
)T 1! (5.13) 
where Q is the lower triangular matrix of E and the correlation matrix of K* is C. The elements of X are 
reordered according to the rank of the corrected matrix K*. This correction factor is incorporated in the 
sampling routine provided in this methodology. 
In Step 10h the columns of the reordered input matrix X* are inverted over their respective cumulative 
distribution functions according to their distribution parameters. The distribution parameters are 
determined either from multi-parameter regressions (Step 10d) or from single parameter regressions or 
assumed values as already defined in the stochastic model (Step 10g). The stochastic system is solved in 
the Uncertainty Analysis in Step 11 (Figure 5.3), to obtain probability distributions and distribution 
parameters (expected value, E, and variance, Var, from the sample estimates given in Equation 3.26 and 
3.27, Section 3.3.4.3) for the desired process variables. This is achieved by sequential simulation of the 
deterministic model in Step 13 at each observation of the uncertain parameters and at the initial conditions 
and operating conditions fixed in Step 12, given the matrix of stochastic input observations with any 
induced correlation structures (X*, from Step 10h in Figure 5.3) and the deterministic model of the 
complete flowsheet defined in Step 5 (Figure 5.2). 
In Step 14 a convergence test is employed to terminate the solution of the stochastic model when the 
sample estimates of the parameters characterising the distributions (mean and variance) of the stochastic 
model output criteria are deemed to remain sufficiently unchanged with increasing samples. The 
convergence test used in this methodology is a tolerance limit on the average squared deviation measured 
in a distribution parameter, w, from the estimate at the current iteration observation, Mb. over a specified 
number of preceding iteration estimates, ma. This limit, Aw, for the qth predicted process output quality 
criterion is shown in Equation 5.14, 
Aw,, < Ew, q 
n1a 
(5.14) 
where w is the mean or variance estimate over in, observations and E is a permitted tolerance. In this work 
a value of I% of the current iteration value of w is suggested for F-, and a value of 100 scenarios for Ma- 
The retaining nature of the employed Hammersley sequence variant allows extra observations to be made 
without disturbing the current sample. This pernuts sequential placement of observations in Step 10i 
(Figure 5.3) in order to satisfy the convergence test in Step 14 without resimulation of the entire sample 
set. Termination of the sampling loop requires the multiple fulfilment of the convergence requirements for 
the mean and variance estimates for all of the desired process performance criteria. 
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Referring to Figure 5.2 the stochastic results of the Uncertainty Analysis can be compared to independent 
data to validate the uncertain model (Step 15). As discussed in the conceptual problem (Section 5.2) both 
the location and spread of the distributions in relation to the data are important in the validation. 
Independent data may already be available from other runs or it can be obtained from model validation 
runs. As stated by Basu et al. (1999) there should be plenty of opportunities to obtain more data for this 
purpose given the nature of pharmaceutical process development. 
In Step 16 Sensitivity Analysis is used to estimate the ranking priority of the key stochastic inputs 
contributing to the uncertainty in the stochastic process output criteria. In an efficient manner the 
sensitivity techniques employed in this methodology reuse the sample results of the Uncertainty Analysis 
to avoid the need for any further simulations of the deterministic model. The appropriate use of specific 
statistical measures which may be calculated in this analysis is discussed next. 
A schematic proposing the recommended measures according to the estimated form of the relationships 
between the inputs and outputs is shown in Figure 5.5. The mathematical definitions of these measures 
have been previously defined in Section 3.4.1. The presence of outliers or non-linear but monotonic input- 
output relationships can have a strong effect on the estimation of linear contributor measures and the use 
of rank transformed sample data may negate this effect in these estimations. This transformation is made 
in Step 16b to account for this eventuality. Hofer (1999) states that as a rule, if the coefficient of 
(16a) Sample results from 
the Uncertainty Analysis 
I 
(16b) Rank transformation 
of sample da 
I 
(16c) Coefficient of detemiination 
R2> RR 2 
Yes No 
use unranked data 
II 
use ranked data 
(16d) Check 
R2, RR 2>0.5 
Yes No 
IF 
(16e) Linear/monotonic input (16f) Non-linear/non-monotonic 
contributions input contributions 
CC, SRC RCC, SRRC CR CRR 
Scatter plots 
Figure 5.5. Schematic for the use of input contribution measures in the Sensitivity Analysis. 
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determination of the unranked data (R 2) is greater than that of the ranked data (RR 2) then the unranked 
data is used for Sensitivity Analysis. This rule is implemented in Step 16c. In addition, the use of linear 
measures may be unsuitable in the presence of highly non-linear models. The R2 is a measure of the 
proportion of the total variation in the output data that is explained by the linear regression model. If the 
R2 (or RR 2) is greater than 0.5 (Step 16d) then linear contributor measures estimated in Step l6e can be 
assumed to explain an adequate proportion of the observed variability in the output data. The correlation 
coefficient (CC) provides an estimation of the total variability in the input associated in a linear manner 
with the variability in the output. The standardised regression coefficient (SRC) measures only the 
variability in the input that is unexplained by the other inputs. This removes the effect of any spurious 
correlations to which the CCs are susceptible. If the R2 (or RR 2) is less than 0.5 then linear contributor 
measures explain too small a proportion of the observed variability in the output data and non-linear 
measures should be used in Step 16f. The non-directional correlation ratio (CR) is used since it is not 
restricted to the estimation of linear or monotonic contributors. If there is any element of doubt then 
scatter plots between individual input-output pairs can be viewed, though these may also be susceptible to 
spurious correlations. 
In addition to the direct identification of the key stochastic input-output associations as shown in Figure 
5.5, process sub-sequence contributions to uncertainty are estimated within an integrated flowsheet. These 
contributions provide a measure of the accumulation and propagation of uncertainty observed in 
particular process properties over certain operational sub-sequences throughout the complete sequence. A 
process sub-sequence criterion may either be related to the operational effectiveness of a stage/sub- 
sequence or it may be a particular stream property. In this way the cumulative influence that a number of 
minor contributors within a particular sub-sequence may exert on important inter-stage criteria is 
estimated. Key sub-sequences may be identified which would not necessarily correspond with the location 
of key input contributions identified using the ranking procedures based on the input-output associations. 
For this analysis it is assumed that the inter-stage criteria comprise of potential inter-stage plant data 
measurements. Each sub-sequence contribution is defined as the difference between the relative 
uncertainty in the two criteria defining a sub-sequence. These contributions are normalised with respect to 
the relative uncertainty in the final sub-sequence criterion to give a sum of the normallsed sub-sequence 
uncertainty contribution factors (SSQ equal to one over the complete process. 
Each SSC estimates the 
fraction of the endpoint uncertainty which has accumulated over a sub-sequence. 
A normalised sub- 
sequence uncertainty contribution of an inter-stage sub-sequence criterion, 
Q, over a sub-sequence, ss, is 
estimated, 
( UB LB (Q UB ri LB QSS - QSS ss-i - t2ss-i 
sscss 
UB LB 
YQ', for ss = I... SS (5-15) 
(QSS QSS ) 
P(), 
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where the uncertainty in each sub-sequence criterion is quantified by the width between the 5 and 95ý7c 
fractiles, QLB and QUB, relative to the mean value, pQ. 
In summary, Sensitivity Analysis (Step 16) is used to estimate the key input uncertainties and process sub- 
sequences which influence the uncertainty observed in the important process performance predictions. 
The inadequacies of the current deterministic process sequence model and associated parameter 
uncertainties are observed from the comparison between available validation data and these predictions. 
The optimal reduction in key parameter uncertainties (Step 17) is discussed in the next section. It is 
suggested that this combined information could be used to (a) focus relative efforts towards improving a 
specific process model within the sequence by inferring the key uncertain phenomena associated with the 
identified process sub-sequence and parameter uncertainties and (b) support decisions concerning what 
data to collect or what experiments to plan (Step 18 - see the data driver feedback loop in Figure 5.2). The 
specific details regarding these decisions are not part of the problem considered in this thesis. 
5.5 Optimisation under uncertainty 
The typical algorithm for the solution of a stochastic optimisation problem is represented by the schematic 
shown in Figure 5.6. This algorithm provides the basis for the stochastic optimisation problems posed in 
this thesis. In a convenient manner the HSS sampling procedure implemented in the Uncertainty Analysis 
(Figure 5.3) is also implemented in the stochastic optimisation algorithm as was proposed by Diwekar and 
Kalagnanam (1997) and Kalagnanam and Diwekar (1997). The uncertain factors in the stochastic problem 
are sampled within the optimisation loop and may be subject to a convergence checking sub-routine for 
Initial decisions 
Nonlinear constrained 
optlrnýisatlon routine 
I Optimal solution 
New decisions 
................... ............................................................................ I .................... 
Sampling routine 
-------------------------- 
Convergence check on 
output distribution 
Stochastic 
objective function 
and constraints 
Deterministic model 
parameters 
Stochastic model ................................... 
................................................................................................. .................. 
Fixed parameters 
Initial conditions 
Figure 5.6. Stochastic optimisation algorithm. 
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the parameters characterising the distributions of the output. If the convergence checking sub-routine is 
selected the algorithm evaluates the deterministic model sequentially at the current decisions determined 
by the optimisation routine, until the specified tolerance in the convergence checking sub-routine is 
satisfied for each function evaluation. In this way the stochastic problem is posed as a non-linear 
programming (NLP) optimisation which can be solved using a gradient-based optimisation technique. An 
alternative option is to assume a fixed sample size (the convergence checking option is not selected) 
which permits the sampling routine to be placed prior to the optimisation loop. In this case the problem 
can be reformulated as a multi-scenario deterministic optimisation problem in which the scenarios are 
evaluated simultaneously at each stochastic function evaluation. This may also be solved as a NLP 
problem. This can save optimisation time by providing better gradient information for the (gradient-based) 
optimiser and by using less scenarios at the expense of solution accuracy (since convergence to a 
particular tolerance level is not guaranteed). 
In this thesis the former approach (convergence checking invoked) is used for reasons based on the desire 
for solution accuracy with efficient approximation of the P-dimensional input uncertainty space where the 
number of factors may be large (e. g. greater than 10). The quality of the gradient information supplied to 
the optimiser may be poor due to the 'random' representation of the stochastic model at each optimisation 
iteration which may increase the number of optimisation iterations and computational time. 
In this work a gradient-based NLP optimisation program (Matlab Optimisation Toolbox fmincon function, 
The MathWorks, Inc., USA) employing successive quadratic programming (SQP) is used. In SQP, at each 
major iteration the NLP problem is modelled as a quadratic programming sub-problem (QP) which is 
solved to obtain a new approximate solution at which a new QP sub-problem is generated. 
To reduce the size of the NLP problem the uncertainties which do not appear to provide any significant 
contribution in the full stochastic process evaluated in the Uncertainty Analysis are not included in the 
optimisation. The important parameters are determined from the Sensitivity Analysis. In addition, less 
strict convergence criteria are employed in the stochastic optimisation as compared to the Uncertainty 
Analysis. This reduces the number of scenarios in the stochastic model, evaluated in each function 
evaluation of the optimisation algorithm. Grossmann and Sargent (1978) justify a reduced accuracy 
approach for the uncertain performance estimation in their work for design under uncertainty, since the 
input parameter distribution functions will rarely be known sufficiently well. 
In a general stochastic programming formulation the decision variables may be scenario independent as in 
the 'here and now' context, or scenario dependent as in the 'wait and see' context. In this methodology the 
former is selected. The reason for this is to reduce the over optimistic uncertain performance solutions 
which would be obtained under the assumption of perfect control with knowledge of uncertaintv 
realisations. This assumption is not made in this methodology since perfect 
knowledge is assumed to be an 
unrealistic situation. On the other hand 'here and now' solutions can 
be more conservative. The 
compromise of incorporating feedback controller models is not employed in this methodology. 
One reason 
is that the control of pharmaceutical operations is often manual. 
Validation of the optimal solution is 
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performed by simulating the stochastic model under the original number of input uncertainties using t:, C) 
stricter convergence limits on the performance distribution parameter estimates. 
The four different stochastic optirMsation problems associated with the methodology in Figure 5.1 C C- 
(Section 5.3) are defined in the following sub-sections. 
5.5.1 Optimal input uncertainty reduction 
Desired levels of reduction in the uncertainty of predicted output criteria can be achieved with reductions 
in the important uncertain parameters of the stochastic problem. A quantitative estimate of the extent of 
reductions required in the uncertainty sources to meet the desired output uncertainty levels can be 
provided. This can be posed as a stochastic optimisation problem which is solved using the algorithm 
shown in Figure 5.6. The solution to this problem constitutes Step 17 in the schematic for combined 
systematic model development and Risk Analysis (Figure 5.2, Section 5.4). The decision variables are 
fractions of the original values (before uncertainty reduction) of the parameters which characterise the 
spread of the input uncertainties. The values of these decisions are passed to the sampling sub-routine 
(from the optimiser) which locates observations from within the redefined uncertainty space. The resulting 
observations form the matrix of parameter scenarios. The deterministic model is solved at each scenario 
given the set of fixed parameters, initial conditions and operating policy within the stochastic model. The 
objective is to maximise the sum of the decision variable fractions whilst maintaining desired levels of 
output uncertainty reduction with the incorporation of inequality constraints on the uncertainty in the 
desired output distributions. The objective function value and constraints are estimated from the 
simulation of the stochastic model and returned to the optimiser. The general formulation for this 
optimisation problem is shown in Problem PI for input uncertainties which are stochastic (assumed to be 
normal) and/or deterministic (uniform), 
Objective function 
ST DT 
max -5d, 
St=l dt=l 
subject to: 
deterministic equations (process models) 
v s=I S, In =1M Jo, 
s, m( o, s, m, o, s, m, Yo, s, m, ýd, st, m, 
odi, 
m 
V S=l S, m=L.. M fs, 
m(-ýS, M, Xs, m, Ys, m, 
ýd Ost, m 
Odt, 
m 
)= 0 
deterministic inequality constraints 
gs, 
m 
(X x0 Odt, m 
)'ý 0V S=l S, m=I... M 
s, niq s, m, 
A's. m, -d, st, m 
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stochastic inequality constraints 
FW(4Dq aq FW((Dq q=l 
decision variable bounds 
0< (5st <I 
0<6dt <1 
st=l... ST 
V dt=l... DT 
uncertainty space characterisation 
ON =fO, tlN(Y' 
6sta f 
st st V st=l... ST 
U : ": 
fodt IU (Pdt '- 6dt A Odt 
, Yd'i + 
3di A Odt 
UB 
_OLB 'ý'Odt = 
Odt 
dt dt dt 
V dt=l... DT 
V dt=l... DT (Problem PI) 
where J, f and g are the vectors of initial conditions, equalities and inequalities. The indices o, s, m, d, q, st 
and dt are associated with the initial conditions, process stages, parameter scenarios, operating policy 
variables (z), stochastic output performance criteria (0) and the stochastic and deterministic uncertainties 
(0). X are the time derivatives of the differential variables, x, and y are the algebraic variables. For a 
dynamic optimisation problem, the operating policy variables, z, comprise the set of the time invariant 
decisions, i), time dependent decisions, v, and operation time, tf. FW((D) is the width between the 5 and 
95% fractiles for the performance criteria, (D, and cc is the desired fraction of the original value of the 
criteria before uncertainty reduction. The prime represents the original value before uncertainty reduction. 
The total uncertainty space, 19, is defined as the stochastic (assumed normal) and the deterministic 
(uniform) space, E)N and Ou, combined. The former are characterised by the mean and standard deviation 
(ýt and cy) and the latter by the mean placed equidistant between upper and lower limits (()UB and ()LB). 
It is assumed that the same distribution means (nominal input parameter values) as determined or assumed 
in the original stochastic problem, are maintained. If the stochastic problem contains decisions in 
correlated inputs, it is assumed that a change in the spread of one of the correlated parameters gives an 
equivalent change in the others, while maintaining the same correlation structure. A trade-off curve may C' 
be constructed between the extent of optimal input reduction and desired level of performance uncertainty 
by solving Problem PI at different values of a. 
5.5.2 Process flowsheet optimisation 
In this problem formulation, process optinusation of the flowsheet performance under uncertainty is 
r.: 1 L- a solution which accounts 
for the considered. Operating policy optimisation of the stochastic model Olves I 
combined influence of all the significant uncertainties included in the problem. 
It does not rely on the 
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identification of limiting scenarios with little chance of occurring In the probabilistic sense and which lead 
to more conservative solutions. 
The operating policy decision variables of a given process flowsheet under uncertainty are optimised for 
performance using the stochastic optimisation algorithm shown in Figure 5.6. The set of decision variables 
can include time dependent, time independent and duration time operating variables for the process stages, 
depending on the dynamic nature of the individual process models and the perceived suitability of 
conceptual operating policies with regard to the equipment (i. e. limited implementation of dynamic 
control profiles). The general formulation for this stochastic optimisation is shown in Problem P2 for a 
stochastic objective in a deterministic quality criterion (D, 
Objective function 
max F(EI(D(xs, mlxs, m, ys, m, Zd, 
ost, 
m, 
odt, 
m)l) Zd 
subject to: 
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0 V s=l... S, M=l M 
f,,, (Xs, 
m, Xs, m, Ys, m -d 
ost, 
m, 
odf, 
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gs, m 
(Xs, 
m, Xs, m, Ys, m, Zd, 
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m, 
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m 
): 5 0 S=l S, m =I... M 
deterministic quality criteria 
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(Oq, 
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where the general continuous deviation function, fde,, introduced by Samsatli et al. (1998), represent a 
variety of one or two-sided deviations of a deterministic quality criterion, 0, from a desired constraint, 0 th. 
The binary variables, 0, allow the representation of both one-sided (non-symmetrical) and two-sided 
deviation functions, d, and d2, to be contained in fd, The use of the hyperbolic smoothing function 
(Samsatli et al., 1998) to approximate the binary variables in the continuous deviation function, fdev, 
means that the stochastic problem including non-symmetrical deviation functions does not contain 
discontinuities due to these deviations. This allows the formulation of a problem which can be solved as a 
NLP optimisation problem using gradient-based methods. A general stochastic function,. F, is used to 
represent the objective function and any stochastic inequality constraints. These can represent robustness 
metrics which may be comprised of the expected value (E) of the deterministic deviation functions. These 
could include probabilistic quantities such as those discussed in Section 3.3.2, including the expected 
value, or typical two-sided measures of variance and Taguchi's quality loss, or one-sided measures such as 
probability of constraint failure and expected extent of constraint violation (Samsatli et al., 1998). They 
are estimated from the sample estimates given in Equations 3.26 to 3.29 (Section 3.3.4.3). The input 
parameter uncertainty space remains fixed, defined by the distribution characterising parameters passed to 
the sampling routine (Step 10d and Step IOg in Figure 5.3, Section 5.4), specified from prior model 
development and Uncertainty Analysis. The decision variables are operating policy variables which are 
specified in the 'here and now' context (scenario independent). In Problem P2 the algorithm passes the 
decisions from the optimiser directly to the stochastic model simulator, bypassing the sampling sub- 
routine since the input uncertainty space remain unaffected by the decisions (as compared to Problem P 1). 
The sampling sub-routine is then invoked by the stochastic model simulator. 
5.5.3 The value of perfect information 
The concept of the value of perfect information (Raiffa, 1968), VPI, can have a useful application to 
process design optimisation under uncertainty as suggested by 
Pistikopoulos (1995). The provision of 
perfect knowledge in replacement of certain sources of input uncertainty can 
be quantified using the VPI 
if physical measurement permits. 
For instance, physical characteristics of important external influences 
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which may be uncertain can be potentially certain if they could be accurately measured. It is assumed that 
this does not extend to the parameter uncertaIntles associated with the deterministic process models for 
which perfect information of the values is unrealistic. 
The complete range of uncertainties considered in this problem are the stochastic and deterministic 
parameter uncertainties (as in Problem PI and P2), O, t and Od, and in the potential certainties, Op,. A 
general definition of the value of information, VI, is defined in Equation 5.16 as a stochastic performance 
objective in some criterion, F(EI(D)), determined over some definition of the uncertainty space, E), 
VI = F(Ee J(Dj) (5.16) 
The VPI is defined as the performance objective achieved with the perfect knowledge of the potentially 
certain properties (VIwait) less the performance objective achieved under uncertainty in these properties 
Mhere), as shown in Equation 5.17. This is illustrated in Figure 5.7 where the VP1 is the average 
difference between Vlwai, andVIhe,, over the range of potential knowledge in Opc (Equation 5.18). Vlwait IS 
defined as the value of information objective (Fwaft) achieved with perfect knowledge of Opc but without 
perfect knowledge of O, t or Odt- Vlhere is defined as the value of information objective (Fhere) achieved 
without perfect knowledge of Op, or 0,, orOdt. The VPI can be approximated as the expected value of Fwai, 
less Fhereover Opc space as shown in Equation 5.19, 
VPI = Eop, 
JV'wait I- Eop,. JVIwail 1 (5.17) 
=E OP, 
JVIwait 
- VIhere 
1 (5.18) 
= Eepc 
ý Fwait, 
m'(Eo,,, ed, 
I'D 1) - Fhere, m' 
( Eo,,, ed,, ep, 
J(Dj)ý (5.19) 
where index m' represents the observations in Op, space. The VPI is computed using the approximation 
given in Equation 5.19. This involves a number of steps shown in Figure 5.8. Independent stochastic 
optimisation problems are solved for VI, aj, and for VIhere- 
In the case of Vl,,,, i,, the entire uncertainty space 
vi 
0 
PC 
Figure 5.7. VPI for potentially certain properties. C- 
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comprises of uncertainties which are viewed by the operating policy decision variables as scenario 
independent (i. e. O, t and 
Odt) and uncertainties which are viewed as scenario dependent (i. e. Opc). This 
means that is necessary to differentiate between the space of the uncertain and potentially certain 
parameters (Step 1a) and perform a number of 'here and now' optimisations under 0,, and Odt space at 
specific realisations in Op, space. The total number of observations, M', and their placement in Opc space 
are determined by the sampling sub-routine in Step 2. Fwai, and Fhe, are both computed at these values of 
Opc. A relatively slack tolerance is recommended for Step 2 to limit the number of observations in Opc 
space to maintain the solution of 'wait and see' problems to a reasonable number. With the solution of M' 
4 wait and see' optimisation problems in Step 3a (one at each observation of Opj, M' optimal values of 
Fwai, and M' vectors of optimal decisions are obtained. In the case Of VIhere, a single 'here and now' 
optimisation is solved in Step 1b, under the entire uncertainty space comprising Ost, Odt and 0p, This yields 
a single 'here and now' optimal decision policy. This policy is implemented in Step 3b to evaluate M' 
values of Fher, at the same reallsations in Opc space as were used for the F, aj, solutions. 
The VPI can then 
be approximated in Step 4 with the values for Fwai, and Fhere using Equation 5.19. 
It is possible that some of the stochastic simulations for Fhe, at the realisations of Opc may predict 
violations in any stochastic inequality constraints employed, since the operating policy decisions are 
detern-Uned from the 'here and now' optim'sation without perfect knowledge of Opc, It is desirable to 
consider these violations as some form of penalty in Fhere so that the VIheire reflects the poor behaviour of 
(1a) Split E) space into 
(Ost, Odt ) and (Opc) 
(2) Sample Opc space giving 
M' observations 
(3a) Solve a 'wait and see' 
optimisation under I 
Ost, Odt) 
space, at each Opc realisation 
--) M' optimal solutions of F, aj, 
(1b) Solve 'here and now' 
optimisation for Fh, 
under 0, Odt, Opc (=- E) space 
---> single optimal decision vector 
(3b) Simulate stochastic system 
under 0, Od, G E) space, at the M' 
realisations in Opc space 
-> M' sub-optimal solutions of Fh,, 
(4) Compute VPI from 
Equation 5.19 
VP1 = EI F, - Ff) 
Figure 5.8. Schematic for the computation of VPI for potential certainty. 
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these stochastic criteria. In this methodology a penalty function, There, is used to penalise the original 
value of Information objective (Fhere) by some function of the extent of any stochastic inequality constraint 
violations, [(Fhere, q, s - Yq,, ) :ý 01, as shown in Equation 5.20, 
VIhere ': -- There 
(Fhere, gq, 
s 
(Fhere, 
q, s - 
Yq, 
s 
)) 
(5.20) 
where yq is the desired constraint limit in the qth criterion Fhere, q, s and P is a binary variable which is one in 
the case of a violation and zero otherwise. 
5.5.4 Decision variable tolerance 
It is unrealistic that a single optimal operating policy can always be implemented due to process 
variability and safety reasons. The maximum amount of tolerance permitted in a 'here and now' optimum 
operating policy can be ascertained from an optirrUsation determining the maximum deviation In the limits 
around the 'here and now' optimal operating policy, subject to stochastic performance constraints. The 
general formulation for this stochastic optimisation is given in Problem P3, where the tolerance is 
modelled as uncertainty in the 'here and now' optimum operating policy values which are assumed to be 
uniformly distributed. 
Problem P3 combines the aspect of the determination of uncertainty space of the input uncertainty 
reduction optimisation in Problem Pl, with the stochastic performance constraints of the process 
flowsheet optimisation in Problem P2. In Problem P3 an extra set of dimensions, Ou, in the overall 
uncertainty space, E), represents the tolerance in the operating policy variables. The decision variables, 8u 
and 8L , are the 
disjoint fractions of the available operating policy range in each direction from the single 
'here and now' optimum policy values, z*, 
UB* 
, 5U - 
Zd Zd 
d UB *I 
Zd Zd 
LB* 
L -7d ýd 
d LB 
Zd 7-d 
(5.21) 
where the superscripts UB* and LB* represent the upper and lower tolerance bounds determined in the 
optimisation and UB and LB represent the bounds on the operating variables. The tolerance is defined as 
the fraction of the total available operating policy range which is occupied by the maximum feasible 
operating policy range. The objective function is the average tolerance over the set of operating policy 
variables. The stochastic optirrUsation algorithm (Figure 5.6) is implemented for the solution of Problem 
P3. The upper and lower bounds on the policy uncertainties are constrained by the desired stochastic 
performance targets and the deterrranistic model equations. The stochastic constraint performance targets n 
(y) may be specified as some function of the performance achieved in the optimal 'here and now' solution 
associated with the z*- 
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5.6 Summary 
A methodology and mathematical techniques are presented for the systematic and quantitative 
management of uncertainty in process sequences described with deterministic models. It is split into two 
major areas of study, both involving stochastic descriptions of the system. The first is associated with 
systematic model development and the second is associated with process optimisation under uncertainty. 
A combined Risk Analysis and systematic model development approach is suggested to systematically 
account for model parameter uncertainties during model building. This aims to provide information to 
focus and support data collection and model development decisions with respect to the predicted 
stochastic response to the quantified uncertainty in the process model of the complete sequence. An 
efficient Hammersley sampling strategy is implemented to provide coverage of the defined uncertainty 
space and generate the stochastic model. Uncertainty Analysis and Sensitivity Analysis sampling based 
techniques are proposed to quantify the uncertainty in important process performance criteria and identify 
the sources of key contributions which could be used to focus the direction of further modelling effort. 
The iterative nature of the systematic modelling procedure pernuts the tracking of the effects of the 
uncertainty contained in the models as more data becomes available and is incorporated in the models. 
Stochastic optimisation problem formulations are stated for four different problem cases which can be 
solved using a conventional stochastic optimisation algorithm. The methodology implements the same 
sampling strategy (HSS) as employed for the Risk Analysis. The first problem case quantifies the required 
levels of parameter uncertainty reductions necessary to achieve desired levels of uncertainty in the output 
criteria. The second problem provides a robust optimal flowsheet operating policy under uncertainty. In 
addition, the value of perfect information is solved using this second formulation. In this methodology the 
VPI is concerned with those external process inherent uncertain properties which could feasibly be 
directly measured a priori. The final problem formulation determines the level of tolerance permitted in 
operating policy variables whilst maintaining target levels of performance uncertainty. 
In the following chapters two case studies are presented to verify the methodology and techniques which 
have been proposed here. The first case study (Chapter 6) investigates a published industrial m ulti-phase 
reactor process. The Uncertainty and Sensitivity Analysis methods are implemented and 
the benefits of the 
robust optimisation method (second problem case) are examýined. 
The second case study (Chapter 7,8, 
I and 9) is more comprehensive, comprising of a complete integrated pharmaceutical process sequence. 
it 
airris to provide a rigorous examination of the methods proposed in this chapter. 
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CHAPTER 6 
CASE STUDY 1: A MULTIPHASE REACTOR PROCESS 
6.1 Introduction 
In the previous chapter an approach to integrated design under uncertainty was proposed. Risk Analysis 
methods for the quantification of uncertainty and identification and ranking of major contributors in 
modelled process sequences are presented within a systematic model development scheme. The stochastic 
problem generated is reduced in size for the stochastic optimisation of process performance under 
uncertainty and tolerance to operating policy variable error. In this chapter, aspects of the Uncertainty 
Analysis and Sensitivity Analysis with the optiM]sation for process performance are applied to a reaction 
process under uncertainty. Case Study I is based on a multiphase reaction process developed with the aid 
of process modelling and computer simulation (Sano et al., 1998). This chapter aims to verify the aspects 
of the methodology mentioned above and to express the pitfalls and benefits associated with the 
consideration of uncertainty in process models. 
6.2 Process description 
Case Study I is based on an exothermic multiphase reaction process and Idnetic model investigated by 
Sano et al. (1998). The process is for the production of a pharmaceutical intermediate, formed from the 
amination of a bromopropyl compound. The authors developed a kinetic model based on reaction 
calorimetry data obtained under laboratory conditions in order to determine the optimum feasible and safe 
operating policy. 
Solid particles of the active pharmaceutical ingredient (API) bromopropyl feed compound (A) reside in an 
organic solvent (methanol) inside the reaction vessel. A fixed volume of a 50 wt% aqueous d1methylamine 
reagent (B) is added to the vessel at a constant flowrate under continuous agitation. The solids gradually 
dissolve and react with the dimethylamine. A diagram of the process is shown in Figure 6.1. The exact 
physico-chemical phenomena for this process are not known. The reaction consists of a parallel-series 
reaction in which the dimethylamine reacts with the dissolved API feed to 
form the desired intermediate 
(C), Equation 6.1, which in turn reacts with the active feed (A) to form a dimeric byproduct (D) in 
parallel, Equation 6.2. D is stated to be very difficult to remove in the 
downstream purification stages. 
A+B --4 C Main reaction 
+C -4 D Sub-reaction 
(6.1) 
(6.2) 
Intrinsic first order reaction kinetics are assumed in the deterministic process model proposed by Sano et 
al. (1998). An initial rate 
limiting period due to the dissolution of solids B, was observed to be 
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Dimethylamine, aq (Bý 
Methanol, org 
Bromopropyl, solid (A) 
Figure 6.1. Reaction process, Case Study 1. 
independent of solvent concentration and agitation speed within the range of conditions approved. A 
crude approximation of first order kinetics (with Arrhenius constant and activation energy) is assumed in 
the model for this dissolution controlled period. This period was observed to last until approximately 55% 
conversion of A for all the conditions considered, at which point the reaction appeared to be limited by the 
intrinsic reaction kinetics. 
The kinetic model is integrated with a standard semi-batch reactor model with constant volume addition 
(of reagent B). Consideration of the cooling capacity of the reactor resulted in a limiting relationship 
between the operating policy variables of feed B addition time, tadd, and isothermal temperature, Ti,,,. For 
the purposes of this study, this relationship is well approximated with Tj, as a quadratic function Of tadd 
(see Figure Al, Appendix A), since data regarding the energy balance is unavailable. The model equations 
used to describe this process are given in Model Al (Appendix A). 
6.3 Nominal optimisation 
Sano et al. (1998), state that one of the objectives for the development of the model was to help determine 
the best operating conditions for maximum product yield, Yc. A reaction time, tf, of less than 8 hours 
(terminated when the rate of conversion of A falls below 0.1%) and a final yield in the impurity, YD, Of 
below 2% are desired be maintained. The optimal results the authors determined through repeated 
simulation of their model are given in Table 6.1. Optimisation of an equivalent model for maximum 
product yield subject to the stated constraints (Problem P4), using a non-linear constrained SQP 
optimlsatlon software, are shown to compare reasonably well (Table 6.1). 
Objective function, 
Integrated design under uncertaintYfor pharmaceutical processes 
max Yc T'so "add 
subject to, 
model equations (Model A I, Appendix A), 
tf 
YD !5 2% 
288: ý Ti,, !ý 313 
05: 5 t,, dd :53.0 
Tiso ý' 7.06(t,, dd 
)2 - 43.50(t,, dd 
)+ 352.67 (Problem P4) 
Table 6.1. Comparison between the optimal literature results (determined through repeated 
simulation) and optimal results obtained with SQP optimisation, Case Study I. 
Sano et at. (1998) SQP optimisation 
Criteria YC (%) Not given 97.1 
YD M -1 1.4 
tf (hr) -7 6.7 
Operating policy Ti,. (K) 298.0 296.8 
tadd (hr) 1.7 1.79 
6.4 Consideration of uncertainty in the stochastic model 
Uncertainty in the model parameters could have a large effect on any results predicted by the model. This 
may be of particular importance regarding the optimal operating policy determined subject to the safety 
constraint and the desired limits on process performance. 
Perturbation Analysis indicates that the uncertain parameters which have a non-negligible influence on 
yield of C, Yc, yield of D, YD and the final time, tf, are the kinetic rate law parameters (Eal, A,, Ea2, A2, 
Eadiss, Ajj, see Model Al, Appendix A), the transition point from dissolution controlled kinetics to 
intrinsically controlled kinetics, Xdiss, and the isothermal temperature, Tj,. These parameters are assumed 
to be uncorrelated and their assumed uncertainties are quantified in Table Al (Appendix A). A total of 
456 scenarios were required to satisfy the convergence criterion of 1% error in the mean and variance 
parameters over a backlog of 25 observations for bothyDand tf. Graphs of the evolution of the mean and 
variance estimatesOf YDare shown in Figure A2 (a) and (b), Appendix A. 
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The main results from Sensitivity Analysis of the Uncertainty Analysis sample generated under the SQP 
nominal optimum conditions are shown in Table 6.2. Since the coefficients of determination computed on 
rank transformed data (RR 2) are greater than those on the unranked data (R 2), then sensitivity measures are 
based on rank transformed data (according to the Sensitivity Analysis schematic shown in Figure 5.5, 
Section 5.4). The effect of rank transformation is shown in the normalised scatter plot (see Figure A3 (a), 
Appendix A) between Yield D and the sub-reaction activation energy (EaD. This plot shows that the 
ranking transforms the non-linear but monotonic relationship shown in the unranked data (dots In Figure 
A3 (a)) to points (circles in Figure A3 (a)) which may be better quantified by linear sensitivity measures. 
The main Sensitivity Analysis results in Table 6.2 indicate that the activation energy parameters in the 
intrinsic reaction rate laws (Ea] and Ea2) are the most strongly related to the observed uncertal I nty in the 
output criteria (Table 6.2). 
Table 6.2. Key SRRC contributors to predicted uncertainty under the 
nominal optimum operating policy, Case Study 1. 
Yield C Yield D Final time 
R" 0.65 0.65 0.73 
0.85 0.80 0.99 
Eal -0.62 0.60 0.99 
A, 0.02 -0-02 -0.03 
Ea2 0.74 -0.76 0.03 
A2 
-0.03 0.03 -0.00 
6.4.1 Stochastic process optimisation problem 
The proposed optirnisation problem under uncertainty aims to maximise a mean-variance objective In the 
product yield (Yc). The operating policy decisions, tadd and Tj,, are scenario independent, assuming the a 
priori 'here and now' mode of control where knowledge of particular realisations of the uncertainties is 
not assumed in the optimal solution. 
One-sided stochastic constraints are incorporated to maintain the desired limitations on the impurity yield 
(YD less than 2.0%) and the final time (tf less than 8 hours). Since certain realisations within the 
uncertainty space may result in values of the endpoint impurity yield and final time exceeding the desired 
limits, expected violations of these limits of 1.5% and I hour, respectively, are permitted. This allows 
some tolerance to the desired limits (E, i,,, the summed extent of violation of those observations failing 
divided by the total number of observations) which permits the determination of optimal solutions which 
are not overly conservative. 
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To solve this problem the stochastic optImIsatIon formulation Is given in Problem P5. This is derived from 
the general formulation, Problem P2 (Section 5.5.2). The binary variable approximations, 0, return zero 
for scenarios failing the desired limits and one otherwise. The general deviation function, d, is zero for 
passing scenarios and d2, is a linear deviation (O-Oh) for failing scenarios. The stochastic optimisation 
algorithm shown in Figure 5.6 (Section 5.5) is used to solve the problem, where the Hammersley sequence 
sampling scheme is used to place observations in the uncertainty space. A reduced convergence criterion 
of ± 2% deviation in the output distribution parameters is pern-kted to reduce the number of observations 
per objective function evaluation. 
Objective function 
maX K 
Probust 
f, T 11" Ynominal 
subject to: 
K) 
(7robust 
2 
anominal 
process model equations (Model A 1, Appendix A) 
binary variable approximations 
ßyD'm =1 
[tanhIZy 
c 
(2.0 
- YD, 
)l + l] 
2 
Af 
'm =1 
[tanhjýtf (8.0 
- tf 2 
stochastic inequality constraints 
E=I-2.0) < 1.5 viollyDI -1(1-&D, M)(YD, m m 
M=j 
IM 
E tf I =- I I-Af 'm 
tf 
'm - 
8.0) !ý1.0 violl ,( mm=l 
decision bounds 
0-50! ý tf !ý3.00 
288! ý Tiso :5 313 
uncertainty space 
Ea 1, Ap 
Ea, A Eadiss, Adiss, Xdiss , 
Tis, = 
lep 1N (PP 
, Grp)l 
V M=l M 
V M=l M 
V M=l M 
(defined in Table A I, Appendix A) 
where p= diss, 1,2 (Problem P5) 
114 
Integrated design under uncertaino, for phannaceutical processes 
The values for the constants of the hyperbolic smoothing functions for the impurity yield and final time 
binary approximations, ýy D and 
ý, 
f, were selected to 
be 160 and 40, respectively. With these values the 
binary approximation smoothing functions calculate zero and one for criteria values to within 
approximately 1% of the threshold values (see Figure A4, Appendix A). 
6.4.2 Optimisation under uncertainty results 
The results for the optimisations under uncertainty in the key parameters are given in Table 6.3, where the 
value for the product yield objective mean-variance weight (K) Is 0.5. These have been validated in an 
Uncertainty Analysis under the uncertainties identified in the original Perturbation Analysis (see Section 
6.4). It is clear that under the non-final optimal operating policy decisions, the expected violation of the 
final time, E, j. j{tf), is significantly greater (4.49 hr) then the desired limit (I hr). In addition, the expected 
yield of impurity, EJYD) at 2.75% with an expected violation, E, i,, IIYD), of 1.39% is not satisfactory. 
Comparing the results obtained when uncertainty was considered, shown in Table 6.3, it can be 
immediately seen that an improvement in the YC mean-variance objective is achieved (largely due to the 
47% reduction in the variance) with maintenance of both the stochastic constraints for E, i,, Iltf) and 
E, i,, I I YD). Huge reductions in the both the expected final time (2.35 hr) and the 5-95% fractile width (5.17 
hr) are observed, with no significant loss in the expected product yield or increase in the impurity yield. 
Cumulative frequency plots, Figure 6.2, show the great improvement achieved with respect to the final 
time but only very slight reductions in the spread. of the predicted product and impurity yields (5-95% 
fractile widths of 15.92 and 7.55 respectively). The plots show that the presence of uncertainty in the 
model parameters result in long tailed cumulative distributions for Yc, YD and tf under the nud-range 
Table 6.3. Validated process optimisation results under uncertainty, Case Study I. 
Criteria Nominal optimal Uncertain optimal 
operation operation 
Scenarios 456 418 
Mean-variance ( Yd 0 0.234 
[E(Yc) (%), Var(Ycl] [94.35,50.41 [94.30,26.91 
EJYD) M 2.75 2.77 
Eftf) (hr) 9.34 2.35 
FW(Yc) 18.73 15.92 
FW I YD) 8.83 7.55 
FW (tf I (hr) 24.97 5.17 
[Prpass(yl): ý 2.0), Prpassftf:! ý 8.0)] [0.59,0.591 (0.53,0.981 
[E, i,,, I YD! ý 2.0), Ej., I tf :ý8.0) 
[1.39,4.49] [1.25,0.05] 
Decisions 
t, dd (hr) 1.79 1.121 
Tj,. (K) 296.8 3 12.4 
115 
Integrated design under uncertainty for phannaceutical processes 
values of the nominal optimum operating policy (isothermal temperature, Ti,,, of 296.8 K and feed 
addition time, tadd, Of 1.79 hr). Hence, the poor performance in the one-sided E, i,,, and Prpass criteria (Table 
6.3). The implementation of a higher Ti,. (312.4 K) and a shorter tadd (1.12 hr) result in a greater rate of 
formation for both the product and impurity with a corresponding lower tf. Under the model uncertainty a 
significant leftwards shift in the tf distribution and reduction in the length of the tail is observed in Figure 
6.2 (c). This results in the vast improvement in E, i,, I(tfl and Prpass(tf) shown in Table 6.3. However, this 
operating policy does not significantly reduce the long tails in the YC and YD distributions. 
Sensitivity Analysis under the robust optimal operating policy indicate the same key contributing Z-- 
k 
U 
4- 
> 
(74 
U 
(a) Yield of product, C. (b) Yield of impurity, D. 
0 
(c) Final time. 
Final time, hr 
Figure 6.2. Cumulative frequency plots for the validated isothermal optimisation results obtained with 
and without uncertainty consideration, 
Case Study 1. 
Key: nominal optimisation, o= optimisation under uncertainty, 
desired upper limit. 
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uncertain kinetic parameters as was observed under nominal policy (Eal and EaD. The significant changes 
from the results under the nominal operating policy (given in Table 6.2) are the increasina strenoth-of the 
linear ranked relations between the uncertainty in Ea2 with that In Yc (0.88 from 0.74) and ý'D (-0.88 from 
-0.76), and the decreasing strength of the linear ranked relations between the uncertainty in Eal with that 
in YC (-0.42 from -0.62) and YD (0.41 from 0.60). This effect is shown in a normalised scatter plot 
between YD and Ea2 in Figure A3 (b), Appendix A. The effect of a shorter process completion time 
induced by a shorter addition feed time and higher isothermal temperature in the robust operating policy 
results in YD (and its uncertainty) being more strongly related to the uncertainty in Ea2 and less so to that 
in Eal. It is postulated that this is probably due to the shorter periods in which the concentrations of A and 
C (strongly dependent on the uncertainty in Eal) are at significant levels with the result that the uncertainty 
in the rate constant k2 propagated from Ea2 has an increasingly stronger influence on rate of formation of 
D. 
Zýý 
r_ 
u 
> 
Figure 6.3. Sensitivity towards the product yield mean-variance weight, Case Study I. 
Key: o= Ef YD 1, o= Vart 
YD) 
- 
The insensitivity of the value used for the mean-variance weight, K, to the robust optimum solution Is 
shown in Figure 6.3. Only at a value of 1.00, for a maxirrusation of E(Yc) with no variance consideration, 
is any significant change in the optimum solution observed. tadd Increases to 
1.50 hr and Ti,,, drops to 
303.3 K resulting in a slight increase in E(Ycj to 94.81% and an increase in 
Var(YC) to 30.91. In benefit, 
a reduced value for Evi,, IIYD) (1.13 from 1.25%) is obtained 
but at the expense of an increase in Ei. lltf) 
(0.52 from 0.05). Clearly for this uncertain process some consideration of the variance In Yc In the 
objective function is an important factor in the resulting 
decisions and stochastic criteria determined. 
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6.5 An alternative operating policy 
From the optimal results under uncertainty shown in Table 6.3, the key area in which further improvement 
would be desired appears to be in YD. A robust optimisation minimising E, i,,, (YDI determined a minimum 
value of 1.12% under the isothermal 'here and now' mode of temperature control. This indicates that the 
possibilities of reducing the expected violation in the YD constraint under the specified uncertainties are 
limited by the isothermal operating policy. Sano et al. (1998) state that a higher quality process may be 
achieved with non-isothermal temperature control. Such a policy is considered in this sub-section, in order 
to increase the probability of passing the YD COnstral I int (only 53% under the robust isothermal optimal 
decisions) and to reduce the expected violation under model uncertainty. The dynamic optimisation 
problem without and with the consideration of uncertainty is formulated as an optimal control problem 
(Problem P6 and Problem P7, respectively) with piecewise constant temperature control, Tnon-iso, pel 
discretised over four intervals in the time horizon, tpe, 
Problem P4 (nominal) / Problem P5 (robust) with revised piecewise constant decision bounds, 
0.2< tpe <3 
288: ý T,,, n-iso, pe !ý 313 
4 
tf =-- 
Itpe 
pe=l 
V pe=l 4 
V pe=l 4 
(Problem P6 I Problem P7) 
For this system the optimal non-isothermal operating policy obtained under uncertainty was the same as 
that determined in the norrUnal optimal control problem (see Table 6.4) with the exception that the 
duration of the final control interval for each observation in the uncertain optimisation varies according to 
the 0.001 conversion rate ternunation criterion. The robust solution was verified with a number of 
different starting points. Subsequent Uncertainty Analysis results under the non-isothermal Policy are 
compared with the robust isothermal case in Table 6.5. The cumulative frequency plots in Figure 6.4, 
show the improvement in the distributions of Yc and YD and the deterioration in tf that is achieved with 
the non-isothen-nal policy. 
Non-isothermal control allows significant improvements in the expected values of Yc (96.3717c) andyD 
(1.81%) coupled with reductions in the uncertainty (quantified by the widths between the 5-95% fractiles) 
in all three output criteria and a significant increase in Prpass ( YD) to 0.74 and an Evjý, (YD) of almost half 
the isothermal value. The only drawback is the increase in E(tf) to 3.96 hr from 2.35 hr coupled with 
slight deteriorations in Prpassftf) and E, j,, jjt& However, the latter Is still well within the desired stochastic 
constraint limit of 1 hr with 96% of the distribution below the 8 hr limit. 
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Table 6.4. Nominal optimum operating policy under non-isothermal 
temperature control, Case Study 1. 
Time interval Tnon-iso Duration (hr) 
1 288.0 0.61 
2 288.0 1.24 
3 288.0 0.50 
4 313.0 1.06 
tf (hr) 3.41 
tadd (hr) 22.5 0 
Table 6.5. Uncertainty Analysis results comparing and robust isothermal and 
non-isothermal temperature control, Case Study 1. 
Criteria Robust Nominal/robust 
isothermal non-isothermal 
Scenarios 418 532 
Mean-variance I Yc) 0.234 0.278 
[E(Ycl (%), Var(Yc)] [94.30,26.91 [96.37,23.48] 
EJYDI (%) 2.77 1.81 
E(tf) (hr) 2.35 3.96 
FWjYcj (%) 15.92 11.89 
FW(YDI (%) 7.55 5.85 
FWf tf) (hr) 5.17 4.85 
[Prpass I YD :! ý 2.0), Prpass I tf !ý8.0)] [0.53,0.981 [0.74 0.961 
[Evi., (YD: 5 2.0), Ej., I tf !58.0)] [1.25,0.051 [0.68,0.081 
The optimal non-isothermal policy consists of an initial minimum temperature period (288 K for 2.35 hr) 
followed by a maximum temperature period (313.0 K of scenario dependent duration according to the 
fulfilment of the process termination criterion). This means that virtually the entire dissolution rate 
limiting period (2.38 hr) occurs during the initial low temperature interval (2.35 hr) in the nominal case. 
Uncertainty Analysis indicates that for 38% of the total observations (532) the transition between the 
dissolution and intrinsic kinetic control is achieved before the end of the low temperature interval and 78 
% before the end of the feed addition (2.50 hr). The longer feed addition time and lower rate of product 
formation result in a reduced concentration of product in the reactor during the initial low temperature 
period, which conspires to minimise the driving force for the impurity formation. A shorter period at a 
high temperature achieves the termination criterion with a reduced opportunity for impurity formation. 
Hence, the desired movement of the distributions for YD and YC under the model parameter uncertainty, 
with the compromising movement of the tf di ibution to the right, as shown in 
Figure 6.4. The i stri 
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Figure 6.4. Cumulative frequency plots for the validated non-isothermal optimisation results, Case 
Study 1. 
Key: e= non-isothermal policy (nominal and robust), o= isothermal policy (robust) , desired 
upper limit. 
postulation behind the optimal non-isothermal policy is supported for the considerations both with and 
without model uncertainty, since Problem P6 and Problem P7 converged to the same policy. 
6.6 Conclusions 
Responses to the presence of uncertainty in a model-based approach have been investigated for a 
multiphase reaction process comprising Case Study 1. Uncertainty Analysis was used to quantify the effect 
of model uncertainty on the output performance predictions. Subsequent 
Sensitivity Analysis identifies the 
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uncertainty in the estimated intrinsic reaction kinetic parameters as being critical to the uncertainty in the 
output criteria. In response to the first management option (see Section 5.3) It may be surmised that 
focusing of experimental effort towards increasing the confidence in these parameters would provide the 
greatest reduction in the output uncertainties as predicted by the process model. Secondly, a stochastic 
process optimisation problem was solved which determined an operating policy providing a significantly 
improved prediction for the distribution location and spread of the final process time under uncertainty 
compared to the nominal optimum policy. However, the predicted product and impurity yield distributions 
remained relatively unaffected by this solution. Thirdly, an alternative non-isothermal operating policy 
was considered. Uncertainty Analysis showed that the nominal optimal operating policy managed to 
improve the location and reduce the uncertainty in the distributions of both the product and impurity yield 
criteria at the expense of an adverse response in the process time distribution. For this case, optimisation 
under uncertainty did not provide an improved solution and the same solution as for the nominal non- 
isothermal optimisation was obtained. 
The information obtained using the proposed Risk Analysis approach aims to allow development 
engineers to make more informed decisions as to how to best improve the potential process performance 
and exploit the process opportunities despite the uncertainty in the models developed to structure the 
available process knowledge. While it is prudent to consider uncertainty when using models to aid process 
development, it can be essential if optimisation techniques are also used to determine processes better able 
to provide desired performances. For Case Study I, this was shown to be true for the isothermal operating 
policy but not for the non-isothermal case. In addition, since it was possible to explain why the optimal 
operating policies Might be better with regard to the uncertainty in the assumed physico-chemical 
phenomena and the required manipulation of the output criteria distributions, some confidence in the 
results under uncertainty may be derived. 
In Chapters 7,8 and 9 the proposed approach for design under uncertainty is extended in a more 
comprehensive case study concerning an industrial process for a therapeutic product, comprised of a 
complete sequence of integrated operations. 
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Chapter 7 
CASE STUDY 11: 1? JSK ANALYSIS APPROACH TO A PROCESS SEQUENCE 
UNDER UNCERTAINTY 
7.1 Introduction 
Application of a method for the robust optImisation of a 'here and now' operating policy under model 
parameter uncertainty for a published pharmaceutical reaction process is portrayed in the previous 
chapter. It shows that a more robust process can be obtained with respect to some criteria but not in 
others. In Chapter 7,8 and 9, a case study comprising a complete integrated process sequence is 
presented. In this chapter Uncertainty and Sensitivity Analysis techniques are employed to manage the 
evolving uncertainty in developing models with incoming process modelling information. Then 
optimisation for desired levels of prediction uncertainty reduction is used to show the required levels of 
input parameter uncertainty reduction. With respect to the methodology, the objectives of the case study 
are to provide: 
1. verification of the methodology, comprising of, 
2. a quantification of uncertainty (Chapter 7), 
3. a priority list for process knowledge (Chapter 7), 
4. a quantification of the effect of increased process knowledge (Chapter 7), 
5. analysis of optimal trade-off between the reduction in performance cnteria uncertainty and that 
required in the uncertain parameters (Chapter 7), 
6. an optimal robust operating policy in the available decision variables (Chapter 8), 
7. the value of information for potentially measurable process inherent uncertainties, (Chapter 8), 
8. a measure of tolerance to error in the optimal robust operating policy variables (Chapter 8), 
9. a basis for the assessment of process flowsheet alternatives under uncertainty (Chapter 9). 
The process operations which constitute the integrated sequence are described in Section 7.2. This is 
followed by a brief evaluation of the modelling effort justifiable In relation to the possible character'sine, 
phenomena and the available data, Section 7.3. In Section 7.4, the Risk Analysis problem is 
defined for a 
first generation of models based on the initial data available and assumptions. 
The results of the 
Uncertainty Analysis and the Sensitivity Analysis are discussed. Iterative results of the effect of new data 
on the modelling effort in the Risk Analysis approach are summarised in 
Section 7.5. Minimum reductions 
in input model parameter uncertainty required to achieve desired reductions in the uncertainty predicted in 
the important output criteria are determined in Section 7.6. 
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7.2 Process Description 
Case Study 11 is based on data provided by a pharmaceutical company. It is derived from a process for the 
production of a chemical drug. The process objective is the production of a crystalline drug product of key 
component actB and of consistent purity with respect to the by-product impurities, actC and actE, from 
feed solids comprising the active pharmaceutical Ingredient (API), actA, and a stereo-isomer impurity, 
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Figure 7.1. Process flow diagram for Case Study 11. 
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actD. The considered sequence comprising of 15 stages is shown Figure 7.1. The key process 
conditions are surnmarised in Table 7.1, where LOD is the level of dampness in solids (defined in the 
filtration model -Model B6, Appendix B). 
An aqueous-organic liquid phase chemical reaction takes place in Stage 1. The description for this process 
stage is based on the details obtained from private communication with a pharmaceutical company. The 
stoichiometric reactions believed to be occurring are shown in Equations 7.1 to 7.4. The reaction 
objective is to produce the drug product, actB, from the feed. Feed solids of actA, stereo-isomer actD and 
Table 7.1. Summary of key process operating conditions for Case Study 11 
Stage 
- 
Key process conditions 
1. Reaction - 77 wt% ±3 wt% actA purity API feed solids and catalyst. 
2 mol eq. (ratio to feed actA) reG solids. 
10.4 mol eq. (ratio to feed actA) 30% aq. reH solution, controlled addition 
rate to maintain a constant temperature, TI. 
Maintain a constant temperature, T, ±I C', throughout entire reaction. 
Termination at -90-95% conversion of actA (typically 2.5-3 hours). 
2. Dilution I volume eq. (ratio to Stage I reH) distilled water. 
15 min agitation period. 
3. Layer separation 30 min settling period. 
Drain heavy organic phase to parallel vessel. 
4. reH destruction 0.4 mol eq. (ratio to feed actA) 6% aq. basel solution per shot, pending 
litmus paper test for residual reH presence. 
15 min agitation period. 
5. reG destruction 0.7 mol eq. (ratio to feed actA) 50% aq. baseJ solution. 
Agitate mixture for 120 min at a constant temperature, T5- 
6. Layer separation 30 min settling period. 
Drain heavy organic phase to original vessel. 
7. pH neutralisation 0.7 mol eq. (ratio to actA feed) baseK solids 
15 min agitation period. 
8. Layer separation 30 min settling period. 
Drain heavy organic phase to parallel vessel. 
9. solF distillation Distil solF until vessel minimum stir volume is reached. 
I bar pressure and zero reflux. 
10. Ist solL distillation Add a fraction of the total solL volume: product ratio between 14 and 15. 
Distil a fraction of the solL. 
I bar pressure and zero reflux. 
11.2nd solL distillation Add remaining fraction of the total solL volume: product ratio. 
Distil solL to achieve a final solL volume: product ratio between 7 and 8. 
1 bar pressure and zero reflux. 
12. Crystallisation in Cool boiling mixture to 25 C' and hold for 60 min. 
solL I bar pressure. 
13. Filtration Vacuum filter the slurry at a constant temperature, 
T13, until -W13(7c LOD is 
achieved. 
14. Washing Rinse the damp solids with a2 volume: product ratio of pure solL at a 
constant temperature, T14, and refilter to the prior LOD. 
15. Dr ing L- Dry with pure N-, at a high temperature to a low LOD value -W, 5%. - 
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reagent reG dissolve in the organic solvent, solF. Controlled addition of the aqueous reagent, reH, leads to 
the production of an oxidant, oxG, in a reaction between aqueous reH and dissolved reG, believed to 
occur at the aqueous-organic phase interface, see Figure 7.2. This oxidant reacts with the dissol 0 ved drug 
components in the organic phase. The key feed API (actA) is oxidised to the desired product (actB). Over- 
oxidation leads to the formation of actC from actB in a consecutive reaction. actC is the critical impurity 
believed to cause problems in the morphology during the crystallisation of the final product. In parallel, 
the feed impurity (actD) is oxidised to a secondary impurity (actE). 
reG + reH -4 oxG 
actA + oxG ---) actB (7.2) 
actB + oxG -) actC (7.3) 
actD + oxG -> actE (7.4) 
The following seven operations, Stages 2 to 8, provide a termination of the reaction and treatment of the 
residual reagents. The termination is precipitated by rapid dilution of the aqueous solution of reH with 
addition of distilled water followed by a period of stirring, Stage 2. An aqueous-organic layer separation is 
conducted after a period of settling, Stage 3. The heavy organic phase is drained to another vessel and the 
aqueous phase is sent to waste. Residual reH and reG are destroyed using aqueous solutions of basel and 
baseJ in Stage 4 and Stage 5, respectively. The organic phase is drained back to the original vessel in 
another layer separation, Stage 6. An aqueous solution of baseK is charged to effect a pH neutralisation, 
Stage 7, followed by a final layer separation, Stage 8. 
The next three operations effect a solvent exchange from solF for a crystallisation from an organic 
solvent, solL. solF is distilled from the vessel to a minimum concentrate, Stage 9. A fraction of a 
Undissolved solids 
Continuous organic phase 
solF 
actA actB 
oxG 
H 
Catalyst 
r 
Dissolved reG 
Disperse aqueous phase 
Figure 7.2. Stage I Bisphasic chemical reaction, Case Study Il. 
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predetermined total volume of solL is added in Stage 10. Some fraction of this is removed in the Stage 10 
distillation, after which the second solL fraction is added and distilled (Stage 11). This alms to maintain a 
desired initial and final solL volume to product mass ratio, without violating the maximum boiling volume 
limit of the vessel. 
The final four operations involve the purification of the product. A crystallisation from soll- aims to 
remove actC and actE to acceptable levels in the product solids (Stage 12). This also acts to remove 
unreacted actA and actD. The solids are filtered and then washed in pure solL to remove residual solution 
containing dissolved impurities before drying (Stages 13,14 and 15). 
Some important process issues conceming the product yield and final quality are indicated: 
0 The controlled addition of reH to the reactor is necessary to prevent a potentially strong exothermic 
reH reaction and maintain a constant low temperature, TI. 
* Maintenance of a constant low temperature in the reaction helps prevent the possibility of increased 
impurity formation. 
* The molar charges for the chemical reagents are estimated based on the initial moles of actA feed in 
Stage 1, and not based on measurements of the species to be quenched. The exception is Stage 4, 
where the complete destruction of residual reH is ensured with the utilisation of a litmus paper test, 
and additional basel charges. 
There is a potential for drug loss in Stage 5, up to 1-2 wt% of the product yield. The presence of C) 
excess baseJ may lead to a product decomposition reaction, due to either an incorrect baseJ molar 
charge, or a prolonged stirring period. 
* The desired values for initial and final solL volume to product mass ratios are obtained from statistical 
design of experiments. These ranges are believed to be important to the behaviour of the subsequent 
crystallisation process. 
* The addition and distillation split of the total solL make up is imposed due to the maximum volume 
limit allowed for boiling within the given vessel. The split may be an important factor regarding the 
quantity of residual solF present in the Stage 12 crystallisation stream and the total process sequence 
time. 
A higher crystallisation temperature may lead to yield loss due to higher solubility of the product while 
a lower temperature may mean increased impurity content in the solids. 
0 Low solubility of product in solL at the controlled wash temperature, T14, means that dissolution of 
solid product in the soll- wash is assumed to be negligible. 
These observations provide limitations on the operating policy and the underlying Issues should provide 
incentives for the use of a modelling-based approach. It is important that such observations can 
be 
considered in such an approach though there may be little mechanistic understanding 
behind them. 
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7.3 Modelling effort 
For this case study the modelling effort alms to predict the quantity of product and impurities obtained at 
the end of the sequence. For optimisation purposes it is important that key control variables are 
characterised in the models. Lumped parameter models are used which may or may not be dynamic in 
nature. The identification of the important controlling factors, the key physico-cherrucal phenomena which 
characterise the desired state transformations, is an important step in a systematic model building process, 
after the definition of the modelling objective. A list of the physico-chemical phenomena which might 
characterise the processes of Case Study 11, are shown in Table 7.2. 
To evaluate the realistic characterisation of these phenomena within a model-based approach, the 
following factors need to be considered: 
9 the benefits which may be obtained from using the models, 
9 the difficulty in developing the models due to the complexity of the phenomena, 
0 availability of related literature, 
availability of relevant process data and ease of measurement of relevant process variables, 
opportunities and availability of resource to obtain more data for model validation and refinement. 
Given these factors, an effort was made to evaluate the realistic modelling opportunity for these 
phenomena, Table 7.2. Where no modelling opportunity is indicated for the characteristic phenomena 
assumed to be present, a very simple mass balance model is implemented instead. Data from a pilot plant 
run at the R&D facilities of a pharmaceutical company (process run name PPR), is available for 
comparison. Specific operating conditions for the PPR plant run given in Table 7.3, are in relation to the 
general process statements in Table 7.1. PPR measurement data is given in Table 7.4. A first generation of 
process models, based on bench scale data where available and otherwise engineering assumptions, are 
provided in Appendix B. 
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Table 7.2. Possible characterising phenomena for the process operations of Case Study 11. 
Stage Physico-chemical phenomena Modelling opportunity 
1. Reaction reG feed solids dissolution Trivial level, limited data 
Reaction stoichiometry Profile data 
Intrinsic reaction kinetics Profile data 
Interfacial mass transfer/mixing Empirical correlation 
Drug mass transfer to aqueous phase Simple tie-line model 
Heat transfer Energy balance possible, no 
temperature related reaction 
rate data 
2. Dilution Reaction stoichiometry x Unclear reagent roles 
Intrinsic reaction kinetics ? Depends on understanding 
concerning reagents 
Interfacial mass transfer/mixing x No available data 
Drug mass transfer to aqueous phase Simple tie-line model 
3. Layer separation Drop sedimentation rate X No available data, complex 
Drop coalescence rate X No available data, complex 
4. reH destruction reH[baseI reaction stoichiometry X No available data 
reHlbasel intrinsic reaction kinetics X No available data 
Interfacial mass transfer/mixing X No available data 
Drug mass transfer to aqueous phase Simple tie-line model 
5. reG destruction reG/baseJ reaction stoichiometry X No available data 
reG/baseJ intrinsic reaction kinetics X No available data 
Drug/baseJ reaction stoichiometry X No available data 
Drug/baseJ intrinsic reaction kinetics X No available data 
Interfacial mass transfer/mixing X No available data 
Drug mass transfer to aqueous phase Simple tie-line model 
6. Layer separation As for Sta(ye 3 
7. pH neutralisation Acid-base reaction stoichiometry X No available data 
Acid-base intrinsic reaction kinetics X No available data 
Interfacial mass transfer/mixino, X No available data 
Drug mass transfer to aqueous phase Simple tie-line model 
8. Layer separation As for Stage 3 
9. solF distillation Vapour-liquid equilibria 
Heat transfer Energy balance possible 
10.1" solL distillation As for Stage 9 
11.2 nd solL distillation As for Stage 9 
12. Crystallisation Crystal growth kinetics Assume simple seeded 
Nucleation kinetics X No available data, complex 
Heat transfer X No available data 
Crystal birth/death phenomena X No available data, complex 
Impurity effects 4 Trivial model, lack of 
understanding and data 
13. Filtration Liquid mass transfer x No available data 
14. Washing Liquid mass transfer/displacement X No available data 
15. Drying Heat transfer X No available data, complex 
I Liquid mass transfer Ix No available data, complex 
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Table 7.3. PPR plant run conditions, Case Study 11. 
Stage PPR plant run conditions 
Operation time 300 min 
Total drug feed mass 469.9 kg 
Drug feed purity 74.1 wt% 
solF 2880 kg 
30% aq. reH 1042 kg 
reH addition time 60 min 
Agitation speed 78 rpm 
2 Distilled water addition 940 kg 
4 6% aq. basel solution 790 kg 
5 50% aq. baseJ solution 46.9 kg 
7 35% aq. baseK solution 260.0 kg 
9 Minimum stir volume 500 dm3 
10/11 Total solL feed 4785 dm 
3 
Total solL removed 2435 dm 
3 
12 Cooling rate (assumed) IT min-' 
Table 7.4. PPR plant run measurements, Case Study 11. 
Stage PPR plant run measurements 
XactA 0.955 
actB content 71.45 wt% 
actC content 0.74 wt% 
actE content 2.88 wt% 
Post reactor crude product mass 345.8 kg 
10/11 Cumulative initial solUproduct ratio 14.7 dm 3 kg- I 
II Final soIL: product ratio 7.2 dm 3 kg- I 
Pre-crystallisation crude product mass 325.8 kg 
14 Post filtration LOD 25% 
15 Dry product mass 29121 kg 
Post drying LOD 6% 
actB dry content 89.4 wt% 
actC dry content 0.24 wt% 
actE dry content 1.4 wt% 
7.4 Risk Analysis 
In the previous section the sequence of operations comprising Case Study 11 is described. The first 
generation of process models, given in Appendix B, provide the first outcome of the iterative process of 
model development for the complete sequence. In this section, the effect of the 
large amounts of 
uncertainty concerning the first to-Zeneration of process models 
in the Integrated sequence is quantified 
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using Uncertainty and Sensitivity Analyses. The effect that additional process data ma bring to the yI L- 
models and the assumed uncertainty within the sequence is also considered. 
In the hypothetical situation that data from complete process sequence runs at subsequent scale-ups 
becomes available, it is proposed that the methodology is used to analyse the predicted uncertainty in the 
current level of models with respect to this data, to determine where the models need to be developed 
further. This corresponds to the validation step in the systematic model development process shown in 
Figure 5.2 (Section 5.4). Since such data is not available for this case study, the PPR plant data (Table 
7.4) is used as the benchmark with which to assess the effect of the uncertainty in the predicted criteria 
using models and parameter uncertainty estimated or assumed to correspond to the current levels of 
knowledge available. The corresponding PPR plant conditions given in Table 7.3 are used in this 
assessment. Estimation of the model parameters and quantification of the parameter uncertainty is based 
on actual data where available. 
7.4.1 Stochastic problem for the first generation model set 
The first generation stochastic system to which the Uncertainty and Sensitivity Analyses are applied with 
respect to the schematic shown in Figure 5.2 (Section 5.4) is defined in this section. The main 
characteristics of the first generation set of deterministic models and the uncertainty inputs to the problem 
Table 7.5. Summary of first generation model characteristics and stochastic problem inputs, Case Study Il. 
Stage Operation Main deterministic model Uncertainty Reference 
characteristics sources (Appendix B) 
I Reaction First order reaction kinetics. Kinetic rate Model B1 
parameters 
2,4,5,7 Reagent Two-phase mass balance with Fractional drug loss Model B2 
addition fractional drug loss assumption due parameter from 
to aqueous phase solubility. 0 rganic phase 
3,6,8 Layer Two-phase mass balance with Fractional organic Model B3 
separation fractional organic phase loss due to phase cut loss 
imperfect phase cut. parameter 
9,10,11 Distillation Batch distillation assuming ideal VLE coefficients Model B4 
VLE with specified reboiler duty 
for estimation of operation time. 
12 Crystallisation Crystal growth kinetics based on Crystal growth rate Model B5 
solute saturation in a seeded batch and impurity 'loss' 
cooling regime, with drug impurity parameters and 
solute concentration 'loss'. saturation data 
13 Filtration Two-phase mass balance attaining Moisture hold-up Model B6 
a desired moisture hold-up. and filtration rate 
14 Washing Two-phase mass balance with Moisture hold-up Model B7 
moisture displacement with wash. and displacement 
15 Drying Two-phase mass balance attaining Moisture hold-up Model B8 
a desired moisture hold-up. and drying rate I 
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are summarised in Table 7.5. 
The uncertain inputs to the stochastic system comprise of those model parameters which generate a 
significant response in important output criteria when individually perturbed from their nominal values. 
Characterisations of the 29 parameter uncertainties assumed in the first generation models are shown in 
Table B2 (Appendix B). For the consecutive reaction rate constants, k, and k2, estimated simultaneously 
using non-linear least squares, the degree of correlation and the parameter standard deviations are 
estimated using a first term Taylor series expansion for the covariance matrix (see Section 5.4 and 
Appendix B for details). For uncertain parameters not estimated simultaneously, standard deviations are 
estimated from the relevant data or assumed (based on the standard deviation being a percentage of the Z-- 
nominal value) or for uniformly distributed uncertainty, range limits are estimated or assumed. 
The non-maintenance of initial (14-15) and final (7-8) desired volumes of solL solvent to expected mass 
of actB prior to crystal Ii sation, identified in Section 7.2 as an important observation with regard to the 
final crystal impurity content, is given some account in the stochastic problem. Violations of these desired 
operating ranges are assumed to give a greater uncertainty in parameters characterising downstream 
criteria believed to be related but for which there is no mechanistic understanding (see Equation B3, 
Appendix B, for mathematical definition). The effect of this added uncertainty is shown in Figure B 10 
(Appendix B) where violation of these desired solvent to product ranges leads to an increase in the 
uncertainty in the impurity concentration 'loss' parameter (from solution) and a corresponding increase in 
the uncertainty in endpoint key impurity content of the crystals. 
7.4.2 First generation model sequence results 
A total of 431 scenarios were required to satisfy the multiple 1% mean and variance parameter error 
convergence criteria (Equation 5.14, Section 5.4) for both the total yield (YT) and endpoint key impurity 
content (wtz,,, c). Graphs of the evolution of the mean and variance of the total yield are shown in 
Figure 
Table 7.6. Summary of first generation model results under uncertainty, Case Study II. 
Stage Criteria PPR Predicted Predicted Data proximity 
Plant data mean fractiles to fractile 
[5%, 95%] interval, % 
I XactA 0.955 0.993 [0.987,0.997] 307 
actB product composition, wt% 71.5 72.9 [72.1,73.4] 49 
actC impurity composition, wt% 0.74 1.21 [0.89,1.481 25 
actE impurity composition, wt% 2.88 8.53 [7.45,9.511 221 
Final soIL: product ratio, dm 3 kg-1 7.2 6.94 [6.83,7.04] 76 
15 actB product content, wt(7c 89.4 90.52 [88.0,93.51 inside 
actC impurity content, wt% 0.24 0.33 [0.19,0.451 inside 
actE impurity content, wt% 1.4 2.78 [1.72,3.70] 21 
71 7577 =T ota 
ýIy 
ieI 
ýd, % -= 
- 
84.2 90.2 [87.2,92.4] 
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Figure 7.3. Cumulative frequency plots for the first generation model set predictions under uncertainty, 
Case Study II. Key: e= predicted results, -= PPR data, --- =5%, 95 % fractiles. 
BII (a) and (b), Appendix B. Scatter plots showing the effect of the induced rank correlation procedure 
for the Stage I k, and k2 uncertain parameters, are shown in Figure B 12 (Appendix B). The results of the 
Uncertainty Analysis are surnmarised in Table 7.6.5% and 95% fractiles are used to quantify the 
predicted uncertainty in the endpoint output and certain inter-stage criteria. If the data does not fall within 
the 5-95% fractiles of the predictions then the proximity values (the final column in Table 7.6) show how 
close the data is to the nearest fractile (5 or 95%), relative to the fractile width. 
For example, in this case study the cumulative frequency plot in Figure 7.3 (a) shows the predicted 
distribution in endpoint total yield under uncertainty in the first generation process model sequence 
relative to the independent PPR plant data (the solid vertical line in the Figure). Since the plant data for 
this criterion does not fall within the predicted uncertainty as enclosed within the 5% and 95% fractiles 
(the dashed lines in the Figure), clearly some process models of the first generation model set may not be 
suitable for prediction of the total yield at the PPR plant scale (as would be expected). Since model 
parameter error has quantitatively been accounted, an element of structural error may be suspected. The 
extent of the error in the prediction distribution indicated by the proximity values, are particularly large 
for the Stage I conversion (307%) and secondary impurity composition (221%). It would appear that the 
large over prediction of the conversion in Stage 1, Figure 7.3 (b), contributes to the observed under 
prediction of the final solL to product ratio and over prediction of the Stage 1-15 total yield. A similar 
assessment may be made concerning the over prediction of the secondary impurity content in the final 
product. 
Sensitivity Analysis is used to estimate the key contributions to the predicted output uncertainty with 
regard to the propagation of uncertainty in certain inter-stacre process properties and the individual input 1ý L- II 
uncertainties of the stochastic model. These indicate the relative importance of the uncertainty in the 
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model parameters characterising the current state of knowledge in the available process models and the 
associated phenomena. 
Contributory process sub-sequences are defined by potentially viable data measurements in this case 
study. It is initially assumed that only the inter-stage criterion of reaction conversion is a measurement 
which can be used to define the sub-sequences for the endpoint total yield. For the impurities, it is 
assumed that the post reaction stream is a potential inter-stage measurement. The relative contributions of 
the sub-sequences associated to inter-stage criteria are shown in Table 7.7. These estimate the fraction of 
the total uncertainty (quantified as the width between the 5 and 95% fractiles) in the endpoint criterion 
which is attributed to each specified process sub-sequence. The initial indication is that the Stage 2 to 15 
sub-sequence contributes the most uncertainty to the predicted uncertainty in the total yield (82% of the 
final uncertainty), while the Stage I reaction contributes the least (18% of the final uncertainty). The 
model parameter uncertainties in the models for Stages 2-15 provide a much larger contribution to the 
uncertainty in the endpoint total yield than the Stage 1 model parameter uncertainties. To reduce the 
uncertainty in the total yield, the sub-sequence contributors immediately indicate that further work should 
be focused on the models and uncertainties assumed in Stages 2-15. This is different to implying that the 
models for Stages 2-15 are the main cause for the deviation in total yield from the PPR plant data. The 
prediction of the key impurity in Stage 1 introduces a greater uncertainty in the final product content than 
all the following operations. The opposite is apparent for the secondary impurity. 
Table 7.7. First generation model sub-sequence contributions to predicted uncertainty, Case Study 11. 
Sub-sequence Total yield Key impurity Secondary impurity 
Stage 1 0.18 0.62 0.34 
Stage 2 to 15 0.82 0.38 0.66 
Endpoint 1.00 1.00 1.00 
If a sample of the pre-crystallisation crude were to be available for analysis, then the Stage 2-15 sub- 
sequence contribution of 0.82 for total yield uncertainty could be decomposed. The new contributions to 
the total yield uncertainty and impurity contents, are shown in Table 7.8. Now it is indicated that 
significant contributions from both the Stage 2-11 (0.35) and Stage 12-15 (0-47) sub-sequences are 
apparent. However, Stages 2-11 do not appear to introduce any additional uncertainty to the impurity 
compositions predicted from Stage 1. This is reasonable considering the realistic assumptions 
incorporated in the first generation reagent addition and layer separation models that any drug loss is 
independent of the concentrations of the other drug species and that there is no loss in the distillations. 
Estimated values of the coefficient of determination close to unity for total yield, key and secondary 
impurity contents for unranked data (0.97,0.98 and 0.99 respectively) and ranked data (0.97,0.96 and 
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0.97 respectively) indicate that the linear input parameter contributors predicted by the Sensitivity 
Analysis should be reliable and rank transformation of the data is not required. Confirmation of this 
assumption is determined by examining the scatter plots between the stochastic inputs and outputs. Scatter 
plots between the Stage 12 crystal growth constant (kg) and total yield and between key impurity content 
and the Stage 12 crystallisation key impurity 'solute loss' parameter (Cacc) are shown in Figure B 13 (a) 
and (b), Appendix B. The relationships indicate that they are adequately measured using linear measures. 
Table 7.8. Effect of more inter-Stage measurements to sub-sequence contributions, Case Study 11. 
Sub-sequence Total yield Key impurity Secondary impurity 
Stage 1 0.18 0.62 0.34 
Stage 2 to 11 0.35 -0.00 -0.00 
Stages 12-15 0.47 0.38 0.66 
Endpoint 1.00 
1 
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Figure 7.4. Uncertain parameter contributor measures for endpoint criteria, Case Study 11. 
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The correlation coefficients (CC) and standardised regression coefficients (SRQ over all the uncertain 
parameters are shown in Figure 7.4 (a), where the parameter index numbers are specified In Table B" 
(Appendix B). The key contributor parameters to the observed uncertainty in the endpoint yield as 
indicated by the CCs are k, (0.74, index 16) then k, (0.38, index 1) and k. -, (-0.38, index 2). However, the 
induced correlation between the product formation reaction rate constant, ki, and the key impurity 
formation reaction rate constant, k2, in the sampling procedure results in a false estimation of the influence 
of k2 to total yield from the CCs. This is because the CCs do not measure the standardised global 
influence. The SRCs show that the influence of k2 (-0.05) is actually negligible compared to k, (0.32), as 
would be expected. The parameters associated with product loss from the reagent addition and layer 
separation stages (indices 6 to 12) provide minor contributions (SRCs between -0.15 to -0.20). The key 
SRC contributors to the final impurity content are estimated as the key impurity 'solute loss' parameter, 
ý=C, (0.78, index 21) then k2 (0.77, index 2) and then the wash efficiency, Tl,,, h, (-0.21, index 26), as 
shown in Figure 7.4 (b). A similar ranking is predicted for the secondary impurity but with a stronger 
influence on the secondary impurity 'solute loss' parameter, CactE, (SRC of 0.96 compared to 0.32 for k3) 
due to better fit of the reaction model for the parallel reaction to the bench scale data. The parameters 
identified as key contributors and priority do not provide any surprising results. Zý 
As may be expected the estimated key uncertain parameter contributors coincide with stages contained 
within the key sub-sequences. Whereas the sub-sequence contributors are useful in providing an initial 
idea to the key areas of the process sequence contributing uncertainty and provide a measure of the 
accumulation of uncertainty at specific points in the sequence based on certain (potentially measurable) 
inter-stage and endpoint outputs of the stochastic model, the CCs and SRCs provide a ranking of 
importance in the uncertain inputs which can differentiate between a large number of individual sources. 
Table 7.9. List of key parameters regarding first generation model uncertainty in ascending order of 
priority, Case Study Il. 
Total yield 
Key Stage Key parameter Characterised phenomena Possible related phenomena 
12 kg Growth kinetics Nucleation kinetics, mixing etc. 
various - complex 
I k, Intrinsic kinetics Intrinsic reagent kinetics, 
solids dissolution, mixing 
2,4,7 Ul Solubility loss Mass transfer rate, 
equilibrium solubility 
3,6,8 U2 Imperfect phase cut Phase dispersion band, 
drop entramment 
Key and secondary impurity content 
Key Stage Key parameter Characterised phenomena Possible related phenomena 
12 ýactAactE Impurity 'solute loss' rate Various - very complex 
I 
I 
k, 
I 
Intrinsic kinetics Intrinsic reagent kinetics, 
solids dissolution, mixing 
14 1 Tj wash 
I Moisture displacement Mass transfer rate 
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The identified key process sub-sequences and key parameter contributors of the predicted endpoint 
uncertainty in the whole process sequence can be used to provide a guide to the key phenomena which are z: 1 
not well characterised and introduce large amounts of uncertainty. Given the identified quantitative 
indicators for the predicted uncertainty, indicated in Table 7.9, a phenomenological knowledg z1- ge priority 
list can be inferred, based on engineering intuition. With this information the data required to progress the 
model development can be ascertained, either to reduce the uncertainty associated with the parameters of 
the current model structures if the uncertain prediction encompasses the current data, or to develop models 
incorporating different phenomena and/or equations. The next step of the methodology is to determine 
how the effect of incoming data and knowledge can improve the current predictions (i. e. following Step 
17 in Figure 5.2, Section 5.4). 
7.5 Effect of new data 
In the previous section, analysis of the process sequence under uncertainty indicated the key contributions 
to the predicted uncertainty observed in output criteria, given the model assumptions and uncertainties 
associated with the current data and level of knowledge. This comprised the first generation of process 
models (see Appendix B). In this section, the effect on the prediction of the key output criteria under 
uncertainty with developing models based on incoming data and observations, is investigated. Uncertainty 
and Sensitivity Analyses are used as before. 
The order by which the new process data is incorporated into the system is not driven by the results of the 
gy, since only a hypothetical situation. of the availability of process development data i methodolo., II is 
represented in this case study and only a limited amount of data is incorporated. Otherwise the 
methodology could provide a driving force for the collection of certain data to progress the model-based 
approach, where identified to be needed. The assumption made in this study is that new data is 
incorporated as and when it becomes available. The availability of new data is given in Table 7.10, in the 
assumed order of incorporation. The revised models and parameter uncertainties associated with each 
level of incorporated knowledge are given in Appendix C. The semi-empirical reactor model is developed 
to incorporate further limiting phenomena to account for the key responses. The layer separation and 
reagent addition models are transformed from speculative assumptions towards more mechanistic type 
models. 
Tracking of the uncertainty (depicted by the predicted 5-95% fractiles) with sequential incorporation of 
knowledge into the system models, as data becomes available, is shown in Figure 7.5 (a) and Figure 7.6 
(a) for endpoint yield and key impurity content predictions, respectively. The cumulative 
frequency plots 
for total yield and endpoint key impurity content given in Figures DI and 
D2 (Appendix D) respectively, 
show the effect of new data on the distributions of these criteria. 
The respective relevant inter-stage 
criteria of conversion and post reactor key impurity composition 
(dashed fractile lines in Figure 7.5 (a) 
and Figure 7.6 (a)) indicate how much how uncertainty 
has accumulated and propagated between the 
r-I 
Stage I and the Stage 15 predictions. Comparing the relative fractile interval widths 
between the Stage 
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Table 7.10. Levels of incorporated knowledge with incoming data, Case Study II. 
Knowledge New data/information Model development action Reference 
level 
0 Bench scale data, First generation of process models. Model BI 
100 gram scale. (Appendix B) 
I Reactor data at 90 rpm, Revised parameter fit to first generation Model BI 
1000 US gallon scale. Stage I model. (Appendix B) 
2 As for knowledge Second generation Stage I model, Model CI 
level 1. incorporating an initial rate limiting period (Appendix Q 
(reagent addition/solids dissolution). 
3 Reactor data at 75,60 rpm, Third generation Stage I model, Model C2 
1000 US gallon scale. incorporating an empirical mixing effect. (Appendix Q 
4 Observations of layer Second generation layer separation model Model C3 
separation phase cuts, (Stage 3,6 and 8), incorporating a durable (Appendix Q 
1000 US gallon scale. two phase dispersion band. 
5 Drug solubility data in Second generation reagent addition model Model C4 
soIF/aqueous system. (Stage 2,4,5 and 7), incorporating (Appendix Q 
equilibrium tie-line solubility data. 
6 Crystallisation yield data, Revised parameter fit to first Model B5 
1000 US gallon scale. generation Stage 12 model. (Appendix B) 
and Stage 15 criteria it appears that while a large proportion of the uncertainty in the endpoint yield 
evolves after Stage 1, the uncertainty in the endpoint key impurity content is mainly due to that generated 
in Stage 1. 
The addition of new data either leads to revised uncertainty characteristics for parameters in the same 
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Fi ure 7.5. Effect of knowledge incorporation to total yield and conversion predictions, 
Case Study II. 
9 L-- 
Key: o= Total Yield, o= Conversion. 
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model structures (knowledge levels I and 6) or to new models structures with different uncertain 
parameters (knowledge levels 2,3,4 and 5), as indicated in Table 7.10. In the former circumstance, new 
sets of data are required to re-estimate the uncertainty in the existing model parameters. This does not 
guarantee a reduction in the uncertainty of the predicted output if there is a wide spread in the new data 
sets or the model structure is inadequate. Hence, there is an increase in the predicted uncertainty in 
endpoint yield for knowledge levels I and 6 in Figure 7.5 (a). In the latter circumstance, while the 
predicted endpoint uncertainty may not decrease with the addition of new data, it is hoped that the 
prediction of the new model is closer to the data. This is indicated from the deviations in the mean 
prediction from the PPR plant data that are shown in Figure 7.5 (b) and Figure 7.6 (b) for total yield and 
key impurity content, respectively. For knowledge levels 2,3,4 and 5, the total yield predictions become 
closer to the data as the model structures are changed, and similarly for levels 3 and 6 for the key impurity 
content. 
Consideration of these deviations with the associated uncertainties, provides an indication of the quality of 
the model system with respect to both the spread in the predicted distribution and accuracy relative to the 
data. The history of the Stage I conversion predictions, Figure 7.5 (a) and (b) shows that both the 
proximity of the mean prediction to the data, and the relative spread in the distribution are required to 
ascertain the quality of the model. At knowledge level 1, the mean prediction is closer to the data and 
under uncertainty the fractiles encompass the data. However, the large increase in the uncertainty of the 
prediction from level 0 to level I (an increase of over 800% in the fractile width) indicates a problem with 
the model. While the incorporation of more knowledge, in level 2, reduces the uncertainty, the prediction 
moves away from the data. Only at level 3, when the mixing phenomena are modelled in Stage 1, does the 
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Figure 7.6. Effect of knowledge incorporation to key impurity composition predictions, Case Study 11. 
Key: e= Dry crystal key impurity content, o= Post reaction crude key impurity composition. 
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prediction in the reaction conversion to the data improve without such a substantial increase in the 
uncertainty. The uncertainty in the predicted post reactor key impurity composition and endpoint content, 
Figure 7.6 (a), are also reduced at level 3, and the prediction accuracy to the data increases, Figure 7.6 (b). 
The change in the accumulation of the uncertainty through the sequence as knowledge is incorporated can 
be analysed by the comparison between the relative magnitude of the inter-stage criteria fractile widths, as 
illustrated in Figure 7.5 (a) for the conversion and total yield criteria. A clearer representation is provided 
with the sub-sequence contributions. 
The contributions to the total yield uncertainty for Stage I and Stage 2-15 sub-sequences are shown in 
Figure 7.7 (a). It is no surprise that the contribution of Stage I to the final uncertainty becomes larger than 
that of Stage 2-15 at level 1, when the parameters of the bench scale Stage I model are fitted to the larger 
scale data. This is redressed with the revised model, level 2. At level 3, the contribution of Stage I 
increases again due to the uncertainty in the mixing correlation employed. With the addition of the pre- 
crystallisation solL to product ratio as a measured inter-stage criterion, Figure 7.7 (b), it is indicated that C, 
the Stage 2-11 sub-sequence becomes an increasingly minor contributor compared to the Stage 12-15 sub- 
sequence with the incorporation of extra layer separation and drug solubility knowledge. 
The importance of the deterministic model structure on the propagation of uncertainty in the stochastic 
model is demonstrated by the increase in Stage 2-15 sub-sequence contribution to the total yield at 
knowledge level 6, as shown in Figure 7.7 (b). At high values of the crystal growth rate constant (kg) the 
Stage 12 crystalliser model predicts that the solute concentration approaches the saturation concentration. 
13 
Z 
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79 
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.0 T: 
(b) Additional sub-sequence. 
Key: *= Old Stage 2-15 contribution, 
*= New Stage 2-11 contribution, 
o= New Stage 12-15 conti-ibution. 
(a) Two sub-sequences. 
Key: o= Stage I contribution, 
*= Stage 2-15 contribution. 
Figure 7.7. Effect of incorporation of knowledge to the total yield uncertainty, Case Study 11. 
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This suppresses the effect of uncertainty in kg to the total yield. At knowledge level 6, the lower revised 
value of kg results in a reduction in the suppression effect the model structure has on its uncertaintN,, 
despite no change in the relative level of uncertainty in kg, 
The stages associated with the key contributing model parameters, identified using CCs and SRCs, do not 
necessarily coincide with the key contributing sub-sequences. For knowledge levels 0,1 and 2, the 
unassociated variabilities in the Stage 12 key impurity 'solute loss' parameter (Ca, tc) and the reaction rate 
constant for key impurity formation (k2) appear to each explain a sirrUlar fraction of the variability in the 
endpoint key impurity content (SRCs of 0.78,0.61 and 0.72 for C,, c, c compared to 0.77,0.58 and 0.66 for 
k2, Table D1, Appendix D). A scatter plot for the knowledge level 0 case, Figure D3 (Appendix D) does 
not indicate a greater relationship between either of these two inputs to the endpoint impurity composition. 
However, the Stage I sub-sequence appears to contribute a significantly greater proportion of the endpoint 
uncertainty than the Stage 2-15 sub-sequence as shown in Figure 7.8. Cumulative frequency plots, Figure 
D4 (Appendix D), show that the magnitude of the uncertainty in the endpoint composition relative to the 
uncertainty in the post reactor composition is not much greater. The propagation of minor uncertain inputs 
in Stage I provide an accumulation of uncertainty which overrides the single effect of the uncertainty in 
Cac, c in Stage 12. In this case it is important to differentiate between the key contributing sub-sequences 
and parameters. Focus on all the uncertainties in the Stage 1 sub-sequence would be more beneficial than 4_: ý 
on the Stage 2-15 sub-sequence, with regard to the uncertainty in the endpoint key impurity composition. 
As the deterministic models are revised to accommodate different phenomena and different uncertain 
parameters are introduced the priority of the uncertainty contributors change. The final list of knowledge 
priorities at knowledge level 6 is given in Table 7.11. Compared to the priorities estimated at level I 
(Table 7.9) the main contributors to the prediction uncertainty in endpoint yield remain the crystallisation 
r. 
"Z: 
Figure 7.8. Effect of knowledge incorporation to the endpoint key impurity uncertainty, Case Study Il. 
Key: o= Stage I contribution, e= Stage 2-15 contribution. 
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Table 7.11. List of key parameters and knowledge priorities in the final generation of models 
(knowledge level 6), in ascending order of priority, Case Study 11. 
Total yield 
Key Stage Key parameter Characterised phenomena Possible related phenomena 
12 kg Growth kinetics Nucleation kinetics, mixing etc. 
various - complex 
1 ki Intrinsic pseudo first order 
drug reaction kinetics 
Intrinsic reagent-drug kinetics 
2,4,7 CFS1* Organic-aqueous phase drug 
solubility 
Mass transfer rate 
Ylý Y2 Rate limiting mixing case Eddy formation and imperfect 
energy dissipation 
Key impurity content 
Key Stage Key parameter Characterised phenomena Possible related phenomena 
I k2 Intrinsic pseudo first order 
drug reaction kinetics 
Intrinsic reagent-drug kinetics 
12 ýactC Impurity solute 'loss' rate Various, very complex molecular 
scale phenomena 
14 71 wash Solution displacement Mass transfer rate 
Y1, Y2 Rate limiting mixing case Eddy formation and imperfect 
energy dissipation 
Secondary impurity content 
I k3 Intrinsic pseudo first order 
drug reaction kinetics 
Intrinsic reagent-drug kinetics 
12 
I 
ýact! 
H_ 
I 
Impurity solute 'loss' rate Various, very complex molecular 
scale phenomena 
14 1 TIwash Solution displacement Mass transfer rate 
and reaction rate constants and drug-aqueous solubility parameters. Uncertainty in the layer separation 
parameters provide no significant contributions. Uncertainty in the Stage I reaction rate constants have 
become more important to the endpoint impurity than the Stage 12 impurity 'solute loss' parameters. At 
the expense of a more accurate deterministic Stage I model, the addition of the mixing effect (level 3) 
introduces minor contributions to the uncertainty in total yield and key impurity content. The SRC values 
of key parameter contributors for knowledge levels 0 to 6 are given in Table DI (Appendix D). 
7.6 Optimal uncertainty reduction 
The key uncertain parameter contributors to the uncertainty in total yield, key and secondary impurity 
content predictions for knowledge levels 6 have already been identified in Table 7.11. The extent of the 
reduction in the uncertainty of these key contributors required to meet a specified reduction in the 
predicted output criteria can be quantified. An optimisation problem of the general 
formulation given in 
Problem PI (Section 5.5.1) is solved for the knowledtc; e level 6 process model system, Problem P8, 
objective function 
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I ity content, Wtaac and wtacE, are maintained by the for total yield, YT, key and secondary impuri mi imum 
reduction in the standard deviations of the normal distributions of: 
the Stage I kinetic uncertain parameters (k, and k3), 
the Stage 12 crystal growth rate parameter 
the equilibrium drug-aqueous phase solubility parameters (a,, 
e the Stage 12 drug component impurity 'solute loss' parameters 
(ýactc and 
ýaCLE), 
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and by the tightening of the lower and upper bounds about the mean of the uniformly distributed Stage 14 
wash efficiency parameter (Tlwash). An equivalent reduction in the uncertainty in the Stage I consecuti%, e 1-ý 
reaction rate constant (k2) is assumed to the reduction determined in the uncertainty of ki. These inputs are 
the key contributing uncertainties to the output uncertainty, identified from the knowledge level 6 L- 
Sensitivity Analysis (Table Dl, Appendix D). It is assumed that a YT 'a1v1ac1C'a'1'1actE are equal to each 
other in Problem P8. 
Problem P8 was solved parametrically at different values of cc to obtain a trade-off curve, Figure 7.9, 
between the required levels of total key input parameter uncertainty reduction (objective function in 
Problem P8) required to meet the desired uncertainty reductions in the output criteria. It appears that the 
required level of parameter reduction increases sharply (objective function decreases) after a desired 
combined output criteria uncertainty reduction of 50% (from the original levels). For desired reductions of 
70% and greater, the problem was infeasible suggesting that other non-key parameter sources of 
uncertainty (which were not included as reducing decision variables) have become significant. 
Individual relationships between key parameter uncertainty reductions and desired output criteria 
uncertainty reductions are shown in Figure 7.10 (a) for kj, k3, kg, cr,, *, and Figure 7.10 (b) for Cactc, ýact& 
Tlwash. These graphs show that the uncertainty in kj, k3 and k. consistently needs to be reduced for all 
desired reductions in output uncertainty while reductions in uncertainty in the other considered parameters 
Cy, l*, CactC, ý, E and Tlwash need only be obtained for desired output uncertainty reductions of greater than 30 
or 40%. Associating the key parameters to the process stages indicates where research effort should be 
directed for different levels of desired output criteria uncertainty reduction. For the endpoint impurity 
contents, reduction in the uncertainty in the reaction kinetics (k3 and k2 via the correlation with kj) is more 
important than the crystallisation parameter uncertainties (ýaac and ýactE) until approximately 50-60% 
C 
C 
> 
. 
Q) 
0 
Figure 7.9. Objective function value, Y-5p, measuring total required levels of input parameter 
reduction against desired levels of output criteria uncertainty reduction, Case Study 11. LI 
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uncertainty reduction in the impurity contents. No such distinction between parameter uncertainties can be 
made regarding uncertainty reduction for the total yield. The optimisation results are tabulated in Table El 
(Appendix E) and computational statistics are presented in Table E9 (Appendix E). 
The change in the sensitivities of the key uncertain parameters to the output criteria are shown in Figure 
7.11 regarding absolute SRC measures (R 2> RR 2>0.90 for all cases). Regarding the total yield, Figure 
7.11 (a) indicates that as the uncertainty in the Stage I reaction rate constant for the product (ki), Stage 12 
crystal growth rate constant (k. ) and the drug-aqueous solubilities ((Y,, *) decrease as optimally determined 
(Figure 7.10 (a)), the SRC values measuring the contributions of the uncertainty in the Stage I time at 
which the initial rate limited period ends (t"', defined in Model Cl, Appendix Q and the reaction mixing 
coefficient (yi, defined in Model C2, Appendix Q increase. A similar effect is shown in Figure 7.11 (b) 
regarding the endpoint key impurity content except that the Stage I reaction rate constant for the key 
impurity (k2) and the Stage 14 wash efficiency Olwash) replace k, and cy,, *. 
These plots indicate the desired levels of uncertainty reduction in the output criteria which may be 
achieved before the key contributor sensitivities change whereupon a change in the experimental and 
modelling effort would become necessary to provide further uncertainty reduction in the output criteria, 
due to the extent of the reductions in the original key parameter uncertainties. For this case study, beyond 
approximately 50-60% reduction in uncertainty in the total yield and impurity content output criteria it 
becomes more beneficial to reduce uncertainty in different uncertain parameters (t" and yl), which would 
require a redirection of the experimental effort since these parameters are associated with different 
phenomena, Stage I initial rate lirruting period and rruxing regime (and may sometimes be associated with 
different process stages, though not in this case). 
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Figure 7.10. Optimal degree of key input parameter uncertainty reduction (from original uncertain 
values) required to meet desired levels of output criteria uncertainty reduction, Case Study 11. 
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Figure 7.11. Change in absolute SRC sensitivities between output criteria and key uncertain 
parameters with optimal uncertainty reductions, Case Study 11. 
7.7 Conclusions 
A comprehensive case study comprising of an integrated sequence of 15 process operations is introduced. 
In this chapter the integration of the proposed Risk Analysis methods with model development iterations 
as more process information becomes available and the knowledge incorporated, is demonstrated. 
For Case Study 11 it is shown that as more information was incorporated into the process models the 
predicted distributions in the output criteria do compare more favourably with the independent pilot plant 
data. In general, the levels of uncertainty decrease with model development iterations but not in every 
instance. Stream variable uncertainties may be amplified or dampened as they propagate through the 
sequence. This is affected by the form of the model equations. An amplifying effect in the uncertainties in 
the Stage 12 solute concentration and total product yield was observed for lower values of the uncertain 
crystallisation growth rate constant (kg) at knowledge level 6. The incorporation of three sets of data can 
be identified as key to the improvement of the distribution characteristics of the total yield prediction. The 
first and most critical is the 1000 US gallon Stage I reaction data at different agitation rates leading to the 
development of the mixing case model (knowledge level 3). The second is the incorporation of drug 
aqueous-organic phase solubility data in the development of the generic aqueous reagent addition model 
(knowledge level 5). The third is the incorporation of larger scale crystallisation yield data (knowledge 
level 6). The knowledge level 3 data is also critical in the improvement and reduction in the uncertainty of 
the prediction for the endpoint key impurity content (given the initial laboratory model, knowledge level 
0). 
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Sensitivity Analysis showed that the relative contributions to uncertainty In the predicted process yield 
became approximately equivalent between the Stage I reaction and the downstream sequence. In the latter 
the contribution due to the uncertainty in the Stage 12 crystallisation grew while that due to the Stage 2-11 
layer separation and solvent exchange operations receded. Uncertainty in the endpoint impurity content 
predictions were estimated to be mainly due to the uncertainty in the reaction model for all the knowledge 
level Risk Analysis iterations. In short and perhaps unsurprisingly, the key uncertain parameters 
(regarding the endpoint total yield and impurity contents) were associated with the intrinsic reaction 
kinetics and the crystallisation process, indicating the areas to which development efforts should be 
directed to increase the understanding and confidence in the process. For the final generation of models 
presented (knowledge level 6 models), optimal reduction in the uncertainties of the key uncertain 
parameter contributors is determined for increasing levels of desired uncertainty reduction in the output 
criteria. The indication is that uncertainty reduction in the reaction rate and crystal growth rate constants 
would be beneficial to obtain any degree of total yield and endpoint impurity content uncertainty 
reduction while additional reduction in the other less critical parameters only become necessary once a 
certain output uncertainty reduction threshold has been passed (Stage 12 crystallisation impurity 'solute 
loss' parameters and Stage 14 wash efficiency uncertainties become important at 50-60% output 
uncertainty reductions and Stage I transition time from initial rate limiting period and reaction mixing 
coefficient uncertainties become important beyond 60%). 
As the Case Study 11 results show, the Risk Analysis methods applied in this chapter perrrut the 
quantification and tracking of the combined influence of parameter uncertainties contained in the entire 
sequence of process models as they are developed in the systematic model development procedures with 
the progression of process development. The Sensitivity Analysis methods allow the efficient estimation 
of the key uncertain parameters of the stochastic system and the internal sub-sequence contributions from 
the results of the Uncertainty Analysis. It is proposed that the information obtained may be used to 
ascertain levels of uncertainty and focus data collection and modelling effort towards those parts of the 
process sequence in which the uncertainty has the greatest Influence on the output. 
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Chapter 8 
CASE STUDY 11: BASE CASE PROCESS FLOWSHEET OPTIMISATION 
UNDER UNCERTAINTY 
8.1 Introduction 
In the previous chapter the Risk Analysis approach was applied to the evolving models comprising the 
process sequence of Case Study II. The key uncertainty contributors were identified and the extent of 
input uncertainty reduction required to meet desired output levels was determined for the final generation 
of models. In this chapter the Case Study 11 investigation is extended to process flowsheet optimisation 
under uncertainty. The process described by the final generation of models in Chapter 7 (knowledge level 
6 models), provides the Base Case flowsheet for this investigation. The general formulations for process 
flowsheet optimisation under uncertainty (Problem P2) and operating policy tolerance (Problem P3) are 
restated for the Base Case. The issues addressed in this chapter are: 
optinusation of an economic capacity of the Base Case flowsheet through manipulation of the 
operating policy variables under no uncertainty in comparison to stochastic optinusation accounting 
for model uncertainties, 
the effect on optimal solutions of different characterisations of the input uncertainties with respect to 
an increase in the size and a change in the shape of the stochastic input distributions, 
the value of perfect information with regard to the potential uncertainty in the purity of the feed API, 
the maximum tolerance to error in the implementation of the Base Case optimum operating policy 
under uncertainty. 
8.2 Base Case problem formulations 
The optimisation problems for the 'nominal flowsheet optimisation, the flowsheet Optimisation under 
uncertainty and the operating policy tolerance optimisation are stated for the Base Case In this sub- 
section. 
8.2.1 Nominal flowsheet optimisation problem 
Optimisation of the Base Case process flowsheet is based on a profitability objective function. The 
profitability, Pty, is defined as the revenue from the end product, less the cost of the main solvents on a 
basis of the total feed mass of active pharmaceutical ingredient (API) charged to the reactor (Stage 1), 
ifity are dollars per kilogram of F,,,, A. 1, and the total 
batch processing time, tT. The units for the profitabi II t-- 
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API feed per hour of processing time. The values of the selling price, Cdn, 8 and solvent costs, CsolF and 
CsoIL, are assumed at 2000 $ kg-' product, 5$ kg-1 solF solvent and 10 $ kg-1 solL solvent, respectively. 
It is assumed that six operating policy variables are available for the optimisation of the base process 
flowsheet, as follows: 
* the Stage I agitation speed N, (rpm), 
9 the Stage I duration time, tfl (min), 
the fraction of the total solL solvent used for the crystallisation (added over Stages 10 and 11), AFIO, 
added in Stage 10 with the remainder added in Stage 11, 
* the fraction of the solL added in Stage 10 removed in the subsequent distillation, RFIO, 
9 the Stage 12 linear crystallisation cooling rate, CR12 (T min-'), 
* the Stage 12 crystallisation holding period, HP12 (min). 
The optimisation problem under no uncertainty for maximum profitability with constraint limits on the 
endpoint key and secondary impurity contents and the pre-crystallisation solF composition, is shown in 
Problem P9. A fixed reboiler duty is assumed in the Stage 9,10 and II batch distillation models. 
objective function 
max 
tf,,, Nl, AFIO, RFIO, CRI2, HP12 
subject to: 
pty 
YT 
tT 
process model equations 
YT = 
F,, 
ctA, l 
x 100% 
inequality constraints 
WtsolF, l I :! ý 0.5 
WtactC, 15 :! ý 0.3 
WtactE. 15 :52.0 
decision bounds 
200: 5 t f', :! ý 400 
15 
E FsolF, 
s 
Cdrug - CsolF sýl 
Zdrug, 15 
15 
Y, FsolL, 
s 
c 
solL 
S=l 
Zdrug, 15 
V S=l S 
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60! ý- N, :! ý 90 
0.4: 5 A F, (): 5 0.7 
0.3! ý RFIO :! ý- 0.7 
0-5: ýý- CR12 <4 
40: 5 HP12: 5120 (Problem P9) 
where YT is the product component (actB) yield over the entire process sequence based on the quantity of 
API feed. 
8.2.2 Stochastic flowsheet optimisation problem 
The proposed optimisation problem under uncertainty aims to maximise the expected potential 
profitability of the Base Case process flowsheet. However, certain realisations within the uncertainty 
space may result in poor process performances in the endpoint impurity contents. A potential loss in 
profitability is modelled as the average profitability which is lost due to violation of desired upper limits 
on either the key or secondary endpoint impurity contents (0.3 and 2.0 wt%, respectively). Some tolerance 
to these violations is allowed to reduce the tendency towards overly conservative solutions. This tolerance 
is quantified by the incorporation of a one-sided stochastic constraint allowing an average profitability 
loss of up to 3.0 $ kga,, A-1 hr-1. 
The operating policy decisions are scenario independent, assuming the a prior, 'here and now' mode of 
robust control where knowledge of particular reallsations of the model parameter uncertainties is not 
assumed in the optimal operating policy solution. This results in six decision variables, as in the nominal 
optimisation given in Problem P9. 
To solve this problem the stochastic optirnisation formulation for the base flowsheet is given in Problem 
PIO. This is derived from the general formulation, Problem P2, Section 5.5.2. The first stochastic 
inequality constraint tries to maintain an expected pre-crystallisation solF stream composition below 0.5 
wt%. In this constraint the general continuous deviation function in Problem P", fd,,, is replaced by the 
solF content at each scenario. The second stochastic inequality constraint maintains an average potential 
profitability loss below 3.0 $ kgactA-l hr-1. The impurity content binary variables, 
0, are one if the 
constraint thresholds are passed and zero otherwise. A profitability loss is returned if either the key or 
secondary content thresholds are violated. However, the profitability loss is not 
incorporated into the 
profitability objective since it is assumed only to be a potential loss which may 
be rectified with further 
purification iterations at further expense (not included in this problem). 
The associated general deviation 
functions in the general Problem P2, d, and d2, are respectively zero and Pty in Problem PIO, i. e. the 
profitability loss is not a function of the extent of the impurity content violation. 
The resulting continuous 
deviation function, fd, is defined as the potential profitability loss. 
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The size of the problem is reduced by limiting the uncertainty space to sensitive Inputs to the output 
criteria, as defined in the uncertainty space characterisation. in Problem PIO. A reduced convergence 
criterion of ± 2% deviation in the output distribution parameters is permitted to reduce the number of 
scenarios per objective function evaluation. 
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The values for the constants of the hyperbolic smoothing functions for the endpoint key and secondary 
impurity contents, ýwt.,, C, 15 and 
ý,, 
t. ', E, 15, 
were selected to be 1000 and 150, respectively. With these 
values the binary approximation smoothing functions calculate zero and one for criteria values to within 
approximately 1% of the threshold value. 
8.2.3 Stochastic operating policy tolerance optimisation problem 
The optimisation problem aims to maximise the tolerances (uncertainty) around the previous 'here and 
now' optimal operating policy variables subject to a stochastic constraint forcing the expected value of the 
potential profitability, E(Pty), to be at least 99% of the 'here and now' optimal solution, EJPty*). The 
total uncertainty space is expanded to include the operating policy variables tolerances, the extents of 
which are the decisions, (5u and (5L, determined in the optirrusation. The formulation for this dd 
optimisation is given in Problem PI 1, 
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8.3 Base Case flowsheet optimisation results 
(Problem P 11) 
The validated results of the optimisation with and without uncertainty are given in Table 8.1. it is 
immediately clear that when the optimal decisions obtained with no consideration of the uncertainty are 
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implemented in the uncertain process, the predicted potential profitability loss (15.08 $ kg,,, A-' hr-1) far 
exceeds the desired limit of 3.0 $ kg,,, A-l hr-1. This appears to be due to low probabilities of passing the 
thresholds on either the key or secondary impurity contents (0.67 and 0.75, respectively), resulting in a 
probability of passing the loss constraint (Prpass) of only 0.5 1. At the expense of a reduction in the 
expected profitability (30.97 from 31.13 $ kgactA" hr-' due to a lower yield), the expected potential 
profitability loss limit is approximately maintained in the validated results of the robust optimisation. 
The optimal decisions, shown in Table 8.2, clearly explain these results. The shorter Stage I reaction and 
Stage 12 crystallisation duration times determined in the uncertain optimisation, lead to a lower expected 
total yield (86.5%) but also restrict the formation of the impurities observed by the lower expected 
endpoint contents predicted (0.22 and 1.42 wt% for the key and secondary impurities, respectively). These 
comparisons are reflected in the cumulative frequency plots for the total yield and key impurity content, 
Figures 8.1 (a) and (b), respectively. The relative behaviours of the secondary impurity content 
predictions mirror those of the key impurity. 
Table 8.1. Validated Base Case process flowsheet optimisation results under uncertainty, Case Study 11. 
Criteria Nominal optimal 
operation 
Uncertain optimal 
operation 
E(Pty) ($ kgactA-l hr-1) 31.13 30.97 
E(Ptyloss)($ kgactA-1 hr-1) 15.08 3.02 
Prpass 0.514 0.894 
[E ( Wtactd, EI WtactE 1, EI wt,,,, F) 1 [0.28,1.71,0.431 [0.22,1.42,0.431 
IFW I Wtactd, FW I WtacLE), FW I WtsoIF 11 [0.17,1.42,0.0021 [0.14,1.19,0.0021 
EjYTJ M 87.9 86.5 
FW(YTI M 4.7 5.4 
Table 8.2. Optimal decisions for the Base Case flowsheet, Case Study Il. 
Decisions Nominal 
optimisation 
Uncertainty 
optimisation 
tf, j (min) 262 251 
N, (rpm) 90.0 90.0 
AFIO 0.40 0.40 
RF, o 0.70 0.70 
CR12 ('C min-') 0.57 0.50 
BIP12 (min) 67 54 
The restricted formation of the key and secondary impurity are coupled with reductions in the 
uncertainties of the predicted endpoint contents (- 16% and - 17% in the respective 5-95c7c fractile widths). 
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(a) Total yield. (b) Key impurity content. 
Figure 8.1. Cumulative frequency plots for validated results for optimisation with and without uncertainty 
consideration, Case Study 11. 
Key: *= nominal optimisation, o= optimisation under uncertainty, -= PPR data. 
However, the uncertainty in the total yield increases by 13%. The shorter crystallisation holding period 
has the effect that the final Stage 12 product drug concentration is further away from the equilibrium 
saturation which in turn has the effect that the propagation of the uncertainties entering Stage 12 are not 
suppressed as much in the output variables. The optimum Stage I agitation speed, NI, and the solL solvent 
exchange decisions, AFIO and RFIO, are unaffected by the incorporation of uncertainties. 
The results of the Sensitivity Analysis for the optimised Base Case are given in Table 8.3 and Table 8.4. 
The drying time, DR15, is clearly the highest ranked contributor to the uncertainty predicted in the 
profitability, followed by the Stage 12 crystallisation growth rate constant (kg) and the Stage I reaction 
rate constant (kj). For the total yield, k., kj, the aqueous-organic equilibrium drug solubilities (cF,, 
*) and 
a 
the delayed Stage I key impurity reaction start time, t, ", exhibit the strongest relationships. For the key 
and secondary impurity contents, the Stage I reaction rate constants are the clearly the strongest 
contributors followed by the uncertainty in the Stage 12 crystallisation impurity 'solute 
loss' parameters 
(ýý,, c and ýacffi) and the Stage 14 wash efficiency 
01wash). The overwhelming importance of the uncertainty 
contained in the Stage I model to the impurity contents is corroborated by the sub-sequence contributions 
shown in Table 8.4. Implementation of the robust decisions compared to the nominal 
decisions did not 
qualitatively (nor significantly quantitatively) affect the outcomes of the 
Sensitivity Analysis. 
From these results it can be inferred that with the importance of the time aspect incorporated in the 
profitability criterion, it would be most beneficial to try and reduce the uncertainty In the 
drying operation. 
However, since drying appears to be an extremely difficult process to model with any 
degree of accuracy 
it may be more realistic to direct action towards improving the current models 
(and parameter estimations) 
of the crystalliser and reactor models, and in particular the kinetics. 
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Table 8.3. SRC ranking of the key input uncertainty contributors to the Base Case flowsheet criteria, 
Case Study Il. 
Criteria R2 Key uncertainty contributors (SRC value) 
pty 0.99 DR15 (-0.768), kg (0.405), ki (0.298), FRO (-0.184), cy,, * (-0.146), t, " (-0.145) 
- YT 0.96 kg (0.68 1), ki (0.465), CY, I* (-0.256), t, " (-0.23 1), X" (0.108), hband, 3,6.8 (-0-09) 
Wta,, C 0.99 k2 (0.848), CactC (0.447), TIwash (-0.320), t, " (-0.240) 
WtactE 0.99 k3 (0.915), CacE (0.331), Tlwash (-0.186) 
Table 8.4. Sub-sequence contributions to the uncertainty in the Base Case flowsheet, Case Study 11. 
Sub-sequence Total yield Key impufity Secondary impurity 
Stage 1 0.47 0.80 0.93 
Stage 2 to 15 0.53 0.20 0.07 
Endpoint 1.00 1.00 1.00 
The fact that the nominal optimal decisions, which maintain the deterministic impurity constraints, 
perform so poorly when extended to the uncertain process system, underlines the importance of the 
consideration of the main uncertainties in the optimisation determining these decisions. This importance 
has been quantified through the stochastic criteria estimated in the optimisation under uncertainty. The 
effect of the optimal decisions on the predicted output criteria distributions can be explained with respect 
to the propagation of uncertainty in the stream variables through the process sequence due to the 
deterministic structures of the process models. 
8.3.1 Robustness Analysis of the input uncertainties 
The importance of the state of knowledge of the input source uncertainties to the results of the process 
flowsheet optimisation under uncertainty (Problem PIO) is investigated and quantified in what Kleijnen 
(1997) terms a Robustness Analysis. Since Problem PIO is constrained by the potential profitability loss 
due to failure of some portion of the upper distribution tails of the endpoint impurity contents, the optimal 
solution and the corresponding decisions may be sensitive to the size and form of the input uncertainties 
(the location of the means are not varied). Two variations to the Base Case problem uncertainties are 
considered for the re-optimisation of the process flowsheet under uncertainty, 
9 Case I considers the sensitivity to the size of the input uncertainties, where the uncertainties in the 
distributions of the original problem are increased by 50%, 
Case 2 considers the sensitivity to the form of the input uncertainties, where uniform distributions 
replace the normal distributions assumed in the original problem. 
The upper and lower bounds are 
fixed at two standard deviations (of the original normal distributions) from the mean value. 
It can be immediately seen from the bar chart showing percent 
deviations in the expected values and 5- 
95% fractile widths of the key criteria from the Base Case, Figure 8.2, that the assumption of uniform 
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input uncertainties (Case 2) imposes very little effect compared with a 5017c increase in the input 
uncertainties (Case 1), relative to the original normal input distributions of the Base Case. A deviation of 
only -0.3% in the expected profitability and virtually identical optimal decisions to those of the Base Case 
are predicted for Case 2. A deviation of -1.217c in the profitability for Case I is predicted, resulting from 
reduced expected yield due to the shorter Stage 1 reaction time (246 minutes) and Stage 12 crystallisation 
time (44 rrunutes). As expected for Case 1, the significant increases in uncertainty in the impurity contents 
(+36.5% and +37.1% in the fractile width of the key and secondary impurity contents, respectively) results 
in the distributions being shifted to the left in order to satisfy the potential profitability loss constraint and 
a decrease in the expected values (see Figure 8.2). 
These observations are reflected in the cumulative frequency plots for total yield and key impurity content 
comparing the three input uncertainty cases, shown in Figure El (a) and (b) (Appendix E), respectively. 
The behaviour of the secondary impurity content predictions mirror those of the key impurity. 
This investigation underlines the importance that the state of knowledge of the input uncertainties can 
have in the Uncertainty Analysis approach to process flowsheet optImisation under uncertainty. Clearly 
this importance can depend on whether the optimisations are concerned with averages or the tails of 
distributions. Within the confines of good assumptions for the input uncertainty bounds, the form of the 
distributions appears to be of negligible significance to the optimal solutions determined. On the other 
hand, a good estimate to the magnitude of the input uncertainties is essential to the results and decisions 
obtained using an Uncertainty Analysis approach to process flowsheet optimisation. This is particularly 
true when the tails of output distributions are important. 
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Figure 8.2. Deviation in optimal results with input uncertainty variations, from the Base Case, Case 
Study 11. 
Key: 0= Case 1, ý-- = Case 2. 
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8.3.2 The importance of process input specification 
The concept of the value of perfect information (VPI) is applied to the Base Case flowsheet with regard to 
potential feed purity knowledge of the API, pf,,. The VPI is defined in Equation 8.1, and approximated in 
Equation 8.2 as the expected gain in the potential profitability when using an informed 'wait and see' 
optimal approach as opposed to the uninformed 'here and now' approach, with penalisation of violations 
in an acceptable profitability loss constraint in the latter. A linear function in the extent of violation in the 
loss constraint penalises the value of information expected with the 'here and now' approach, VIhere- 
VPI = Eg 
P. 
JVIwait 
- VIhere 
I 
= Epf, l 
(EO,,, 
e,,, 
lptYwait J),, 
- 
(8.1) 
[( 
Eo,,, O,,, Pf., 
JPtYhere J)M, 
- JOPtyloss, here, m' 
(( Eo,,, 
Od,, Pf,, 
I 
PtYlOSS here 
1) 
m, 
- 3.0)] (8.2) 
where m' are the observations in pfj space. Under potential uncertainty in the feed purity of 74 ±3 wt%, 
the VPI with knowledge of this uncertainty is a profitability of 11.46 $ kgactA-l hr-1. It is clear from the 
increasing value of the VPI with increasing feed purity, Figure 8.3 (a), that at low values of pfj (below 
72.5 wt%) the main contribution to the VPI is incurred. As indicated in Figure 8.3 (b) the VIhere is greatly 
reduced for these values of feed purity. The relatively large violation of the profitability loss constraint is 
shown by the dashed line representing the VIher, without any penalisation of the constraint violation. A 
shallow optimum in the value of the feed purity (-74 wt%) is observed in the Vl,,, i, solutions, Figure 8.3 
I- 
> 
(a) Value of Perfect Information. (b) Value of Information. 
Key: * Vlwait, 0 -: ": Vlhere7 
= unpenalisedVlhere 
Figure 8.3. Value of feed purity information to potential profitability, Case Study 11. 
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(b). This could be useful knowledge if the feed purity can be more closely specified. At lower feed purities 
optimal solutions are constrained by the increased propensity for formation of the secondary impurity in 
the Stage I reaction leading to high values in the endpoint secondary impurity content. At higher feed 
purities the greater amount of product formed results in increasing proportions of the key impurity. 
The importance of certain a priori . knowledge to the process has been quantified in the form of the VPL 
The results show that this value can be very sensitive within certain ranges of the available information. 
8.4 Base case operating policy tolerance optimisation results 
Solution of Problem P 11 gives an optimum value for the average tolerance of 0.088, shown in Table 8.5. 
This is the maximum average fraction of the space of all the operating policy variables (defined by the 
upper and lower policy bounds) within which a feasible solution is permitted under error or uncertainty in 
the implementation of the 'here and now' optimal policy. As shown in Table 8.5, the solution is tightly 
constrained by the stochastic constraints on the expected potential profitability (30.66 $ kga,, A" hr-1, at 
99% of the 'here and now' optimal solution), the expected potential profitability loss (3.00 $ k(3actA-' hr-1) 
and the pre-crystallisation solF content (0.50 wt%). 
The resulting tolerance limits around the 'here and now' optimal operating policy variables (given 
previously in Table 8.2) on the operating policy are given in Table 8.6. The tolerances permitted on the 
reaction time (tfj) and the crystallisation time OHF12) indicate that the expected profitability criteria is 
relatively insensitive to the total yield due to a strong dependence on the overall process time to which the 
available optimisation operating policy variables provide a relatively small contribution. Virtually no 
tolerance is acceptable in any of the other operating policy variables, hence the relatively low value for the 
average tolerance. The values of the optimal decisions (6u and 8L) are given in Table E5 (Appendix E). dd 
Table 8.5. Results for tolerance optimisation of the Base Case flowsheet operating 
policy, Case Study II. 
Objective Average tolerance 0.088 
Stochastic constraints E(Pty)($ kgactA-1 hr-1) 30.66 
E(Ptyloss)($ kgactA-1 hr-1) 3.00 
E(WtsoIF) (0/0) 0.49 
Table 8.6. Tolerance limits for Base Case optimal operating policy, Case Study 11. 
tf. 1 N, AFjo RFjo CR12 HP12 
(min) (rpm) ('C min- (min) 
, 
UB 267 90.0 0.41 0.70 0.52 64 d 
_ 
LB '135 89.5 0.40 0.68 0.50 43 4, d 
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8.5 Conclusions 
In this Chapter the use of a multiscenario stochastic optimisation approach for the optimisation of 
integrated flowsheets under model parameter uncertainty is demonstrated with respect to the set of models 
comprising the Base Case process flowsheet of Case Study 11. Its application allowed the selection of 
'here and now' operating policy decisions to optimise and manage certain aspects of the distributions of 
the uncertain output predictions. An expected profitability objective function is optimised within a 
threshold on an expected profitability loss due to failure in endpoint impurity contents. This action 
corresponds to the second management response identified in Chapter 5. Under no uncertainty, the 
nominal optimal decisions result in poor behaviour of the endpoint impurity content distributions and a 
high potential profitability loss when the quantified model parameter uncertainty is considered in 
Uncertainty Analysis. This highlights the importance of the consideration of uncertainty in the process 
optimisation. 
It is also shown that the state of knowledge of the model uncertainties is important with respect to the 
magnitude but not so much to the characteristic distribution. The value of perfect information in 
potentially uncertain process stream inputs is considered with respect to the feed purity. It was found that 
below a certain value in the feed purity (72.5%), perfect knowledge had a very significant impact and that 
a shallow optimum value existed (-74%). 
The key uncertainties under the optimal policy decisions are identified in the Sensitivity Analysis with the 
conclusion that realistic efforts to reduce the current levels of uncertainty in the profitability and yield 
should be primarily directed towards improving the confidence in the crystallisation kinetics followed by 
the intrinsic rate constant for the product reaction. The ability to provide a better prediction for the time 
taken for the drying is the key factor in reducing the uncertainty in the profitability due to its dependency 
on the total batch process time. However, the provision of a useful mechanistic model for drying may be 
unrealistic considering the complexity of the physical phenomena associated with drying. To reduce the 
uncertainty predicted in the endpoint impurity contents the analysis (not unexpectedly) strongly indicates 
that efforts aimed at reducing the uncertainty in the Stage I intrinsic reaction kinetics would be the most 
rewarding. This information, based on systematic and quantitative procedures, provides focus to the 
actions which may be invested towards the development of more reliable models for the first management 
response (Chapter 5). 
A further stochastic optimisation determined the maximum uncertainty allowed around the optimal 'here 
and now' operating policy values of the Base Case flowsheet. The upper and lower tolerance limits are 
constrained to meet a small relaxation of the 'here and now' profitability together with the original 
stochastic constraints. This quantifies the relaxation permitted to the optimal operating policy actions 
determined in association to the second management response. rý 
The third management response, considering alternative process flowsheets, is investigated in Chapter 9. 
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Chapter 9 
CASE STUDY 11: ASSESSMENT OF ALTERNATIVE PROCESS FLOWSHEET 
OPTIONS 
9.1 Introduction 
In the previous chapter stochastic optimisation of the Base Case flowsheet under uncertainty in the model 
parameters was shown to provide a better solution than the equivalent optimal solution under no 
uncertainty. In addition, the maximum permitted tolerance around the values of the optimal operating 
policy was determined, to achieve an expected profitability within 99% of the 'here and now' optimal 
solution. In this chapter three alternative process flowsheet options are assessed with respect to optimal 
performance and permitted operating policy tolerance. 
9.2 Process flowsheet alternatives 
Four alternative flowsheet options are considered: 
* Base Case, the original process flowsheet and associated uncertainties, 
9 Alternative 1, back extraction of post-reaction aqueous phase with solF, 
9 Alternative 2, recycle of prior solL mother liquor into the crystal li sation, 
e Alternative 3, removal of the crystal wash operation. 
Alternatives 1,2, and 3 are briefly discussed in the following sections. The stochastic optimisations for 
expected profitability, Problem PIO, and operating policy tolerance, Problem P1 I, are solved for each 
flowsheet option under their respective uncertainties. 
9.2.1 Alternative 1: Post-reactor back extraction 
The total product yield may be increased with the solF back extraction of residing organic components in 
the Stage 3 layer separation aqueous waste stream. The additional Stage 3A solF back extraction and 
Stage 3B layer separation are shown in Figure 9.1 in comparison with the Base Case flowsheet shown in 
Figure 7.1 (Section 7.1). A compromise is incurred at the expense of the extra solF solvent required, the 
increase in the total batch process time for the additional extraction and layer separation operations and 
the increase in the distillation time during the removal of solF. The number of uncertain inputs to the 
stochastic process is increased by the additional uncertainties in the drug solubilities associated with the 
Stage 3A model, and the uncertainties associated with the subsequent layer separation model, Stage 3B. Z) 
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Figure 9.1. Process flowsheet showing the additional back extraction in Altemative 1, Case Study 11. 
The quantity of pure solF used in the back extraction is set as a fraction of that added in the prior reaction, 
RsolF-back- It is an additional decision variable in the optimisation under uncertainty, between bounds of 
0.01 and 0.5. 
9.2.2 Alternative 2: solL mother liquor recycle 
The recycle of solL mother liquor from a prior crystallisation may be desirable to obtain higher yields if 
the desired impurity levels can be maintained. The addition of recycled drug product in the mother liquor 
may allow shorter reaction and crystallisation times reducing the possibility of impurity formation and 
crystallisation take-up. The reduction in the quantity of pure solL solvent required is another benefit. 
However, the possibility of the build-up of impurities may be critical with uncertainty assumed in the 
composition of the mother liquor recycle. The process flowsheet for Alternative 2 is sin-ular to the Base 
Case but with the addition of the solL mother liquor recycle stream to the pure solL solvent feeds in the 
Stage 10 and II distillations, shown in Figure 9.2. The ratio of the solL mother liquor recycle to the pure z: - 
solvent (at constant total solL mass), R,. LL_rcycIe, is set as a decision variable in the optimisation under 
uncertainty, between bounds of 0.01 and 0.5, with the total quantity of solL remaining the same as for the 
Base Case. 
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Figure 9.2. Process flowsheet showing the solL mother liquor recycle in Alternative 2, Case Study II 
9.2.3 Alternative 3: No post-filtration crystal wash 
The crystal wash operation is removed in Alternative 3. The removal of the crystal wash operation in 
Alternative 3 saves time and the quantity of pure solL solvent required but the lack of residual trace 
impurity removal may limit the reaction and crystallisation operations. The pertinent part of the process 
flowsheet of Alternative 3 is shown in Figure 9.3. The only change in the stochastic system definition is 
the removal of the uncertainty assumed in the efficiency of the wash. 
14. DRYING 
Evaporate 
Dry cryst 
13. HL I KA I IUN 
Filtrate 
[261 
- Crystal slurry strean 
Figure 9.3. Process flowsheet showing the final stages in Alternative 3, Case Study 11. 
9.3 Comparison of optimal process flowsheets under uncertainty 
Comparison between the optimal alternate flowsheets are made with respect to the criteria presented by 
subsequent Uncertainty and Sensitivity Analyses, 
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* expected values for profitability, total yield, and key and secondary impurity content, 
uncertainty in the process variable pred] III 1tv content, ictions for total yield, and key and secondary impur" . 
0 the major contributions to the uncertainty In the profitability, total yield, and key and secondary 
impurity content. 
Comparison of the deviations in the optimal expected values of the potential profitability from the Base 
Case value (30.97 $ kgactA-' hr-1, Table 8.1, Section 8.1) shows that Alternative 2 is the best with a 4.217c 
improvement over the Base Case, as indicated by the deviations in the bar chart, Figure 9.4 (a). On an 
annuahsed basis, the 4.2% improvement in profitability (32.26 from 30.97 $ kg,,,, A-' hr-') becomes a 
significant annual improvement of $5.65 million, assuming back-to-back batch cycles of 500 kg API feed. r__ 
The estimated annualised improvement for Alternative I Is $0.70 million and Alternative 3 is $2.98 
million (over the Base Case). The process flowsheet stochastic optimisation results are sununarised in 
Table E2 and E3 (Appendix E). 
Back extraction of the post reactor aqueous stream in Alternative I results in the best flowsheet prediction 
for expected yield (89.2%) and the lowest expected endpoint impurity contents. The assumption of 
independent drug component solubilities leads to a higher transfer of the relatively high concentration of 
drug product to the organic phase but very little transfer of low composition impurities. The decreases in 
expected impurity content may not be that significant since the potential profitability loss constraint 
(based on the impurity content thresholds) is still maintained. It does indicate that the spread in the 
impurity content distributions is increased, as shown by the deviation in fractile width in Figure 9.4 (b), 
but only significantly so for that part of the distribution below the impurity threshold (see Figure E3 (b), 
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Figure 9.4. Deviations in optimal results under uncertainty for alternative flowsheet options, from the 
Base Case, Case Study 11. 
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Appendix E). Despite the significant yield increase (89.2% compared to 86.5% in the Base case), the 
expected profitability is constrained by the extra solF solvent cost and particularly the increase in the total 
batch process time due to the back extraction, layer separation and increased distillation time required for 
solF removal, Stage 9. 
Recycle of the solL mother liquor in Alternative 2 provides the best profitability (32 26 $ kg,, -1 hr-1 or tA 
$141 million per year with the annuallsed assumptions mentioned above) due to the reduced solL solvent 
cost and lower reaction and crystallisation times, see Table E3 (Appendix E) for the optimal decisions. 
The lower impurity formation in the reaction is offset by the introduction of impurities in the recycle 
stream. At the optimal operating conditions the slight increase in the expected impurity contents shown in 
Figure 9.4 (a) are fairly insignificant. 
Although removal of the crystal wash in Alternative 3, results in a slightly lower yield expected due to the 
shorter reaction time which is required for the maintenance of the expected profitability loss constraint, 
this reduction is less significant to the profitability than the lower total process time and lower solL 
solvent usage. The cumulative frequency plots for profitability, total yield and key impurity content, see 
Figure E2 and E3 (a) and (b), Appendix E, show the distributions predicted with each flowsheet option. 
Without any uncertainty assumed in the model parameters, the results for optimisation of profitability 
under no uncertainty leads to the same conclusion that Alternative 2 has the potential to provide the best 
profitability. However, as observed previously with the Base Case flowsheet, the norrunal optimal 
decisions for the alternative flowsheets provide very poor performance with respect to the potential 
profitability loss under the uncertainties considered. 
9.3.1 Comparison of uncertainty in output criteria predictions 
The uncertainty in the predictions associated with each flowsheet alternative is also an important criterion 
for comparison when using the model-based approach. From Figure 9.4 (b), Alternative 2 predicts the 
greatest uncertainty in the total yield by a significant margin (16% more than the Base Case). However, by 
far the greatest uncertainty in the endpoint key and secondary impurity content are predicted for 
Alternative 1 (18% and 15% more than the Base Case, respectively). If the uncertainty associated with the 
prediction is an important issue in the flowsheet selection then the increased prediction uncertainty and the 
possibility of the further modelling effort required to reduce these uncertainties should be considered in 
the cases of the Alternative 2 and Alternative I options. However, the increased uncertainty in the 
predicted impurity contents for Alternative I is mainly due to the portion of the distributions below the 
upper threshold limits. 
9.3.2 Comparison of uncertainty contributions 
Sensitivity Analysis is used to compare how the alternative process options with their associated levels of 
knowledge in the integrated flowsheets can affect the key contributions to the uncertainty in the 
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Table 9.1. Key alternative flowsheet SRC contributors to predicted uncertainty, Case Study 11. 
Base Case Alternative 1 Alternative 2 Alternative 3 
Profitability DR15, k., ki, As Base case DR15, kg, kj, FR13, As Base case 
FR13, CTsI" Wtsoll-rn], 2.10, C7sl* 
Total yield kg, ki, cys, * As Base case ký, kI, cysl*, As Base case 
WtsolL ml. 2.10 
Key impurity k2, CactC, TIwash As Base case As Base case k2, Cac, C, LOD13 
content 
Secondary k3, CactE, TIwash As Base case As Base case k3, CactE 
impurity content , I 
predictions. The main results are given in Table 9.1 and Figure 9.5. More complete results for the 
uncertainty contributors are given in Table E4 (Appendix E). With the consideration of time importance, 
the assumed long duration of the drying operation and the relatively large amount of associated r) 
uncertainty, make the drying time, DR15, the key uncertainty contributor to the potential profitability for 
all the flowsheet alternatives. 
While no change in the top ranked SRC contributors are observed following Sensitivity Analysis of 
Alternative 1, the addition of the back extraction results in a small decrease in the Stage 2-15 sub- 
sequence contribution to the total yield uncertainty and increases to the key and secondary impurity 
content uncertainties, as shown in the bar charts shown in Figure 9.5. Although the actual observed 
changes in the uncertainties of the key impurity compositions through the process between Alternative I 
and the Base Case are small (fractile width, FW, of 0.434 wt% for the post-reactor key impurity 
composition and 0.172 wt% for the endpoint impurity content in Alternative 1, compared to the FW of 
0.444 wt% and 0.145 wt% in the Base Case), the significance lies in the shift in the contribution to the 
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Figure 9.5. Sub-sequence contributions to predicted uncertainty, for flowsheet alternatives, Case Study 11. 
Key: m= Stage 1 sub-sequence, 0= Stage 2-15 sub-sequence. 
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sub-sequence within which the uncertainty is being introduced and propagated. This shows that with the 
use of a solF back extraction, the contribution to the uncertainty in the endpoint impurity content is 
increased over the Stage 2-15 sub-sequence in Alternative I (compared to the Base Case) and that if 
greater quantities of solF are used in the extraction (the optimal value is only 5.2% of the quantity used in 
the reaction) that the Stage 2-15 sub-sequence contribution to the uncertainty may increase in a more 
significant manner. The opposite effect is observed with regard to the uncertainty in the total yield. These 
observations may have important connotations with respect to the state of knowledge that can be 
ascertained over certain parts of the process sequence and what can be done to improve it. 
In Alternative 2, the uncertainty in the product composition of the recycled solL mother liquor, WtsolL 
nil. 2, lo, becomes the fifth ranked contributor to profitability uncertainty and the fourth ranked to the total 
yield uncertainty. In contrast the uncertainties in the drug impurity compositions of the recycle appear to 
have negligible effect on the endpoint impurity contents. With elimination of the wash operation in 
Alternative 3, the uncertainty in the level of dampness of the post-filtration solids stream, LOD13, becomes 
an important factor to the key impurity content. This would be expected since any quantities of the key 
impurity contained in the residue moisture is no longer removed from the crystal product. 
With the introduction of different contributors or changes in the relative contributions of the common 
sources of uncertainty associated with alternative flowsheets, qualitative judgement regarding the 
possibility of the relevant process stage model improvement and uncertainty reduction becomes important 
if the levels of predicted output uncertainty are desired to be limited. 
9.4 Comparison between flowsheet operating policy tolerances 
The basis for this comparison between each flowsheet alternative is the maximum average tolerances 
achieved under a percentage based relaxation in the 'here and now' optimal expected potential 
profitability and an examination of the trade-offs between the key operating policy tolerance windows. 
The former quantity represents the average fraction of the total operating policy space available in all the 
considered variables (defined by the upper and lower policy bounds), within which policy uncertainty 
permits a feasible solution. It can take values between zero for no tolerance to operating policy uncertainty 
about the optimal values, to one for complete tolerance within the specified policy bounds. 
Comparison of the average operating policy tolerances with a 99% achievement of the 'here and now' 
Table 9.2. Alternative flowsheet operating policy tolerance optimisation results, Case Study 11. 
Average 
tolerance 
E(Pty) 
$ kgactA-l hr-1 
Operating policy variables 
Base Case 0.088 30.66 tcl, NI, AF10, RFIO, CR12, I-IP12 
Alternative 0.080 (0.090) 30.81 as Base Case + 
RsoIF 
back 
_ Alternative 2 0.083 (0.081) 31.94 as Base Case + R,,,, L , ycl, 
Alternative 3 0.055 31.33 as Base Case 
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optimal expected profitability is shown in Table 9.2. This basis measures the relative degree of relaxation 
for each flowsheet in an unbiased manner. Otherwise, the use of a constant expected profitability 
constraint threshold value would give a greater relaxation advantage to the flowsheet with the greatest 
'here and now' optimal profitability. The policy variables considered are the same as those used in the 
flowsheet optimisations. Table 9.2 indicates that the Base Case flowsheet is the most tolerant to error in 
the 'here and now' optimal operating policy, although the values for Alternatives I and 2 are very close. 
The average tolerance values for all the flowsheets are relatively small since negligible tolerances are 
permitted in the Stage I agitation speed (NI), the Stage 10 solL addition and removal fractions (AF10 and 
RFIO), the Stage 12 crystallisation cooling rate (CRID nor in the fraction (of the Stage I quantity) of solF 
for the back extraction (Rsoff_back) in Alternative 2, or the fraction of solL mother liquor recycle employed 
in Stage 10 and II (Rsoll--recycle) in Alternative 3. The values of the optirrusation decision variables and the 
tolerance limits for Alternatives 1,2 and 3 are given in Tables E6, E7 and E8 (Appendix E), respectively. 
It is immediately clear that Alternative 3 has a rather lower average tolerance (0.055) than the other 
flowsheets. The removal of the wash operation acts to remove some of the tolerance to error in those 
operating policy variables controlling the formation and crystallisation of the impurities, the Stage I 
reaction time (tfj) and the Stage 12 crystallisation holding period (HP12), respectively. This may be 
reasonable to expect. 
The bracketed values for Alternative I and Alternative 2 in Table 9.2, are the average tolerances over only 
the operating policy variables common to all the flowsheet alternatives (tf,,, NI, AFIO, RFjo, CR12, I-IP12)- 
Comparing these average tolerances removes the bias in the averages associated with additional policy Cl 
variables (solF back extraction ratio and solL mother liquor recycle ratio operating policy variables, 
Rso]F-back and R, 011--recyclel available in Alternative I and Alternative 2, respectively). Under this comparison 
E 
C 
0 
a) 
(a) Stage I Reaction time. 
"0 
(b) Stage 12 Crystallisation holding period. 
Figure 9.6. Tolerance limits for operating policy variables for alternative flowsheets, Case Study 11. 
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the average tolerance of Alternative 1 (0-090) becomes comparable to that of the Base Case (0.088) 
The tolerance limits on the Stage I reaction time (tf, I) and the Stage 12 crystallisation holding period 
UIP12) are compared between the flowsheets, in Figure 9.6 (a) and (b). These policy variables are the only 
two in which any significant tolerance is permitted regarding the expected profitability objective and 
profitability loss associated with the total yield, key and secondary impurity content criteria. The dots 
encompassed by the tolerance limits are the 'here and now' optimal values and the dashed lines are the 
bounds on the decision variable. The large tolerance in Alternative I tfI (69 min) is offset by a small 
tolerance in IIP12 (8 min). For the Base Case the opposite is true, where the UP12 tolerance (25 min) is 
offset by that in tfI (32 min). The tolerance limýits on N, and CR12 are very narrow and on AFIO and RFIo 
they are the same for each flowsheet. The limited tolerance in both tfI and I-IP12 for the removal of the 
wash operation in Alternative 3, is observed in Figure 9.6. 
9.5 Conclusions 
In this Chapter the third management response to process uncertainty regarding the assessment of 
alternative flowsheet options (see Section 5.3) is implemented for Case Study 11 for three alternative 
flowsheets. Stochastic optimisation approaches are used for the quantified assessment of the alternative 
process flowsheet options with respect to the expected profitability and loss criteria under model 
parameter uncertainty and the maximum permitted tolerance in the subsequent optimal operating policy. 
This permitted the selection of the best flowsheet according to these different criteria under their 
respective model uncertainties. 
It was shown that the Alternative 2 flowsheet achieves the best expected profitability under a soft 
potential profitability loss constraint due to endpoint purity violations. The recycle of solL mother liquor 
saves solvent cost. In addition, the introduction of recycled product permits a shorter reaction time 
(reducing the formation of impurities) and a lower crystallisation holding period. The drawback is the 
observed increase in uncertainty in the total yield, resulting from the introduction of uncertainty in the 
mother liquor product composition. 
The Base Case flowsheet appears to be the most tolerant to uncertainty in its 'here and now' optimal 
operating policy variables, although there is little difference between the Base Case and Alternatives I and 
2. The Stage I reaction time and the Stage 12 crystallisation holding period were the only policy variables 
exhibiting tolerance with respect to the profitability criterion. The average tolerance associated with 
Alternative 3 is significantly lower than for the other flowsheets due to the removal of the wash 
purification operation. This provides a compromise to the improved profitability predicted 
for this option. 
The overall results presented in this chapter show that although the Alternative 2 
flowsheet (soll- mother 
liquor recycle) predicts the greatest profitability (annualised $2.67 million greater than the nearest rival 
option, Alternative 3) the flowsheet with the greatest degree of operating policy tolerance is the 
Base 
Case. However, the Base Case exhibited the lowest expected profitability. 
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Chapter 10 
CONCLUSIONS AND FUTURE WORK 
10.1 Conclusions 
In this thesis the subject of uncertainty in a model-based approach for the design of pharmaceutical 
processes is addressed. Quantitative uncertainty management considerations are systematically applied to 
model building procedures and to the optimisation of complete integrated process sequences. 
Chapter 1 introduces the motivation for the work within the context of the pharmaceutical industry. A 
background to the process development challenges faced by pharmaceutical industry together with the 
current role of process modelling is given in Chapter 2. It is acknowledged that significant benefits could 
be achieved with a more comprehensive use of model-based approaches. The opportunities to integrate 
systematic model development procedures with current process development cultures are apparent but the 
necessity not to increase process development cycle times further may be seen to provide a key stumbling 
block in the short term. Chapter 2 ends with a long term future vision for the integration of model-based 
approaches with process development cultures in the pharmaceutical industry. 
Aspects of uncertainty in the context of model-based applications are discussed in Chapter 3. A range of 
Uncertainty and Sensitivity Analysis methods are discussed. In a stochastic system framework, the major 
emphasis of the problem considered in this work is defined to support deterministic process model 
parameter uncertainties as opposed to inherent system variabilities which are irreducible. Sample based 
approaches for the quantification of the combined influence of parameter uncertainties propagating to the 
process performance variables are identified. A variety of Sensitivity Analysis techniques and measures 
are defined and compared in terms of the limiting criteria of efficient computation and information they 
contain. These aim to identify the key uncertain input sources contributing to the predicted uncertainty in 
the output performance criteria. It was concluded that methods which are computationally efficient and 
flexible to manipulation in different analysis situations would be the most amenable for this work. 
Methods for design optimisation under uncertainty are reviewed in Chapter 4. In general these problems 
involve multiple scenarios, either stated a priori or generated from bounded ranges of parameter 
uncertainty or from probability distributions. Methods involving equipment design and control variables 
as decisions were discussed. These were categorised into three classes: approaches using bounded range 
characterisations of uncertainty and which aim to guarantee a fixed degree of 
feasibility, approaches using 
probabilistic information on the uncertainties and which aim to determine more accurately the 
feasible 
region, and approaches using probabilistic information on the uncertainties and which consider the entire 
space of the uncertainties and permit levels of partial feasibility. 
It was concluded that the robust partial 
feasibility approaches were the most suitable for the problem considered in this thesis. 
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Three management responses to the presence of large amounts of uncertainty in the available models are 
considered in this work: identification of the key sources of uncertainty, manipulation of the available 
operating policy decisions and consideration of alternate process topology. In Chapter 5a methodology 
based on a Risk Analysis approach for model uncertainty is proposed for the provision of these responses. 
This approach is integrated with systematic model development procedures so that the uncertainty in the 
important process output criteria are quantified and the key sources of input uncertainty are identified. 
A stochastic description of the process system is generated with probability distributions for input 
parameter uncertainties based on the process data and parameter estimation methods where possible. This 
is approximated with the simulation of a set of deterministic models at discrete realisations in the defined 
input uncertainty space in an efficient Hammersley sampling based approach. In this way the combined 
influence of a large number of uncertainties over a complete process system can be measured. Efficient 
Sensitivity Analysis techniques which directly use the sample results of the Uncertainty Analysis are used 
to estimate linear, monotonic and/or non-monotonic nonlinear relationships between the uncertain inputs 
and the outputs. An estimation method for process sub-sequence contributions to uncertainty in related 
inter-stage stream properties is used to determine the cumulative and propagative effects on the 
uncertainty in inter0stage process qualities within the process sequence. 
A stochastic optimisation algorithm is used for the solution of four different stochastic programming 
problems. The key components of the stochastic system generated in the Risk Analysis approach provide 
the basis for these multiscenario optirrýsation problems. General formulations are stated for the estimation 
of the smallest reduction in the stochastic input uncertainties required to meet certain output requirements, 
process flowsheet optimisation under uncertainty for a desired process or economic objective, for the 
estimation of the value of perfect information in potentially certain process properties and for the 
determination of maximum operating policy error tolerances maintaining desired levels of performance 
under uncertainty. These problems take into account the entire space of the uncertainties and do not rely 
on worst case scenarios. 
Two case studies have been investigated to verify the methodology. In Chapter 6 the basic components of 
the Risk Analysis approach and stochastic process optirr: iisation under uncertainty are demonstrated for a 
multiphase reaction process model, Case Study 1. Uncertainty Analysis showed that model uncertainty was 
important and the optimum operating policy deterinined with no consideration of uncertainty resulted in 
very poor performances in some of the important criteria. Optimisation under uncertainty was able to 
provide significantly more desirable distributions in these poor performance aspects. Sensitivity Analysis 
methods were able to identify the key parameters for which reductions in uncertainty would be most 
beneficial. It is concluded that the methods implemented in Case Study I verify that this approach can 
provide useful information to the process development engineer. The significant (adverse) effect on 
optimised processes that uncertainty can impose was shown and that although better solutions can be 
achieved using optimisation under uncertainty techniques, this is not always guaranteed and it may be 
more beneficial to consider alternative process options or operating strategies. 
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A comprehensive case study of an integrated sequence of 15 process operations is introduced in Chapter 
7. Here the Risk Analysis methods proposed in Chapter 5 are demonstrated in a more rigorous manner as 
they are applied within the confines of systematic model development procedures. The combined 
influence of all the potentially significant parameter uncertainties in the complete process sequence is 
measured and the uncertainty in the important output criteria is tracked as more process information is 
incorporated into the model development. Key process sub-sequences were identified as contributing 
relative amounts of uncertainty to the output criteria predictions. Specific key uncertain parameters were 
identified over the entire process sequence and the lack of understanding in the associated physico- 
chemical phenomena was inferred. The endpoint process criteria of yield and impurity content were most 
sensitive to the uncertainty in the models for the reaction and crystallisation operations. This may be a 
reasonable expectation from engineering intuition. Trade-off levels between the minimum reductions in 
the key uncertain parameters to meet target levels of uncertainty in endpoint yield and impurity contents. 
These indicated the relative levels of uncertainty reduction required in different sources, for decisions 
concerning further data collection and resourcing levels. 
OptiMisation under model uncertainty of the complete process flowsheet is addressed in Chapter 8. An 
optimal operating policy which takes into account the combined influence of the important uncertainties in 
the sequence provides better performance than the nominal policy, in terms of a profitability objective. 
Specified tolerance to potential losses in profitability (due to violation of desired impurity content limits) 
is included through the use of one-sided stochastic constraints. Tolerance to error or uncertainty in this 
optimal operating policy is determined for a specified relaxation of the optimum objective function value. 
For this case study the key policy variables exhibiting tolerance to error were associated with the reaction 
and crystallisation operations. The value of perfect information in potentially measurable properties is 
determined for uncertainty in the purity of the active pharmaceutical ingredient (A. PI) feed stream to the 
reactor. This knowledge was indicated to be very important for purity levels below a certain level beyond 
which significant drops in profitability could otherwise be incurred. 
The third management response is addressed in Chapter 9. Implementation of the Risk Analysis approach 
in the stochastic optimisation techniques provide useful information for comparison between alternative 
process options based on the associated levels of process knowledge. For Case Study II this comparison is 
made between four alternative options with respect to the expected profitability objective and the 
associated uncertainty and the degree of operating policy error tolerance permitted. This allows a 
desired 
trade-off to be made at the discretion of the decision maker. 
The main conclusion of this thesis is that the systematic incorporation of quantitative 
Risk Analysis 
methods for uncertainty inclusion in a model-based approach is able to provide useful information to aid 
the integrated design of complete pharmaceutical processes with even simple models. 
The results of the 
case studies provide evidence that the management of uncertainty 
in a systematic manner is not only 
prudent but also has the potential to improve the quality of the process. 
In the second case study, tracking 
of the uncertainty with incoming development data indicated the availability of which 
data had the most 
beneficial impact on the uncertainty contained in the models. With the indication of the key uncertainties 
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in the current process sequence models, engineering judgement can be used to deduce the presence of 
associated phenomena which are significant but unconsidered. This information could be used to focus 
efforts within the development process. 
Since the results of the case studies appear reasonable and could be explained logically, some confidence 
can be drawn from the conclusions made. In the second case study, the relative importance of the reaction 
and crystallisation operations with regard to uncertainty in endpoint yield and impurity content levels 
provides confidence to the prior expectation that these would be the critical stages of the integrated 
process sequence. With this in mind it can be postulated that with the availability of more realistic models 
and more accurate quantification of the model uncertainty the results and conclusions would still be useful 
and valid (within the limiting assumptions). 
The evidence provided in this work should provide encouragement for the incorporation of uncertainty 
management and model-based support tools into process development cultures. What Is shown in this 
work is a basis for a systematic framework where process development procedures and process modelling 
tools are complementary. Referring back to Figure 2.1 (Chapter 2) indicating the typical roles of the key 
stake-holders within pharmaceutical process development, it can be postulated how such a combined 
framework can be used to link the different data collected and the resulting information determined by 
each stake-holder. The chemists provide a model of the intrinsic chemistry and reaction pathways. The 
development engineers then combine this knowledge with engineering phenomena associated with scale- 
up and pilot plant equipment within the paradigm of the framework. Though the same data may be 
collected and a rational basis for the collection of additional data provided, it is how this data is processed 
and how the information is used which is the essence of the framework. The integration of specific process 
operation knowledge with that of the other processes in the sequence is also seen as an essential element 
of process decision-making. The output is an estimate of the level of risk associated with the prediction of 
process performance given the current structured knowledge for the complete sequence and an evaluation 
of risk management response options, in an underlying (computational) framework where relevant 
information from all the stake-holders has been incorporated in a systematic and iterative manner. In this 
way the process characterisation passed to the pilot plant and ultimately the production engineers has a 
more rational and structured basis, which can be used to help determine better plant operating conditions 
and what measurements to take to improve the rationality. As Basu et al. (1999) pointed out, ultimately 
less scale-up iterations and higher quality processes and shorter development times could be expected. 
However, it is acknowledged that a limiting factor depends on how systematic model development 
procedures can be successfully implemented without substantially increasing the strain on resources and in 
particular the time observed with current practices. While it is also acknowledged that some processes 
remain too difficult to model reliably and in other cases empirical models may still need to be 
incorporated, ultimately the aim is that with advances in the understanding of the processes a shift towards 
more mechanistic modelling approaches will follow. This is why the potentially important uncertainties 
should be systematically incorporated into the structured process knowledge to identify areas where 
improved mechanistic understanding would be beneficial. An important feature of the methodology 
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presented in this thesis is the flexibility to easily implement deterministic process models ranging from C 
very simple mass balances to more complex models, so that useful information can be obtained from its 
application in early stages to the later stages of process development. The efficiency of the Hammersley 
sampling scheme and that of the employed Sensitivity Analysis measure estimations should permit the 
incorporation of more complex models with a greater number of parameters without creating an C' 
impractical computational demand. While it is proposed that the information and results determined in this 
work provide a new and useful contribution in this field, there certainly remains further issues which 
should be addressed in order to advance the case. 
10.2 Future work 
One of the main assumptions of the combined model development and Risk Analysis methodology is that 
the uncertainty is contained in the process model parameters and the model structure is correct. A further 
step would be to incorporate procedures which also determine the adequacy of the proposed model 
structures in the face of parameter uncertainties. Implementation of techniques for this concept would be 
strongly dependent on the quality of the data made available for modelling. One approach incorporates the 
fuzzy set theory for non-random uncertainties (Kubic and Stein, 1986). This was used to provide measures 
of model structure confidence which incorporates expert knowledge. They are expressed as membership 
functions and ignorance factors which test the validity of structural assumptions and the need for 
experimental data to validate the model. Zhang and Qlan (1998) combined fuzzy and deterministic models 
into an integrated hybrid flowsheet so that poorly understood operations could be better expressed using 
expert knowledge. This could have application in the analysis of complete pharmaceutical process 
sequences where the solid phase operations are particularly poorly understood, but the objective remains 
to develop mechanistic models where Justifiable. 
Since uncertainty in process knowledge and model development are inherently dependent on the available 
data, further involvement in the design of laboratory experiments/pilot plant data collection is a logical 
advance for the methodology proposed in this thesis. Work by Pinto (1998), Martinez (2000) and Asprey 
and Macchietto (2000 and 2002) are examples where the link between experimental design and model 
discrimination and model parameter uncertainty is addressed. It is important that knowledge obtained 
from experimental designs be transformed into knowledge contained in deterministic models. With an 
increased emphasis on obtaining experimental data, methods like those of Vasquez and Whiting (1999) 
and Vachhani et al. (2001) considering systematic and random errors in the experimental data used to 
estimate model parameters, would add an important aspect to the analysis of the uncertainty. 
In the case of 
highly non-linear models, methods which determine more accurate estimations of 
joint correlated 
parameter uncertainties than is captured assuming linearisation methods employing 
Taylor series 
expansion based covariance matrices (as assumed in this thesis) would 
be more appropriate. The work of 
Vasquez and Whiting (2000) and Rooney and Biegler (2001) provide recent advances in this area. 
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The applicability of the approach proposed in this work to the difficulties of scale-up is worth 
consideration. While energy considerations were largely neglected In the case studies presented in this 
thesis for simplicity, future work should certainty consider uncertainty and optimisation in more rigorous 
models which describe heat transfer and mixing phenomena as are often problematically encountered. 
Application of process modelling towards the examination of critical parameters, safe determination of 
practical achievable operating ranges and process specification failure limits in Sensitivity Analysis and 
process validation and possibly even in conjunction with the stipulations of the regulatory authorities has 
already drawn the attention of Wright and Bramfitt (1997) and Basu et al. (1999). The work presented in 
this thesis aims to provide one step towards the progress required to meet these visions. 
The formulation of the stochastic optimisation of the process flowsheet could be improved by including 
information concerning state variable measurements by using feedback correction policy methods (as 
proposed by Terwiesch et al. (1994) and Bhatia and Biegler (1997). This would reduce the degree of 
conservatism of the 'here and now' approach but avoid the optimistic and unrealistic assumptions inherent 
in the 'wait and see' approach. 
Since the formulation of the stochastic programming problem with one-sided stochastic constraints is 
approximated as a stochastic optimisation with non-convex binary approximations, this results in a non- 
convex NLP for which gradient information may not be of good quality and the global optimality of 
solutions is not guaranteed. Alternative non-gradient based optimisation methods (e., (),,. genetic algorithms, 
simulated anealling) to the SQP method used in this work are designed to be more reliable in obtaining 
non-local optima and less dependent on the initial points. However, consideration of the computational 
demand such methods require is important. The efficient Hammersley sequence sampling method as used 
in this work to approximate uncertain quantities still required more than a hundred deterministic model 
evaluations per objective function evaluation. The incorporation of more complex models may prove to be 
computationally prohibitive. The cubature integration method introduced by Bernardo et al. (1999) 
improves efficiency in some cases but a more generic method would be useful. Consideration should be 
given to other low discrepancy number sequences which exhibit greater efficiency in P-dimensional space. 
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NOTATION 
a= Taguchi loss proportionality constant or radix-R integer coefficients 
A= Fourier cosine coefficient or Arrhenius coefficient (dM3 mol-' hr-1 second order 
reaction) 
AF = fraction of a total solvent feed quantity added to an operation 
b= least squares point estimate of a multi-linear regression coefficient, or vector of these 
estimates 
B = Fourier sine coefficient 
c = sequence of points generated during computation of the Hammersley sequence points 
C = general cost function or desired correlation matrix of an uncertain factor matrix or 
material price ($ kg-1 material) 
C = desired rank correlation matrix of an uncertain factor matrix 
CTag = cost incurred for a Taguchi performance tolerance violation 
= parameter correlation matrix 
Cov = covariance 
cc = correlation coefficient 
CR = correlation ratio or crystallisation cooling rate ('C min') 
d = (equipment) design variables 
di, d2 = general one-sided deviation functions 
det = determinant 
DC = differential coefficient 
DR = drying rate (min kg-1 solids) 
e = Hammersley sequence points 
E = expected value or correlation matrix of a substitution matrix of the uncertain 
factor 
matrix 
Ea = activation energy (dm 
3 mol" hr-, second order reaction) 
E, i,,, = expected value of the extent of a 
deterministic constraint violation 
f= general deterministic model equations 
fde v= general 
two-sided deviation function 
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F= deterministic flexibility index or general stochastic objective function or feed mass 
(kg) 
Fcc = value of the F-distribution with an area ot to its right 
FCV = fractional contribution to output performance variance 
FR = filtration rate (min kg-1 solids) 
width between al % and(X2 %fractiles 
9= general deterministic inequality constraints 
G= Fourier transformation function 
h= general deterministic equality constraints 
hband = height of a two-phase dispersion band (in) 
H= Hessian matrix 
HP = crystallisation process isothermal holding period (min) 
= Jacobian matrix of model parameter estimation predictions or total number of 
inequality constraints 
JO = general deterministic initial conditions 
k= constant in Chebyshev's rule or reaction rate constant (units dependent on reaction 
order) 
kg crystal growth constant (in min-' (kg kg-1 solvent)"") 
K substitution matrix of the uncertain factor matrix 
K rearranged substitution matrix of the uncertain factor matrix 
L= Taguchi's cost associated with a quality loss or a lower triangular matrix of a desired 
correlation matrix 
LOD level of dampness of solids (%) 
M, number of preceding sample observations used for convergence tolerance test 
Mb = current sample observation iteration number 
M= total number of scenarios, periods or sample observations 
M/ total number of sample observations (scenarios) in potentially measurable 
uncertainty space 
N number of measurement data points used in a model parameter estimation problem 
or normal distribution or agitation speed (rpm) 
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ni sample size required to evaluate individual variance integrals in measures of 
importance 
p= purity (wt%) 
P= total number of uncertain factors (dimensions) or number of parameters in a model 
parameter estimation problem 
Pft = profit 
Pr = probability 
Prpass 
= probability of passing a constraint 
Pr, j., = probability of deterministic constraint violation 
PC = perturbation coefficient 
PCC = partial correlation coefficient 
Pty = profitability ($ kgApi-1 hr-1) 
Ptyloss = potential profitability loss ($ kgApj_1 hr-1) 
Q = inter-stage sub-sequence quality criterion or lower triangular matrix of an non- 
identity correlation matrix 
R feasible region or prime number 
R2 coefficient of determination 
Rsol-back fraction of a feed quantity of solvent used in a back extraction 
Rsol-recycle fraction of a feed quantity of solvent which is from a recycle 
RF fraction of a solvent feed quantity removed in an operation 
RSC = response surface coefficient 
RSS = residual sum of squares between the vector of deterministic model performance 
outputs and the vector of regression model performance outputs 
S sample standard deviation or Fourier space 
S2 residual variance of a model parameter estimation problem 
S FAST Fourier amplitude sensitivity test index 
So Sobol' sensitivity index 
SF stochastic flexibility index 
SRC standardised regression coefficient 
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SS, Vj, = sum of squares of the distances from the mean value of the deterministic model 
performance output 
SSOO = sum of squares of the distances from the mean value of the uncertain factor 
SSq, O = sum of products of distances from the deterministic model performance output and 
uncertain factor values from their respective means 
SSC = sub-sequence contribution to endpoint performance uncertainty 
t= time (hr, Case Study I or min, Case Study 11 - units analogous with available case 
study data) 
t // = time at which initial rate limited period ends, Case Study 11 (min) 
t, = value of the Student t-distribution with an area (x to Its rltght 
T= bounded region of deterministic uncertainties or temperature (K, Case Study I or 'C, 
Case Study 11 - units analogous with available case study data) 
TSS = total sum of squares of the distances between deterministic model performance 
outputs and its mean 
Ul = fraction of drugs originally in the organic phase which are soluble in the aqueous 
phase (reagent addition model, Case Study 11) 
U2 = fraction of drugs originally in the organic phase which is cut into the aqueous phase 
(layer separation model, Case Study 11) 
U= uniform distribution 
covariance matrix 
Var = variance 
VI = value of information 
VPI = value of perfect information 
w= distribution parameter (mean or standard deviation) 
wf = weighting factor 
wt = weight percent (7c) 
W= level of dampness (% LOD) 
x= derivatives of differential variables with respect to time 
state variables or differential variables 
X= matrix of uncertain factor values or conversion 
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X= matrix of uncertain factor values with a desired correlation structure 
y= algebraic variables 
Y= yield, based on active pharmaceutical feed 
z= control (operating policy) variables 
z= mass (kg) 
Greek letters 
cc = confidence 
p= binary variable 
X= objective value of the max-min-max sub-problem equivalent to the feasibility test 
8= fraction of the original spread of the uncertainty 
82 = fraction of the variability of the deterministic model performance output that is 
explained by the variability in the uncertain factors 
deviation or tolerance 
6= error or tolerance limit 
0= deterministic quality criterion 
(D = deterministic objective quality criterion (or a vector of these values) 
(D = predicted value of a quality criterion from a regression model (or a vector of these 
values) 
= sample mean of deterministic model performance output 
7 desired constraint target 
71 power characterising the mixing regime on the rates of reaction 
71 = power characterising the effect of mixing on the parameter characterising the initial 
rate limiting period 
flwash = crystal wash operation efficiency 
inverse radix number 
K= mean-variance weighting parameter 
ýI = population mean or nominal value (or vector of these values) 
time dependent operating variables or gaussian quadrature collocation point 
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0= uncertain factor (or vector of these values) 
0= sample mean of uncertainty factor 
E) = total uncertainty space 
eu = input uncertainty space over uniformly distributed space 
ON = input uncertainty space overjoint normal distributed space 
P= Pearson product moment population correlation coefficient 
cr = population standard deviation 
Gs[ 
= equilibrium solubility of solute in organic-aqueous phase mixture (wt(T) 
1) = time invariant operating decisions 
angular frequency 
binary approximation parameter 
T= penalty function for the penalisation of stochastic constraint violations 
C= first order rate constant for loss of impurity concentration (Min- I) 
Subscripts 
add = addition 
d= index for operating policy variables, of total D 
diss = dissolution 
dt = index for uniformly distributed input uncertainties, of total DT 
f= final or feed 
here = 'here and now' optimal solution 
i= index for iteration number 
iso = isothermal 
i= index for Fourier coefficients or index for inequality constraints 
k= index for radix-R integer coefficients 
m= index for sample observations (scenarios) in uncertainty space, of total M 
m/ = index for sample observations (scenarios) in potentially measurable uncertainty 
space, of total M' 
n= index for data points used in a model parameter estimation problem, of total N 
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nominal = nominal optimum operating policy 
non-iso = non-isothermal 
0 = value at time zero 
P = index for parameters estimated in a model parameter estimation problem or in the 
entire stochastic problem, of total P 
PC = index for potentially measurable uncertainties, of total PC 
pe = index for time period in optimal control problem 
q = index for output performance criteria, of total Q 
r = index for uncertain factors in a stochastic problem, where r#p 
robust = robust optimum operating policy 
s = index for process stages, of total S 
ss = index for process sub-sequences, of total SS 
st = index for normally distributed input uncertainties, of total ST 
std = standardised 
T = endpoint 
v = index associated with radix-R integer coefficients 
wait = ýwait and see' optimal solution 
Superscripts 
c critical value 
L lower range 
LB lower bound 
N nominal value 
th constraint threshold value 
U= upperrange 
LJB = upper bound 
= optimal value 
= original value (associated with a prior problem solution) 
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Appendix A 
CASE STUDY I 
The deterministic model equations, uncertain parameter models and additional results for Case Study I are 
stated in Appendix A. 
A. 1 Deterministic process model for semi-batch reactor 
Component mole balance, 
dmA 
= -ki 
MAMB 
2 
MAMC 
dt VT VT 
dmB 
=v 
mBo k, MAMB 
dt YBO VT 
dmc 
k, 
MAMB 
k 
MAMC 
dt VT VT 
dm D k, 
MAMC 
dt VT 
Arrhenius equations, 
Piss )A, exp _ 
La, 
+ 
[odiss 
Adiss exp _ 
Ladiss 
Tis, Tiso 
A, ex _ _ýa Ti, 0 
Odiss ý- 
I if XAX diss 
0 if XAX diss 
Volume change, 
dVT 
==0 
dt 
1) 
11, 
tadd 
1 
tadd 11 
VBO 
t 
add 
Termination condition, 
193 
Integrated design under uncertainty for phannaceutical processes 
XA 
". 
M AO - MA 
MAO 
dXA 
= 
kjMAMB 
+ 
k2MA'? 'C 
< 0.001 hr-1 
dt VTMAO VTMAO 
Cooling capacity constraint on operating policy variables, 
Tiso, 
max 
ý! 7.06(t,, dd 
)2 
- 43.50(t,, dd 
)+ 352.67 
Output criterion, 
yD= MD X 100% 
MAO 
Initial conditions (inside reactor) 
MAO = 1.075 moles 
171 BO -:::: 
MCO «-20 
DO :::::: 
VT =0.7 dM 
XAO =0 
where 
A Arrhenius coefficient, dM3 mol-' hr-1 (second order elementary reaction) 
Ea activation energy, U mol-1 
k rate constant, din 3 mol-1 hr-1 (second order elementary reaction) 
in moles, mol 
t time, hr 
T = temperature, K 
V = volume, dm 
3 
x = conversion 
Y = yield, % 
1) = volumetric flowrate, drn 
3 hr-1 
subscripts 
(Model A I) 
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add = feed B addition 
diss = dissolution 
f = endpoint 
ISO = isothermal 
max = maximum value 
T = total value 
0 = initial value 
I = main reaction 
2 = sub-reaction 
The assumptions made in this model are: 
e elementary reactions, 
perfect mixing, 
duration of the initial dissolution period is only dependent on conversion, 
* constant rate of feed B addition, 
isothermal operation, 
use of a quadratic approximation for the cooling capacity limitation on the operating policy variables 
(see Figure Al). 
The available decision variables are the addition time (of a predeterinmed quantity of B), tadd, and the 
isothermal temperature, Tj,, The total moles of B added is 3.01 moles, the value Of Xdiss IS 0.55 and the 
estimated values of Eadi, s, Eal and 
Ea2 are 78.98,90.46 and 65.97 U mol-1, respectively, and Adj, A,, and 
A2 are 1.76x 1013 , 
4.68x 1015 and LON1010 dM3 mol-1 hr-1, respectively. The kinetic parameters were 
determ-ined through plots of In(k) versus I/T, where the experimental data points have been taken from 
Sano et al. (1998). 
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"1 
Figure Al. Approximation of cooling capacity constraint, Case Study 1. 
Key: *= data points (Sano et al., 1998). 
A. 2 Uncertainty and Sensitivity Analysis 
The probability distribution characterisations for the parameter uncertainties considered in the Uncertainty 
Analysis for Case Study I are assumed to be uncorrelated and are given in Table Al. Figure A2 shows the 
evolution of the mean and variance parameters for the predicted impurity yield. The scatter plot between 
normalised values of impurity Yield D and the sub-reaction activation energy, Figure A3 (a), shows the 
effect of rank transformation for the computation of monotonic but non-linear relationships using linear 
>. 
(a) Mean. 
18 
16 
14[ 
12 
u 
r_ 10- 
6 
\ 
(b) Variance. 
Figure A2. Evolution of distribution parameter estimates with sample observations for the impurity 
yield, Case Study 1. 
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Table Al. Uncertainty characterisation in the parameters of Case Study 1. 
Parameter Normal distribution, N(ýt, cy) 
Uniform distribution, U(min, max) 
Eal N(90.46x 103,1017c nominal) 
A, N(4.68x 1015,10% nominal) 
Ea2 N(65.97x 103,10% nominal) 
A2 N(1.00xIO1O, 10% nominal) 
Eadi,, N(78.98x 103,10% nominal) 
Adiss N(I. 76x 1013,10% nominal) 
Xdiss N(O. 55,10% nominal) 
Ti,,, U(- I 
. 
00c4tTi"), +I . 
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(a) Effect of rank transformation (nominal 
policy). Key: ob = unranked data (SRC = -0-59), 
o= ranked data (SRRC = -0.76) 
(b) Effect of different optimal operating 
policies on rank transformed data. 
Key: e= robust policy (SRRC = -0.88), 
o= nominal policy (SRRC = -0.76). 
0 
Figure A3. Normalised scatter plots between Yield D and sub-reaction activation energy (Ea2) sample 
results, Case Study 1. 
measures. Figure A3 (b) shows the increased strength in the monotonic relationship 
between Yield D and 
sub-reaction activation energy under the robust optimum operating policy. 
A. 3 Accuracy of the hyperbolic smoothing function 
The binary variable approximation curves in Figure A4 (a) and (b) show the hyperbolic smoothing 
function for values of 160 and 40 for the impurity yield and final time criterla, respectively. At these 
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Figure A4. Binary variable approximation hyperbolic smoothing curves, Case Study 1. 
values of the constants, the binary approximations calculate zero or one for predictions that fall within 1% 
(dotted lines) of the desired threshold value (dashed lines). 
A. 4 Computation statistics 
The computational statistics for the optirri=isation problems solved for Case Study I are listed In Table A2. 
They were solved using the MATLAB (Version 6.0) programming software and the Optimisation Toolbox 
function for non-linear constrained optimisation algorithm based on SQP. They were performed on a 
RS6000 IBM workstation. The CPU times for the stochastic optimisation problems were approximately 
two orders of magnitude greater than the CPU times for the respective nominal optimisation problems, 
indicating that the direct solution of a stochastic problem poses a substantial computational burden even 
with the use of an efficient sampling technique. 
Table A2. Computational statistics for optimisation problems, Case Study 1. 
Problem CPU time Optimisation Function 
formulation (seconds) iterations evaluations 
Nominal isothermal process P4 5.3 20 85 
optimisation 
Stochastic isothermal process P5 339 13 55 
optimisation 
Nominal non-isothermal process P6 27.3 36 361 
optimisation 
Stochastic non-isothermal process 
optimisation (over a number of P7 1XI03 to 8x 103 50 to 85 500 to 800 
starting points) I I 
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Appendix B 
B. CASE STUDY 11: FIRST GENERATION PROCESS MODELS 
The deterministic models, associated modelling assumptions and uncertain parameter c haracteri sat ions for 
the processes comprising the complete process sequence investigated in Case Study 11 are stated in 
Appendix B. In addition, an expression is given which is used to account for additional levels of 
parameter uncertainty due to the violation of desired ratios or ranges in inter-stage state variable 
measurements. Some additional Uncertainty Analysis results for Case Study II are presented. 
B. 1 Reaction model 
The available bench scale data for the reaction comprises concentration- time profiles of each drug species, 
reG and reH. The following experimental results and analysis are obtained from private communication 
with a pharmaceutical company. These are discussed to understand the assumptions in the model. With 
this data it is assumed an intrinsic kinetic model for the reaction process can be developed. Since the fates 
of aqueous reagent, reH, solid organic reagent, reG, and the resulting oxidant, oxG, are complex and not 
well understood, it is not possible to develop a rigorous kinetic model which accounts for these species. 
Under the conditions used oxG does not appear to be a limiting factor in the kinetics of the drug reactions. 
Simplified pseudo-first order reaction kinetics based on the stoichiometry shown in Equations BI and B2, 
are assumed in the organic solvent phase. The first generation model for the Stage I reaction is given in 
Model BI and the process diagram is shown in Figure B 1. 
actA, g -> actB,,,. -ý actCor- 
(B 1) 
actDorg ---ý actEorg (B2) 0W 
solF, F,,,, F 0 
reH, FreH 10 Zl, ýorg 
2Liquidphase 
Active pharmaceutical 
ZIJ, aq 
ingredient feed, Fd, g 
Figure B 1. Stage I reaction, Case Study 11. 
Feed specification, 
Pf 
li fdrug, i 100 drug 
199 
Integrated design under uncertaint. yfor pharmaceutical processes 
Fr, 
H = molratio F, 11 RMMreH- 
fdrug, 
l 100 
RMMdrug, l wtaq,,, 
VreH = _FreH 
PreH 
Drug component mole balance, 
dMI, 
org 
dt = -klml, org 
dM2, 
org_ 
=kImI, Org - 
k, M 2, org dt 
dM 
3, org k2M2, 
org dt 
dM4, 
org. 
=0 -k3M4, org dt 
it"'t, 
I I tf 
dM5, 
org 
=0 k3M4, org dt 
lto, 
t, 
=I 
t 'tl 
Solvent balance, 
1,6, org 
FsolF 
1,7, org 
0 
Z 1,8, org 
FreH 
End point criteria, 
ij, org '= 
RMMimi, 
org for i=l 5 
1000 
Moj, org - MI, org X, =- 
Moj, org 
IJ, org x 100 for i=l 5 Compi 5 
l, i, org 
Initial conditions, 
mO, i '= 
fdrug, i 
x 1000 for I ... 5 (Model B 1) RMMdrug, i 
where 
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comp = composition by weight, wt% 
f= component feed mass, kg 
F= total stream feed mass, kg 
k, = first order rate constant for main reaction, min-' 
k2 = first order rate constant for consecutive reaction, min-' 
k3 = first order rate constant for sub-reaction, min-' 
m= moles 
molratio mole ratio of reagent to moles of active pharmaceutical ingredient in feed 
Pf purity of active pharmaceutical ingredient feed, wt% 
RMM relative molecular mass (in aqueous streams, refers to RNM of solute compound) 
V volume, m3 
wtaq = reagent strength in aqueous solution, wt% 
x conversion 
z mass, kg 
p density, kg M-3 
subscripts 
aq = aqueous phase 
i = component species I actA, actB, actC, actD, actE, solF, solL, aq) 
0 initial condition 
org = organic phase 
t' = reaction starting time (zero), min 
tf = time at which sub-reaction starts, min 
tf = total time of Stage I operation, min 
Possible degrees of freedom include Fdrug, MOlratiOrcHý wtaqreH and tf. The main assumptions made in this Cý 
model include: 
pseudo first order stoichiometry and elementary reaction kinetics (oxG in excess throughout), 
observation of intrinsic kinetics in the assumed reactions (perfect mixing throughout), 
the sub-reaction for the secondary impurity (actE) starts after 60 minutes, 
no feed solids dissolution effects, 
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9 instantaneous addition of reH feed, 
9 reG and reH species are not explicitly modelled, since their fate is not understood, 
0 isothermal operation and no other limiting heat transfer effects, 
9 no mass transfer of drug species from the organic phase to the aqueous phase. 
The fitted parameter values for the bench scale model are given in Table B I. Since the predicted drug 
component profiles exhibit a reasonably good fit to the bench scale data, see Figure B2, the assumptions 
of pseudo-first order kinetics and perfect mixing appear satisfactory for this system. 
Table B 1. Parameters for the bench scale Stage I model, Case Study 11. 
Fitted model parameter values Imposed laboratory conditions 
k, = 0.0169 min- I tf = 360 min 
k2 = 7.14 x 10-5 min-' pfj = [81.7,0,0,18.3,0] wt% 
k3 = 1.66 x 10-3 min-' Fduý = 0.100 kg 0 
t'= 60 min molratiOreH = 10.4 
wtaqrcH = 30% 
(A 
:F 
Time, mýin 
0 
2 
Time, min 
(a) Key to data points: o= actA, *= actB, x= actD. (b) Key to data points: *= actC, += actE. 
Figure B2. Bench scale drug profile predictions for the first generation Stage I model, Case Study II. 
B. 2 Reagent addition model 
0 
A mass balance comprises the first generation model used to 
describe the addition of aqueous reagent 
operations. The first generation model for the Stage 2,4,5 and 
7 reagent addition operations is given in 
Model B2 and the process diagram is shown in Figure B3. C- t- 
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2 Liquid phase zl, i,,,, g 10 
Zl, ýaq Z2, i, org 2 Liquid phase 
Feed steam F 
Z2, i, aq (aqueous/organic) 
Figure B3. Reagent Addition, Case Study 11. 
Feed specification, 
F= VFPF for distilled water 
or 
F= molrat'o F RMM F 
M03 100 
for aqueous solution RMM I wtaq F 
Drug component balance, 
Z 2, i, org == 
(1 
-UI 
)Z 
IJ, org fo r1=15 
for 1=1 5 2, i, aq = 
(U 
IZ IJ, org 
+Z IJ, aq 
Solvent balance 
7 for i=6 8 , 2, i, org =Z IJ, org 
Z 2,8, aq ::::: Z 1,8, aq 
Zl, i, aq = Zl, i, aq 
fo ri=6,7 (Model B2) 
where ul is a parameter representing the fraction of drugs in the organic phase of the input stream, which 
are soluble in the aqueous phase and the component species, i, are (actA, actB, actC, actD, actE, solF, 
solL, aq). An additional parameter, u, not explicitly expressed in Model B2, is used specifically for the 
Stage 2 dilution model to represent the time in nunutes, after the desired Stage I termination point (tf,,, 
whereupon the diluent is added), that passes before the reaction has fully terminated. Degrees of freedom 
could be either VF for the addition of distilled water or molratiOF and wtaqF for the addition of an aqueous 
reagent solution. The main assumptions of this model include: 
* instantaneous addition of feed stream, F, 
9 instantaneous reactions, no mixing effects, 
* no limiting heat transfer effects, 
any mass transfer of drugs to the aqueous phase, Z2, i, aq due to solubility, is represented 
by parameter ul, 
and is assumed instantaneous and the same proportion for each drug species, 
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* solubility of solF in the aqueous phase, Z2, i, aq, is unimportant and is assumed to be zero. 
B. 3 Layer separation model 
A simple mass balance comprises the first generation model used to describe layer separations. The first 
generation model for the Stage 3,6 and 8 layer separation operations Is given in Model B3 and the 
process diagram is shown in Figure B4. 
2 Liquid phase zl, i,,,,, 
10 Z2, i, org 
Zl, i, aq 
10 
ý 
Z3J, org 
Pý Z3j, aq 
Organic liquid phase 
Aqueous waste stream 
Figure B4. Layer separation, Case Study 11. 
Component mass balance 
Z -,, i, org : --(I -U -) 
)z 
J, i, Org fo rI... 8 
ý 3, i, org U2Z IJ, org 
fo rI... 8 
Z3, i, aq Zl, i, aq 
fo rII... 8 (Model B3) 
where U2 is a parameter representing the fraction of organic phase of the input stream, which is an 
undesired cut in the aqueous waste stream phase and the component species, i, are jactA, actB, actC, 
actD, actE, solF, solL, aq). There are no degrees of freedom in this model. The main assumptions made in 
this model include: 
* light aqueous phase (reH) Is disperse, heavy organic phase (solF) 
is contInuous, 
o no mixing or time-dependent effects, 
no aqueous phase hold-up in the output organic stream, 
Z2, so that the efficiency of subsequent 
chemical destruction or solvent exchange operations is maintained 
(i. e. instead a small amount of t: ) 
organic phase 
loss, 4i, orgo, is incurred in the aqueous phase cut, ZO, 
any organic phase hold up (within a dispersion band) retained 
in the aqueous waste stream, Z3, IS 
characterised by the parameter fractionU2, 
9 no drug solubility in the aqueous phase. 
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BA Batch distillation model 
The model used here is a batch distillation from a reboller, with an energy balance to evaluate the vapour 
flowrate to the top product. A total condenser is not explicitly modelled but its operation is assumed. The 
first generation model for the Stage 9,10 and II solvent exchange operations is given in Model B4 and Z: ý 
the process diagram is shown in Figure B5. 
Solvent feed, Fj Z3J Top product 
Organic liquid phase, zjj z-,, i, Retained bottoms 
Figure B5. Batch distillation, Case Study II. 
Component mole balance, 
dM LJ 
dt yi 
vflow for i=l 8 
2J M L, i RMM i 
for i=l 8 
Z3, i Fi 
COMP FJ 
_Z "'i 
for 
100 
Energy balance 
d(MLHL) 
= -HvVflow + Q, dt 
Vapour-liquid equilibrium 
yj = xi Ki for i=l 
8 
Ki = 
Po" for i=l 8 
p 
Total liquid mole balance, 
inL, i 
Product volume, 
3J 
vtop 
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888 
+z xigradi 
Ybot 'z-- 
i=6 i=6 
8 xi 
i=6 
I 
i=6 A 
Enthalpy, 
HL XiCPL, i 
8 
Hv Xi (CPL, i + 
dHpVo, 
i) 
Liquid mole fraction, 
MLJ =: XiML for i= LA 
Normalisation equations, 
8 
Yj 
Xi 
Initial conditions, 
mo, j =: Fj + Z1j 
I for i=I 8 
100 RMMj 
where 
Cp pure component heat capacity, J/kmoUK 
dHpvO pure component heat of vaporisation, J/kmol 
F mass solvent feed, kg 
H enthalpy, J/kmol 
K vapour liquid equilibrium K-value 
in = moles, kmol 
M= total moles 
PO pure component pressure, Pa 
P total pressure, Pa 
Qr reboiler duty J/h 
(Model B4) 
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volume, m3 
Vflow = vapour flowrate, kmoUhr 
x= liquid phase mole fraction 
y= vapour phase mole fraction 
z= mass, kg 
subscripts 
bot = bottom product 
i= component species (actA, actB, actC, actD, actE, solF, solL, aq) 
F= solvent feed stream 
L= liquid phase 
top = top product 
v= vapour phase 
The assumptions made in this model include: 
* distillation time is an important variable otherwise a constant vaporisation rate model could be used, 
the condenser is not explicitly modelled (not assumed to be a limiting factor), but total condensation is 
assumed in the equation for top volume (V,, p), 
the physical properties, dHpv,, and CPL9 for the drug components are unknown, so the properties for 
d ioctylphth a late (ChemCAD V database, Chemstations, Inc., USA), C12H3804 (RMM = 390), are 
assumed due to a similarity in RMM (its properties predict no vaporisation under the range of 
operating conditions considered in this case study), 
the physical property methods used are: ideal VLE from K-value model, the generic physical property 
equations for pure component vapour pressure, heat of vaporisation for pure liquid components and 
pure liquid component heat capacities, as specified in the physical property library of the ChemCAD V 
simulation software, 
0 operation at zero reflux and I bar pressure, 
0 the assumption that an estimation for the maximum available reboiler duty per hour is available, 
* the equation for bottom volume Mot) is derived from an assumed linear function between drug solute 
concentration and solution density when solF is the only solvent present (the bottom volume 
estimation is only required for the solF single solvent case), where the gradient (gradi) is assumed to be 
0.5 for solF (i=6) and the intercept is the pure solvent density (p). 
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Possible degrees of freedom in this model could include the reboiler duty, QR, and the initial quantity of 
mixture, zj, and pure solvent feed, F. 
B. 5 Cooling batch crystallisation model 
The cooling batch crystalliser model used in this case study incorporates conventional growth kinetics for 
the product drug component, in which the method of moments is used to solve the population balance. 
Hulbert and Katz (1964). The first generation model for the Stage 12 crystallisation is given in Model B5 
and the process diagram is shown in Figure B6. 
Liquid phase zIj No 10 Z2, i, crys Slurry phase 
Z', i, fiq 
Figure B6. Crystalliser, Case Study 11. 
Seeded moments, 
dN, 
=O dt 
dL' 
= GNs dt 
dA' 
= 2GLs dt 
dv '= 3GAs 
dt 
Growth kinetics, 
G= kgAC2,2, liq 
Solute concentration balance, 
AC c 
C -), -), Iiq :ý Co, 2,2, liq - 
Zpc 
zpc = VA- f" 
Component mass balance, 
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ZpcZ), 
7, liq 
7 2,2, liq ZI, 2 - Z'-1,2. crys 
Z ', i, crys Z 2,7, liq 
(Co, 
2, i, liq - C2, i, liq fo r i'= 1,3,4,5 
42, i, liq =: ZIJ - '72J, crys fo ri=1,3,4,5 
Z 2, i, liq '= Z Ij fo ri=6,7,8 
Z 2, i, crys =0 fo ri=6,7,8 
Impurity growth, 
dCi, 
liq 
= ýiC2, ijiq fo ri=1,3,4,5 dt 
Initial conditions, 
N 
zO'S 
3 fv pc LO, 1,7, liq 
Lo, 
s 
Ao, 
s -: 
Zo, 
s 
F 
p, Lo, s" 1,7, liq 
zo's 
VO, 
s 
Pc , 1,7, liq 
Nom = Lom = Ao, n = 
Vom = 
l'i for 1=1,3,4,5 Co, 2, i, liq 
Z-1,7 
Operating policy, 
dT 
= CR 0 dt f 
tf = t'+ HT 
(Model B5) 
where 
A total crystal surface area, m2 kg-1 solvent 
c solute concentration, kg kg-1 solvent 
C* 1 
-1 solvent equilibrium solubility solute concentration, kg kg Cý 
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CR = cooling rate, T min- 
I 
fV = volumetric shape factor 
F = overall shape factor 
9 = kinetic order of growth 
G = growth rate, m min-' 
HT = holding time, min 
kg = kinetic growth rate constant, m min- (kg kg-1 solvent)"' 
L = total crystal length, m kg-1 solvent 
N = number of crystals, kg-1 solvent 
time, min 
tI= time at which holding temperature is achieved, min 
tf = termination time, min 
T= temperature, T 
V= total crystal volume, M3 kg-' solvent 
z= stream mass, kg kg-1 solvent 
P= crystal density, kg m -3 
= first order rate constant for loss of impurity concentration, min-' 
subscripts 
crys = solid phase 
i= component species JactA, actB, actC, actD, actE, solF, solL, aq) 
liq = liquid phase 
0= initial value 
PC product crystal 
s seeds 
Possible degrees of freedom for the batch crystallisation model could include: CR, HT, L,,,,, Z,,,,. The 
assumptions in the crystalliser model include: 
seeded operation, with Z,, kg of crystals of size L., and no nucleation, 
a power law function is suitable to describe growth kinetics for the crystallisation of the product drug-, 
210 
Integrated design under uncertaintyfor pharmaceutical processes 
0 since a lower holding temperature is believed to lead to increased crystal impurity content, but no data 
or mechanistic knowledge is available, the holding temperature is not considered a degree of freedom. 
due to the lack of understanding regarding the drug impurity effects, their crystalline presence is 
explained using first order solute loss functions of liquid phase drug impurity concentration (as 
opposed to an alternative assumption of linear impurity concentration loss which is not sensitive to 
changes in the initial value), and independent to temperature (the holding temperature remains 
constant), 
* since data is not available concerning the presence of crystalline Impurities other than the drug 
components (i. e. reG, solF, solL) no characterisation for these effects is portrayed in the model, 
although the presence of solF in the pre-crystallisation stream is considered an important criterion in 
this case study, 
* estimation of growth rate constant, kg, is based on solubility data for an alternative high relative 
molecular mass organic compound in pure solL solvent (based on three temperature data points and 
fitted with a2 nd order polynomial, RMM = 354, Crossfire Beilstein Database, Beilstein Cherniedaten 
und Software GmbH) since solubility data for the drug is not available in this study, 
* the limitation in process understanding precludes crystal size distribution (CSD) prediction, 
e an assumed fixed value for growth rate order (g = 1.2) due to lack of profile data points, 
* perfect cooling control at a constant rate and associated heat transfer effects are not limiting, 
9 size independent growth, 
* perfect spheres assumed for overall shape factor (F) and volumetric shape factor (f, ), 
9 the initial mixture is at the composition boiling point predicted by the ideal VILE batch distillation 
model with the physical properties of dioctylphthalate (ChemCAD V) used to represent the unknown 
drug properties. 
B. 6 Filtration model 
The first generation filtration operation is described with a simple mass balance. The lack of available 
data precludes the use of conventional filtration/centrifugation models found in chemical engineering 
literature. The first generation model for the Stage 13 washing operation is given in Model B6 and the 
process diagram is shown in Figure B7. 
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Slurry phase zl, i,,, y, 
z,, i,,, y, Solid phase 
ZIJ, fiq 
Z-,, i, fi, Residual moisture 
10 Z3, i, Filtrate stream 
Figure B7. Filtration unit, Case Study 11. 
Component mass balance, 
2, i, crys =Z IJ, crys fo r 
8 
1Z2, 
i, liq 
LOD =8 
i=l 
8x 
100% 
Z ", t, liq 
+Z2, i, crys 
8Zl, 
i, liq 
8Z2, 
i, liq 
8Z 
3J, liq 
_ fo r LA 
Zl, i, liq Z 2, i, liq Z 3, i, liq 
Batch filtration time, 
8 
tf = FR ll'i, crys 
where 
FR = filtration rate, min kg-1 solids 
I= component species I actA, actB, actC, actD, actE, solF, solL, aq I 
LOD = level of dampness in solids, % 
tf = operation time, min 
(Model B6) 
No degrees of freedom are associated with this model, since not enough information is available to justify 
a model which relates an operating policy to performance. The assumptions for the filtration model 
include: 
no change in the slurry liquid composition such that the composition of drugs In entrained In the damp 
solids, Z2,0iq is the same as in the filtrate, 40iq, 
0 no change in dry solids composition or mass, 
ea pre-determined desired value of the level of dampness (LOD) 
is achieved, 
a fixed processing rate per mass of solids, independent of scale, 
LOD and CSD. 
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B-7 Washing model 
The first generation washing model consists of a mass balance with displacement of residual moisture with 
wash solvent. The first generation model for the Stage 14 washing operation is given in Model B7 and the 
process diagram is shown in Figure B8. 
Solids ZIJ, crys po z-,,,, c,, Solid phase Residual moisture zl, j, hq Z2, i, liq Residual moisture 
Wash solvent F 10 Z3j Rinse waste 
Figure B8. Washing unit, Case Study 11. 
Non-wash solvent component mass balance, 
8 
1-2, 
i, liq 
LOD 
8 
i=l 
8x 
100% 
IZ2, 
i, liq +I z "'i, crys 
i=l i=l 
Z 2, i, crys --": Z l, i, crys for i=l 8 
2, i, liq "':: 
(I 
- 71wash 
)Zl, 
i, liq 
3, i ý 71wash Z l, i, liq 
Wash solvent component (solL, i= 7) mass balance, 
8 
2,7, liq l7wash 
)ZI, 
7, liq + 71wash 
1: ZI 
, i, liq 
i=l, i*7 
8 
Z3,7 -'-": 
(77wash 
ZI, 7, liq +F- 71wash 
Y, Zl, i, liq 
i=], i*7 
for 1=1 ... 6,8 
for i= I ... 6,8 
(Model B7) 
where 
F= mass of wash solvent feed, kg 
LOD = level of dampness in solids, ge 
tf operation time, min 
Tlwash wash efficiency, representing the split 
fraction of initial residual moisture which is 
replaced with pure wash solvent 
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and subscript i represents the component species factA, actB, actC, actD, actE, solF, solL, aq). No 
degrees of freedom are associated with this model, since not enough information is available to Justify a Cý 
model which relates an operating policy to performance. Assumptions for the washing, model include: C, 
*a final LOD equal to the initial LOD is achieved, 
a fractional displacement of the initial residual moisture (zj, j, jjq) with pure wash solvent (F) represented 
with an assumed wash efficiency (ilwah), 
negligible dissolution of crystalline drug components in the pure solL wash solvent (operated at 
ambient temperature), 
9 the composition of the displaced residual moisture is equal to the composition of the initial moisture, 
e no change in dry solids composition or mass, 
*a fixed wash time, independent of scale. 
B. 8 Dryer model 
Mass and heat transfer effects are likely to be complex and a lack of data and general understanding of the L- 
drying process permits only a simple mass balance model based on an efficiency measure in drying rate. 
The first generation model for the Stage 15 drying operation is given in Model B8 and the process 
diagram is shown in Figure B9. 
10 Z2, i, crys 
Solid ZIJ, crys Z2, i, fiq 
Residual moisture zj, j,, jq 10 
10 Z3J 
Figure B9. Drying unit, Case Study 11. 
Drug component mass balance, 
2, i, (-rvs -= Zl, i, crys 
fo r i'= 18 
for L. -5 2, i, liq Z IJ, liq 
Solvent component mass balance 
LOD = 
8 
2, i, liq 
Z "J, liq Z 
100% 
Solid phase 
Residual moisture 
Evaporate stream 
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85Z 
ZZ 100 
i=6 - 
LOD 
8 
1Z2, 
i, liq 
Z2, i, liq i=6 
8 
I 
-- l, i, liq 
z=6 
Z3, i l, i, liq - Zl-, i, liq 
-' - 
Z2, i, crys 
+ Z2, i, liq 
. 
100% Pdrycrys 
55 
Z ', i, (-rys 
+Z --), i, liq 
i=l 
8 
tf = DR Zl, i. crys 
where 
DR = drying rate, min kg-1 solids 
LOD = level of dampness in solids, 
for i=6 8 
for i=6 8 
for i=l 5 
(Model B8) 
Pdrycrys = purity of final crystals, dry weight percent % (excluding solvent moisture) 
and subscript i represents the component species JactA, actB, actC, actD, actE, solF, solL, aq). No 
degrees of freedom are associated with this model, since not enough information is available to justify a 
model which relates an operating policy to performance. Assumptions for the drying model include: 
e no change in dry solids composition or mass, 
any drug components In the in'tial residual moisture 
(Z1,0iq) is retained and does not leave in the 
evaporate(Z3, i), 
*a pre-determined desired value of the LOD is achieved, 
a fixed processing rate per mass of sollds (DR), independent of scale, LOD, CSD and ambient 
temperature. 
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B-9 Uncertainty in first generation models 
Table B2. Uncertainty characterisation in the parameters of the first generation models, Case Study 11. 
Stage Parameter Normal distribution, N(ýt, cy) 
(stochastic 
i 
model Uniform distribution, U(min, max) Parameter index) 
I k, (1), k2 (2) 
10-6 k, 169 x 10"ý' ZZ7 x- L80 x 104 * 
7.14 x ICF5 180 X IU-8 148 x 10-10 
jk 
2 
k3 (3) N(1.67 X 10-3,1.51xlO-4) 
t' (4) N(60,10% nominal) 
2 U, (5) UQ, 6) 
ul (6) U(0' 0.01) 
3 U2 (7) U(0' 0.01) 
4 ul (8) U(0' 0.01) 
5 ul (9) U(0' 0.01) 
6 U2 (10) U(0' 0.01) 
7 ul (11) U(0' 0.01) 
8 U2 (12) U(0' 0.01) 
9 Vp, solF, A ( 13) N(I 0 1.6,0.25 % nominal) 
Vp, solF, C 
(14) N(- 12.2,0.25 % nominal) 
grad,,,, F (15) N(O. 49,10% nominal) 
10 Vp, solF, A ( 13) N(101.6,0.25% nominal) 
Vp, solF, C 
(14) N(- 12.2,0.25% nominal) 
gradsolF ( 15) N(O. 49,10% nominal) 
11 Vp, solF, A (13) N(101.6,0.25% nominal) 
Vp, solF, C 
(14) N(- 12.2,0.25 % nominal) 
gradsolF (15) N(O. 49,10% nominal) 
12 kg (16) N(6.6 1X 10-5 2.3 IX10-5) 
C2loC* (17) N(O. 005 6,5 % nominal) 
C30oC* (18) N(O. 0 110,5 % nominal) 
C78oC* (19) N(O. 2530,5% nominal) 
ýactA (20) N(O. 0025, c%ý, A) 
a ýarlA =f ýratio(solL product)l 
CactC (21) N(O. 0058, Gý. tc) 
C'ýariC =f 
tratio(solLproduct)j 
Cacti) (22) N(O. 002 1, crc., D) 
a ýarlD =f fratio(soMproduct)l 
ýa,: ý (23) 
N(O. 0034, cr;, E) 
=ff ratio (solL product) or ý artE 
13 FR (24) N(O. 5,10% nominal) 
LOD (25) N(25,1017c nominal) 
14 Tlwash (26) U(0' 1) 
LOD (27) N(25,10% nominal) 
15 DR (2 8) N(2.0,10% nominal) 
LOD (29) N(6,10% nominal) 
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B. 10 Uncertainty from violation of predetermined operating ranges 
To accommodate the lack of understanding and mechanistic knowledge regarding possible consequences 
due to deviations from desired operating conditions obtained from design of experiment analyses, an extra 
degree of uncertainty is incorporated. This introduces a form of the stochastic system model where the 
uncertainty is dynamic, dependent on future decisions or knowledge. In these instances it is assumed that a 
deviation of a particular measured criterion from the desired value or range results in an increase in the 
prior uncertainty for a parameter characterising the possible consequence, 
ao, e 
clo'i = 
QUB + QLB QUB _ QLB if Qj, i 22 
QUB + QLB QUB _ QLB)) 
U,, e X+gj Qj, i 2j12 
UB LB Q UB 
-Q 
LB 
if Qj, i - 
Qj + Qj. ii 
22 
a=I... E) 
for j =I ... J (B3) 
I. =I... I 
where cro, j is the standard deviation used to generate the ith parameter scenario Oi, (T(), o is the standard 
deviation of uncertain parameter 0 used if no range violation occurs, Qj is the value of the jth criterion and 
g is the factor by which (YE)j increases linearly from cFG with deviation of Qj outside the desired criterion 
range QjUB and QjLB. In a conservative assumption, the standard deviation for a given uncertain parameter 
increases additively for deviations from multiple criteria ranges (which may be associated with the 
uncertain parameter in question), as shown in Equation B3. In the event of a criterion deviation outside the 
desired range, the uncertain parameter scenario is re-sampled from the newly characterised distribution. 
For the violation of the total initial and pre-crystallisation desired soll- solvent volume to product mass 
ratio operating ranges (14-15 and 7-8, respectively) it is assumed that the uncertainty (standard deviation) 
in the Stage 12 crystallisation parameters characterising the crystal impurity content, Ci, increase linearly 
at a rate of unity with extent of the (additive) deviations from the limits of the initial and 
final solvent ratio 
ranges. 
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B. 11 Uncertainty Analysis results for the first generation of models, Case Study II. 
Figure B 10 shows the quantitative effect of employing the expression for additional uncertainty (Equation 
B3) due to the violation of the desired initial and final range in the predicted solvent to product ratio 
(latter shown in Figure B 10 (b)) on the crystallisation key impurity 'solute loss' parameter (ýactC), Figure 
I 
0 
U 
5 2 2.5 3 3.5 4 
Key impurity loss parameter 
4ý5 5 
x lo-, 
(a) Key impurity 'solute loss' parameter. 
Key: 9= with additional uncertainty, 
o= without additional uncertainty. 
0 
>1 
u 
C70 
'30 
p 
z u 
Z 
cro 
30. 
U 
0 
(b) Pre-crystallisation solL solvent volume 
to product mass ratio. 
(c) Key impurity content. 
Key: *= with additional uncertainty, 
o= without additional uncertainty. 
Figure B 10. Effect of additional uncertainty in crystallisation 'solute loss' parameter for the key 
impurity due to violation of desired solL solvent volume to product mass operating range, Case Study 
11. 
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B 10 (a), and on the endpoint impurity content (wticc), Figure B 10 (c). 
Figure BII shows the arrival of sampling convergence in the evolution of the mean and variance 
parameters for the predicted total yield. The effect of inducing rank correlation using Iman and Conover 
(1982) technique, as expressed in Figure B12, is discussed. The parameter regression covariance matrix 
for the knowledge level 0 Stage I reaction rate constants, k, and k2, was determined assuming linearisation 1-ý 
around the optimal estimates from which the associated correlation matrix is obtained (as stated in Section 
5.4), 
ý=[2.27 X 10-6 - 1.80 X 10-8 ý=[1.0 - 0.9820] 
- 1.80 X 10-8 1.48 X 10-10 
j' 
-0.9820 1.0 
(B4) 
C is set as the desired correlation matrix for the sample generated k, and k2 vectors. A matrix K, 
obtained from an independently generated Hammersley sequence sample, has a correlation matrix E, 
E= 
[_ 1"o - 0.0024] 
0.0024 1.0 
(B5) 
Since E is close to the identity matrix (the correction for K* is not required) and the correlation and rank 
correlation (E* and E*rk)matrices of K* are close to each other, 
E* = 
[_ 1*0 - 0.9821], 
0.9821 1.0 
1.0 -0.9829 E, k 0.9829 1.0 
1 
(B6) 
then the desired rank correlation can be induced into k, and k2 sample vectors by rearranging the elements 
according to the rank order of K*- The resulting sample correlation matrix for the 431 sample of k' and k2 
is, 
1.0 - 0.9866] 
0.9866 1.0 
(B6) 
which is close to the desired correlation matrix, C Figure B 12 (a) shows the contrast of the rearranged 
observations of the independent Hammersley sample matrix 
for a desired correlation of -0.9820 (dots) to 
the unit hyper-cube sample matrix (circles), before 
inversion over the standard normal cumulative 
distribution. X* is expressed for the normally distributed k, and k2 parameters with the same desired 
correlation in Figure B12 (b). The circles represent the 
distributed observations before the induced 
correlation and the dots represent the observations a' 
fter the rearrangement. The 95% confidence regions 
assume linearisation of the model about the optimal parameter estimates 
(see Section 5.4). The 
inducement of the correlation in the sample appears to 
be reasonable compared to the 95% confidence 
region for the correlated parameters (the solid ellipse). 
The scatter plots in Figure B13 shows that the 
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linear Sensitivity Analysis measures (CC and SRQ based on unranked data are adequate measures of the 
key uncertain parameter contributions for the performance criteria shown. 
-0 
Cd 
v 
:E 
(a) Mean. 
,01 
a. ) 
0 
a. ) 
U 
ca 
>0 
(b) Variance. 
Figure B 11. Evolution of distribution parameter estimates with sample observations for the total yield 
of the first generation of models (knowledge level 0), Case Study 11. 
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Appendix C 
C. CASE STUDY 11: PROCESS MODEL REVISIONS INCORPORATING LEVELS 
OF KNOWLEDGE 
Appendix C contains revised process models and uncertainty characterisations for Case Study II. These 
are associated with the employment of additi I into ional experimental data or pilot plant measurements 
systematic model development procedures. 
C. 1 Knowledge level 1. First generation Stage 1 reactor model fitted to new data 
Profile data from a 1000 US gallon reaction process operated at 90 rpm (the maximum agitation possible 
in the equipment), is available. Fitting the parameters of the first generation Stage I model to this new 
data introduces an increase in the amount of uncertainty in the confidence region for the k, and k2 
parameters (Table C I) compared to the uncertainty in the parameter fit to the bench scale data (Table B2, 
Appendix B). 
Table C 1. Revised uncertainty characterisation in the parameters of the first generation Stage I 
model, fitted to new data, Case Study II. 
Stage Parameter Normal distribution, N(ýt, cy) Increasein CV2 over fit to 
bench scale data (Table B2) 
I ki kj = 146 x 10-2 168 x 10 - 7.10 x 10-8 
7.4 
k2 
ICF5' 7.10 X 10-8 3.28 X 10-10 k2 =133x 
2.2 
k3 N(9.92x 10-4 , 2.56x 
10-4) 1.7 
tf N(60,10% nominal) - 
C. 2 Knowledge level 2. Second generation Stage I reactor model 
A second generation Stage I model is proposed. From the new profile data at the larger scale (1000 US t-- 
gallon, 90 rpm), an initial rate limiting period is observed in the product reaction. The possibility of non- 
instantaneous addition of reH and/or the dissolution of solid reG is postulated in Table 7.2 (Section 7.3). 
Since the role of the reagent species on the observed drug reactions is unclear and it not possible to 
differentiate between these two phenomena without further investigation or data, the rate of reaction is 
assumed to proceed at a constant rate, kj"', during the initial rate limited period. This leads to a second 
generation Stage I model, comprising: 
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the first generation Stage I model (Model B I, Appendix B), with the exception of the following dru. c, 
mole balances, 
dlnl, 
org 
- -kl" 
k, Ml, org dt 
dm-, org k k, ml, org - knil, oro dt 
it 
dM 
3, org 0 
dt 
mo, IX" k' 
t 
I=k, 
ni I, Org 11 tý, t 
it 
tf 
(Model C I) 
where the notation is defined in Model BI (Appendix B) and additionally 
ki" = zero order rate constant during initial rate limited period, mol min- I 
time at which initial rate limited period ends, min 
X. Of = conversion at which initial rate limited period ends 
The same assumptions apply to this model as for the first generation Stage I model (Model B 1, Appendix 
B), with the exception of: 
*a zero order (linear profile) initial reaction rate limiting period, assumed to be independent of scale 
(since there are not enough data points to justify any other assumption), in which C and X" remain 
constant given the same operational reH addition time (I hour), 
the reaction for the formation of the key impurity starts after the end of the initial rate of product 
formation limiting period. 
The fitted parameter values for the second generation model are given in Table C2 and the uncertainty 
characterisations are given in Table C3. The second and first generation model profile predictions for the 
new 1000 US gallon reactor data, the solid and dashed curves in Figure Cl, respectively, compare the 
difference due to the structural revision. There is a clear difference in the actA and actB drug component 
profiles when a rate limiting phenomena is introduced. Very similar values for the k, rate constant are 
obtained (0.0168 min-' compared to the first generation model value of 0.0169 min-' based on bench scale 
data) leads to the conclusion that at 90 rpm agitation, close to fully disperse conditions are achieved in the 
1000 US gallon vessel, indicating intrinsic kinetic control. Despite keeping the same first order equation 
structure for the rate of secondary impurity formation, the change in the fitted value of k3 (9.92 x 10-4 
compared to 1.67 x 10-3 min-') with the 1000 US gallon data has a 
large effect on the prediction for the Z_ II 
secondary impurity (actE), Figure CI (b). 
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Table C2. Parameters for the second generation Stage 1 model, Case Study 11. 
Fitted model parameter values Imposed operating conditions 
ki = 0.0168 min-' tf = 230 min 
k2= 7.98 x 10-5 min-' wt% Fdruij = [79.1,0,0,20.1,0] 
k3= 9.92 x 10-4 min-' Fd,.,, ý = 195.3 kg 
t'= 60 min molratiOreH = 10.4 
X" = 0.37 Wt % FreH = 30% 
75 min 
Table C3. Uncertainty characterisation in the second generation Stage I model parameters, Case Study 11. 
Stage Parameter Normal distribution, N(ýt, cr) 
kj, k2 k, =168xlCF2 146xlO-6 -WxIOý 
k* = 7.98 x IG-5' 161 x ICF8 177 x ICF'O 2 
k3 N(9.92x 10-4 2.56x 10-4) 
t/ N(60,10% nominal) 
x1f N(O. 37,10% nominal) 
t ft N(75,10% nominal) 
(t) 
2 
Time, min 
(a) Key: Pilot scale data points 
actA, *= actB, x= actD. 
lo 
Time, min 
(b) Key: Pilot scale data points 
o= actC, += actE. 
Figure CI. Pilot scale (1000 US gallon, 90 rpm) drug profile, Case Study 11. 
Key: -= Second generation model prediction, ---- = 
first generation model prediction. 
io 
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C. 3 Knowledge level 3. Third generation Stage 1 reactor model 
Profile data becomes available at 60 and 75 rpm, at the 1000 US gallon scale. With this data, in addition 
to the 90 rpm data, it is possible to develop a third generation Stage I model, to account for mixing 
effects. The intention is to use this model to predict the agitation required to 0 maintain a desired 
performance of the reaction. The development of the rmxing case is stated from private communication 
with a pharmaceutical company. The parameters and associated uncertainties for the assumed mixing 
model incorporated in the third generation Stage I model, are identified in this section. 
The reaction data obtained to develop the second generation Stage I model indicated that close to fully 
disperse conditions (intrinsic kinetics observed) were obtained at 90 rpm in the 1000 US gallon reactor. It 
cannot be assumed that the 78 rpm agitation conditions in the PPR plant vessel achieves fully disperse 
conditions. If the relative importance of the Stage I model to the overall process sequence is high, then 
any effect of mixing on the reaction kinetics is likely to be a key factor. The third generation model 
comprises: 
the second generation Stage I model (Model C 1), 
kj N ]Y' 
k j, &sp Ndip 
k, " 
=[N 
]Y2 
Ndisp 
I, disp 
(Model C2) 
where the notation is defined in Model CI (Appendix Q and Model BI (Appendix B) and additionally 
N= agitation speed, rpm 
71 =a power which characterises the mixing regime on the intrinsic rates of reaction 
72 a power which characterises the effect of mixing on the parameter k' characterising 
the initial rate limiting period 
subscripts 
disp = fully disperse 
i= reaction rate constant index ( 1,2,31 
Assumptions for the third generation Stage I model include: 
* the predicted mixing regime is valid at both the 1000 US gallon and PPR plant scales, and all the drug 
reactions are similarly affected, 
an agitat on of -90 rpm gives close to fully disperse conditions in the PPR plant vessel, i. e. a similar VII 
power input per unit volume is achieved to that in the 1000 US gallon scale 90rpm run, 
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9 the power, Y2, adequately describes the effect of agitation on kj" with respect to the assumed disperse 
value, k, Asp" (based on m,,,,, X"' and t" at 90 rpm in Model C2), 
0 t" is independent of agitation (i. e. tdisp" = t", based on comparison of concentration profile data). 
The parameter values for the third generation Stage I model are given in Table C4. The uncertainty these 
parameters are characterised in Table C5. 
Table C4. Parameters for the third generation Stage 1 model, Case Study 11. 
Fitted model parameter values 
t" = 75 min 
Xdisp" = 0.37 
ki, 
disp = 0.0168 min- 
k2, 
disp = 7.98 x 10-5 min-' 
k3, 
disp = 9.92 x 10-4 min- 1 
t" = 60 min 
yj = 1.2 
72 = 2.0 
Table C5. Uncertainty in the parameters of the third generation Stage I model, Case Study 11. 
Stage Parameter Distribution, N(ýi, cF), U(min, max) 
kj, k2 x U-6 - 168 x 10ý 1 46 kj = 168 x 
10-2 
ý=[ 
1 I X ICF5 
'-x 10 -8 -10 k2 = 7.98 6 177 x 10 
k3 N(9.92x 10-4 , 2.56x 
10-4) 
tI N(60,10% nominal) 
Xdisp N(O. 37,10% nominal) 
t fl N(75,10% nominal) 
Yi U(I. 2-0.37,1.2+0.37) 
Y2 U(2.0-0.92,2.0+0.92) 
Development of the mixing case using a mixing correlation (Godfrey et al. 1989), based on the actA 
profiles under different agitation rates, indicated that a dispersion limited mixing regime (no mass transfer 
lirnitation) is observed for this system. This was determined from a plot of the observed kj"/ kl, disp", 
against N, when compared with the correlation relationship of (N/Ndisp) 
Y' and kl, di, p and Ndi, p are assumed 
to be the values from the 90 rpm data. A value of, the power yj of 1.2 (predicting a dispersion limited 
regime) appears to fit the observations reasonably well. A similar relationship was assumed to predict the 
effect of mixing on the k, " parameter and a value of 2 
for the power Y2 appears to fit the observations. 
Since these are linear relationships the uncertainty in the values of the log plot gradients, 71 and Y2, are 
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estimated from the standard equation used to predict a confidence interval for the true slope of a single 
variable linear regression model. The uncertainties for yj and Y2, shown In Table C5, are estimated at a 
90% confidence level given three data points. 
CA Knowledge level 4. Second generation layer separation model 
A simple development for the layer separation model assumes observations of the possible presence of a 
durable dispersion band of uncertain height in the phase cut following a pre-determined settling time. The 
quantity of aqueous droplets contained in continuous organic phase band depth is described, as opposed to 
the assumption of a total drug loss fraction(U2) used in the first generation layer separation model (Model 
B3, Appendix B). The second generation layer separation model is given in Model C3 where the stream 
number and phase indices refer to Figure B4 (Appendix B). 
Organic phase volume loss, 
V3, 
org = 
hband Avessel 
(I-E) 
Component mass balance, 
"Oro V"O, Po' for i LA 3, i, org = 1000 X8 
Z l, i, org 
Z'), i, oro = Zl, i, org 3, i, org 
fo r LA 
Z 3, i, aq =-- Z l, i, aq 
fo ri=I... 8 (Model C3) 
where the notation is defined in Model B3 (Appendix B) and additionally 
Avessel cross-sectional area of vessel, m2 
hband height of a two phase dispersion band, in 
V3, 
org volume of organic phase within dispersion 
band, M3 
equilibrium disperse phase hold-up fraction in dispersion 
band 
= density of organic phase, kg dM-3 Porg 
0 
There are no degrees of freedom in this model since past observations 
do not appear to justify detailed 
investigations to model the complex 
dependence of disperslon band height on settling and coalescence 
rates, relating time and agitation effects. 
It is assumed that the diameter of the PPR plant vessel is 2.13 
metres (with a height to diameter aspect ratio of 
1: 1, in the 2000 US gallon PPR vessel). The main 
assumptions made in this model 
include those made in the first generation layer separation model (Model 
B3, Appendix B) with the exception that: 
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an equilibrium dispersion band height, hband, is assumed to be attained, independent of vessel 
geometry, the relative volumes of aqueous and organic phases, mixing and dynamics (since settling 
and coalescence rate data is unavailable), 
the density of the organic phase Is estimated from the linear function of drug concentration also used in 
the first generation batch distillation model (Model 134), 
an approximate value within the range of 0.5 to 0.75 is assumed for the equlllbrlum value of the 
disperse phase band hold-up (Godfrey and Slater, 1994), E*. 
The assumed parameter values for the second generation layer separation model are given in Table C6, 
and the associated uncertainties in Stages 3,6 and 8 are given in Table C7. 
Table C6. Parameters for the second generation layer separation model, Case Study II. 
Model parameter values 
hband 
-"'0-01 M 
F-* = 0.63 
Table C7. Uncertainty characterisation in the second generation layer separation models, Case Study 11. 
Stage Parameter Uniform distribution, U(min, max) 
3 hband U(O, 0.02) 
F, U(0.5,0.75) 
6 hband U(O, 0.02) 
U(0.5,0.75) 
8 hband U(O, 0.02) 
U(0.5,0.75) 
C. 5 Knowledge level 5. Second generation reagent addition model 
Incorporation of liquid-liquid equilibrium tie-lines for loss of drugs through aqueous phase solubility 
effects provides a prediction for drug loss based on an estimation of physical property behaviour as 
opposed to a fractional loss assumption, ul, used in the first generation reagent addition model (Model B2, 
Appendix B). The model for the second generation reagent addition model comprises: 
the first generation reagent addition model (Model B2, Appendix B), with the exception of the 
following drug mole balances, 
zsl ýI - 71.1, org - I, i, aq 
for i=L. -5 
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Zorgsv ýZ1,6, org 
7 
100 
- Wt% F 
loo - Wt%aq 
laqsv ý-- VFPF 
( 
100 
+VI, 
aq Paq 100 
2, i, org , Z2, t, aq "- 
f 
(Z, 
, 
Zorgsv 
I 
Zaqsv 
1 si, orgsv, aqsv for i=L. -5 (Model 
C4) 
where the stream number and phase indices refer to Figure B3 (Appendix B) and the notation is defined in 
Model B2 (Appendix B) and additionally, 
v= volume, m3 
f= function determining solute split based on physical property equilibrium tie-line 
solubility data and phase mass, 
stream mass, kg 
equilibrium solubility of solute in organic-aqueous phase mixtures, wt% 
subscripts 
aqsv = pure aqueous solvent 
orgsv = pure organic solvent 
sl = drug solute 
F= reagent feed 
aq = aqueous phase 
The possible degrees of freedom are either the volume of distilled water added in the dilution operation or 
the addition reagent to active drug ingredient feed mole ratio governing the aqueous reagent strength. The 
uncertainty characterisations of the parameters in the second stage reagent addition model are given in 
Table C8. 
Table C8. Uncertainty characterisation in the second generation reagent addition models, Case Study Il. 
Stage Parameter Normal distribution at 9517c confidence, N(ýt, cy) 
Uniform distribution, U(min, max) 
2 U, U(3,6) 
CFII* N(equilibrium tie-line data point, 10%. nominal) 
4 as, N(equilibrium tie-line data point, 10% nominal) 
5 Cys, N(equilibnum tie-line data point, 10% nominal) 
7 CTII* N(equilibrium tie-line data point, 10% nominal) 
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Uncertainty is considered in the aqueous phase solubility equilibria data. The same assumptions appl, v to 
the second generation reagent addition model (Model B2, Appendix B) with the following exceptions: L- 
equilibrium solubility is observed at the endpoint of the operation, replacing the fractional loss 
parameter, u 1, 
the solubility behaviour of each drug component species is the same with the effect that the same tie- 
line data can be used, 
the solubility behaviour of each drug component species is independent of each other and the presence 
of any other impurities. 
C. 6 Knowledge level 6. First generation Stage 12 crystallisation model fitted to new data 
Input and output drug product concentration data for the Stage 12 crystallisation process from a process 
sequence run of similar scale to that referred in Appendix C. 2 (1000 US gallons), is available. However, 
without further profile data, revision of the first generation model structure (Model B5, Appendix B) is 
unjustified. This data is used to revise the value of k to 6.1 x 10-5 compared to 7.94 X 10-5 m min-' (kg 9 z: 1 
kgsolvent-')"' obtained from the bench scale data. The uncertainty in kg is assumed to be normally 
distributed, N(6.1 X 10-5,10% nominal). No data is available to revise the values of the other parameters 
in the first generation Stage 12 model. 
230 
Integrated design under uncertainrY for phannacelitical processes 
Appendix D 
D. CASE STUDY 11: RESULTS FOR THE EFFECT OF INCOMING DATA 
Additional results for Case Study 11 are presented in Appendix D, which have been referred to in Chapter 
7. The cumulative frequency plots for the predicted total yield at different levels of knowledge are shown 
in Figure D1. Knowledge level 6 shows evidence that it provides the best prediction to the plant data since 
the distribution clearly encompasses the data point value (solid vertical line). Figure D2 shows the 
corresponding plots for the predicted key impurity endpoint content and that knowledge levels 3,4,5, and 
6 exhibit the least uncertainty for this criterion. The main Sensitivity Analysis results for the different 
knowledge levels are shown in Table DI. The scatter plots for knowledge level 0 data, Figure D3, verify 
that the scatter of the key impurity reaction rate constant, k2, and the key impurity 'solute loss' parameter, 
CactC, with the endpoint key impurity content, are comparable (SRC of 0.78 and 0.77, Table DI). The 
relative uncertainty for the post-reactor key impurity composition and the e. ndpoint content, shown in the 
cumulative frequency plots, Figure D4, indicate that a large proportion of the uncertainty accumulated in 
the endpoint criterion appears to be already present after Stage I (corresponding to a Stage I sub- 
sequence contribution of 0.62 compared to Stage 2-15 contribution of 0.38). 
1 
0.8 
croß 
(U 1- 
42 
u 
tu 
730.4 
U 
0.2 
0 7 
Total yield, 
(a) Key: e= Knowledge level 0, 
o= Knowledge level 1, 
*= Knowledge level 2, 
+= Knowledge level 3. 
(b) Key: *= Knowledge level 4, 
*=Knowledge level 5, 
o= Knowledge level 6. 
Figure DI. Cumulative frequency plots of total yield prediction under uncertainty, Case Study 11. 
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Figure D2. Cumulative frequency plots of key impurity content prediction, Case Study II. 
Key: *= Knowledge level 0, o= Knowledge level 1, Knowledge level 2, 
+= Knowledge level 3,4,5, and 6. 
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Figure D3. Scatter plots of the key parameters with the endpoint key impurity content, Case Study 11. 
Key: 9= Key impurity reaction rate constant, k2, o= 
Key impurity 'solute loss' parameter, ý=C- 
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Figure D4. Cumulative frequency plots of inter-stage key impurity composition under uncertainty, 
Case StudY 11. 
Key: *= Post-reaction key impurity composition, wt%, o= Endpoint key impurity content, wt%',. 
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Table D I. Main SRC Sensitivity Analysis results for levels of knowledge incorporation, Case Study 11. 
Endpoint criteria 
Knowledge Total yield Key impurity Secondary impurity 
level content content 
0 R2 0.97 R 0.98 R 0.99 
kg 0.82 CactC 0.78 CactE 0.96 
ki 0.32 k2 0.77 k3 0.32 
Ul -0.17 to -0.20 TIwash -0.21 71 wash -0.19 
U2 -0.15 to -0.18 1 
I R2 0.80 R2 0.96 R2 0.97 
k, 0.80 CactC 0.61 CactE 0.76 
kg 0.40 k2 0.58 k3 0.60 
Ul -0.12 to -0.13 TIwash -0.18 TI wash -0.10 
U2 -0.10 to -0.12 
' 2 R2 0.97 R2 0.99 R2 0.97 
kg 0.79 CactC 0.72 k3 0.73 
ki 0.30 k2 0.66 CactE 0.67 
Ul -0.15 to -0.22 11 wash -0.20 TIwash -0.14 
U2 
1 -0.16 to -0.21 1 
3 R2 0.97 R2 0.99 R2 0.99 
kg 0.67 k2 0.89 k3 0.89 
ki 0.58 CactC 0.54 CactE 0.44 
t -0.29 t -0.27 TIwash -0.15 
U2 -0.13 to -0.21 TIwash -0.25 
Yi -0.16 Yi -0.14 
Y2 -0.16 Y2 -0.13 
Ul -0.13 to -0.14 
4 R2 0.97 R2 0.98 R21 0.99 
L 0.60 _ k2 0.89 k3 0.87 
ki 0.58 ýactC 0.55 ýactE 0.45 
C 
-0.30 t" -0.26 Ilwash -0.15 
Ul -0.14 to -0.17 TIwash -0.25 
Y1 -0.15 Y1 -0.14 
Y2 -0.15 Y2 -0.12 
5 R2 0.97 R2 0.99 R2 0.99 
kg 0.64 k2 0.75 k3 0.88 
k, 0.47 CactC 0.63 Cacff 0.44 
Cysl -0.23 to 0.44 
C 
-0.27 '9wash -0.14 
C -0.29 Ilwash -0.20 
Y1 -0.17 Yi -0.15 
Y2 -0.15 Y2 -0.12 
6 _ R2 0.97 R2 0.99 R2 0.99 
L 0.77 k2 0.75 k3 0.88 
k, 0.38 CactC 0.63 
CactE 0.44 
(TýI* -0.20 to 0.36 t" -0.26 
TIwash -0.13 
C -0.24 Ilwash -0.19 
Y1 -0.14 Yi -0.15 
1 Y2 -0.12 Y2 1 -0.12 
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Appendix E 
CASE STUDY 11: OPTIMISATION RESULTS 
Appendix E contains additional optimisation results for Case Study 11 which have been referred to in 
Chapter 7,8 and 9. These include input uncertainty reduction optimisation results, Robustness Analysis on 
parameter uncertainty characterisation results and results presented for the analysis of alternative process 
flowsheets regarding flowsheet optimisation under uncertainty, Uncertainty and Sensitivity Analysis and 
optimal operating policy error tolerance results. Computational statistics are presented for the Case Study 
II optimisation problems. 
EA Optimisation results for uncertainty reduction. 
The results in Table El show how the optimal key input parameter uncertainties vary with parametric 
increases in the desired reduction in the output criteria (total yield, key and secondary endpoint impurity 
contents). No feasible solution was found for desired uncertainty reduction levels above 60% (of the 
original uncertainty in the knowled e level 6 model). Computational statistics for this problem are given 9 4: 1 
in Table E6. 
Table E I. Optimisation results for optimal key input parameter uncertainty reductions for knowledge level 
6 Base Case flowsheet stochastic model, Case Study II. 
Desired uncertainty reduction in output performance, % 
0 10 20 30 40 50 60 70,80.90 
Objective function, 7.00 6.30 5.94 5.56 4.83 3.93 1.72 - 
Decisions Sa 1.00 0.93 0.73 0.64 0.47 0.28 1.0XIO-1 
ki 
(5 a 
1.00 0.82 0.81 0.56 0.50 0.40 9.1 X 10-2 
k9 
(5, 
1.00 1.00 0.72 0.98 0.58 0.39 0.34 
CIS/ 
6 
1.00 0.82 0.68 0.55 0.49 0.40 0.27 Infeasible 
k3 
(5 C 1.00 
1.00 1.00 0.83 0.92 0.82 6.3x 10-2 
cacic 
(5 Cy 1.00 
0.97 1.00 1.00 1.00 0.93 0.44 
CaclE 
1.00 0.77 1.00 1.00 0.86 0.69 1.1 x 10-'- 
5 95% YT, % 7.63 6.87 6.10 5.34 4.58 3.82 3.05 
Fractile width Wt""C' % 0.17 0.15 0.13 0.12 0.10 0.08 0.05 
Wtaeffi, % 1.43 0.98 1.15 1.00 0.86 0.71 0.40 
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E. 2 The importance of the state of knowledge of the uncertainties results 
The results of the Robustness Analysis to input uncertainty distribution, Figure El, shows only a limited 
difference between output criterion distributions predicted using either normally or uniformly distributed 
input uncertainties (Case 2), but as expected, a significant difference when the input uncertainty spread is 
increased (Case 1). 
0. 
(a) Total yield. 
:i 
r- 
U 
0. 
(b) Key impurlty content. 
Figure El. Cumulative frequency plots for validated optimisation results under input uncertainty 
variations, Case Study Il. 
Key: o= Base Case (normally distributed), Case 1 (50% increase in spread, normally distributed), 
x= Case 2 (uniformly distributed). 
E. 3 Alternate flowsheet optimisation under uncertainty results. 
Tables E2 and E3 and Figures E2 and E3 show the process flowsheet stochastic optimisation results for 
the four alternative flowsheets considered in Case Study 11 (Chapter 9). Alternative 2 returns the best 
profitability predictions under uncertainty. Only the Stage I reaction time (tfj) and Stage 12 crystallisation 
holding period (HP12) decision variables appear sensitive to the different flowsheet configurations. Table 
E4 shows the main results of the Sensitivity Analysis where only SRC measures were required. 
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Table E2. Validated alternate process flowsheet optimisation under uncertainty results, Case Study II. 
Criteria Base Case Alternative I Alternative 2 Alternative 3 
7, - -T EI Pty 1 ($ kgtA hr-1) 30.97 31.13 32.26 31-65 
E(Ptyloss)($ kgatA-' hr-') 3.02 2.97 3.04 3.10 
Prpass 0.894 0.904 0.905 0.901 
c), EI wt,,,, E) 1 (Ef wta,, [0.22,1.42] 
[0.21,1.361 [0.23,1.421 [0.23,1.421 
[FW I Wtactd, FW I Maud 1 [0.14,1.19] [0.17,1.36] [0.15,1.14] [0.14,1.19] 
E(YT) 86.5 89.2 86.9 85.6 
FW f YT) 5.4 5.4 6.3 5.7 
Table E3. Optimal decisions for alternate process flowsheet optimisation under uncertainty, Case Study 11. 
Decisions Base Case Alternative I Alternative 2 Alternative 3 
tf, j (min) 251 247 247 241 
N, (rpm) 90.0 90.0 90.0 90.0 
A-Flo 0.40 0.40 0.40 0.40 
PJFIO 0.70 0.70 0.70 0.70 
CR12 ('C min-) 0.50 0.50 0.50 0.50 
HF12 (min) 54 1 
52 47 50 
Rso[F back- 0.05 Rso[L 
-recycle = 
0.5 
0.8 
C70.6 
2 
4. 
0.4 
C-) 
0.2 
Figure E2. Cumulative frequency plots for potential profitability, Case Study 11. 
Key: += Base Case, *= Alternative 1, o= Alternative 2, x= Alternative 3. 
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I 
08 
1-1 u C: 
ý70 6 
> 
.Z 
02 
82 
(a) Total yield. 
ýý 6 
0- 
94 
Figure E3. Cumulative frequency plots for validated optimisation results under input uncertainty 
variations, Case Study 11. 
Key: += Base Case, *= Alternative 1, o= Alternative 2, x= Alternative 3. 
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Table E4. Key SRC contributors to predicted uncertainty for flowsheet alternatives, Case Study 11. 
Base Case Alternative I Alternative 2 Alternative 3 
Profitability R2 0.98 R2 0.99 R2 0.99 R2 0.96 
DR15 -0.77 DR15 -0.77 DR15 -0.75 DR14 -0.75 
k 9 0.40 k 9 0.40 kg 0.42 k 0.43 
k1 0.30 k, 0.31 k 0.28 k 0.32 
FR13 -0.18 FR13 -0.16 FRO -0.15 FRO -0.18 
(Ys, -0. l. 5 (YII* -0-10 WtsolL ml, 2 
0-11 cyý, * -0.14 
CYII* -0.10 
Total yield R2 0.96 R2 0.96 R2 0.97 R2 0.98 
kg 0.68 kg 0.70 kg 0.66 kg 0.69 
ki 0.47 k, 0.49 k, 0.43 k, 0.48 
CYII* -0.26 CTI, * -0.16 CYSI -0.17 crý, * -0.24 
WtsolL ml, 2 0.16 
Key impurity R2 0.99 R2 0.98 R2 0.99 R2 0.99 
content k2 0.85 k2 0.68 k2 0.77 k2 0.89 
ýactC 0.45 ýactC 0.65 CactC 0.55 ý=C 0.50 
Ilwash -0.32 Ilwash -0.27 Tlwash -0.36 LOD13 0.14 
Secondary R2 0.99 R2 0.98 R2 0.99 R2 0.99 
impurity content k3 0.91 k3 0.79 k3 0.84 k3 0.93 
CactE 0.33 CactE 0.56 ýacffi 0.45 CactE 0.34 
TIwash -0.19 Tj wash -0.17 TI wash -0.22 
E. 5 Alternate flowsheet operating policy tolerance optimisation results. 
The optimal control variable range tolerance fraction decisions for the four process flowsheet alternatives 
based on 99% achievement of their respective 'here and now' optimal mean profitabi Ii ties, are given in 
Tables E5, E6, E7 and E8. Zero 8 values indicate no tolerance in a particular policy variable deviation 
direction. 
Table E5. Optimal decisions for the Base Case operating policy tolerance, Case Study 11. 
tfl N, AFjo RFjo CR12 HP12 
U 0.110 0 0.042 0 0.006 0.153 
,5L ZIL-- 
0.309 0.015 0 0.081 0 0.784 
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Table E6. Optimal decisions and tolerance limits for Alternative I operating policy tolerance, Case Study 
tf, l N, AFjo RFjo CR12 HP12 Rso[F-back 
8u 
Z, J 
0.281 0 0.042 0 0.001 0.001 0.027 
,5L "I 
0.544 0.001 0 0.081 0 0.713 0.001 
z 
UB 
dI 290 90.0 0.41 0.70 0.50 52 0.067 
LB 
d 221 90.0 0.40 0.68 0.50 44 0.052 
Table E7. Optimal decisions and tolerance limits for Alternative 2 operating policy tolerance, Case Study 
11. 
tf, l N, AFjo RFjo CR12 HP12 
RsoU, 
-recycle 
(5, U Z, / 
0.127 0 0.042 0 0.016 0.065 0 
(5z, l 
0.488 0.034 0 0.081 0 0.892 0.098 
UB 
Zd I 
266 
I 
90.0 
I 
0.41 
I 
0.70 
I 
0.56 52 
II 
0.500 
LB 
Zd 
I 224 89.0 0.40 0.68 0.50 41 0.4 
Table E8. Optimal decisions and tolerance limits for Alternative 3 operating policy tolerance, Case Study 
ii. 
tf, l N, AlFjo RFjo CR12 
HP12 
U 
Zd 
0.110 0 0.042 0 0.004 0.042 
L 0.059 0.006 0 0.081 0 0.816 
UB 
Zd 258 90.0 I 0.41 I 0.70 I 0.51 I 53 
LB 
Zd 238 89.8 0.40 0.68 0.50 42 
E. 6 Computation statistics 
These stochastic optimisation problems were solved using the MATLAB (Version 6.0) program-ming 
software and the Optimisation Toolbox function 
for non-linear constrained optimisation algorithm based 
on SQP. They were performed on a 
RS6000 IBM 
, 
workstation. The stochastic optin-iisatlon problems 
involving decision variables which redefine 
the input uncertainty space in some way (optimal input 
V 
uncertainty reduction - 
Problem type PI, and maximum operating policy tolerance - Problem type P3) 
required CPU times of an order of magnitude greater 
than the stochastic flowsheet optimisations of fixed 
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space definition (Problem type P2). The latter required CPU times two orders of magnitude greater than 
their respective nominal opti I imisation problems. 
Table E9. Computational statistics for optimisation problems, Case Study II. 
Problem CPU time Optimisation Function 
formulation (seconds) iterations evaluations 
Input parameter 10% red'n P8 2.46x 104 53 548 
uncertainty reduction: 20% red'n (type P I) 5.02x 104 120 1094 
Base case 30% red'n 3.04x 104 78 753 
40% red'n 5.45x 104 123 1129 
50% red'n 6.12x 104 139 1312 
60% red'n 1.01X, 04 24 1 
Nominal flowsheet optimisation: P9 67 11 102 
Base case 
Uncertain flowsheet optimisation: P10 3256 11 66 
Base case (type P2) 
Uncertain flowsheet optimisation with Type PIO 3719 12 77 
input uncertainty variation: (type P2) 
Case I 
Uncertain flowsheet optimisation with Type P10 4149 13 85 
input uncertainty variation: (type P2) 
Case 2 
Uncertain flowsheet optimisation with Type P10 3213 11 66 
uncertain feed purity: (type P2) 
Base Case 
Nominal flowsheet optimisation: Type P9 50 27 197 
Alternative I 
Uncertain flowsheet optimisation: Type P10 5365 10 85 
Alternative I (type P2) 
Nominal flowsheet optimisation: Type P9 19 10 77 
Alternative 2 
Uncertain flowsheet optimisation: Type P10 2387 6 41 
Alternative 2 (type P2) 
Nominal flowsheet optimisation: Type P9 19 12 79 
Alternative 3 
Uncertain flowsheet optimisation: Type P10 3028 11 80 
Alternative 3 
Operating policy tolerance optimisation: PH 1.93x 104 52 411 
Base Case (type P3) 
Operating policy tolerance optimisation: Type P3 4.08x 
104 77 798 
Alternative I 
Operating policy tolerance optimisation: Type P3 3.85x 
104 80 806 
Alternative 2 
Operating policy tolerance optimisation: L- 
Type P3 2.72x 104 73 605 
Alternative 3 
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